1494 Antibodies Companies - Worldwide

About 3S Pharmaceutical Group 3S Pharmaceutical Group is a leading bio-pharmaceutical company integrating R&D, production and sales, with a focus on improving the life quality of patients with high-quality medicines to benefit human health. At present, the Group owns more than 80 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, among others, cancer, autoimmune, kidney disease, metabolism and dermatology. The Group owns 4 R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 25 kinds of products under R&D, 16 kinds of them are under R&D as the national first-class new drugs. The Group also owns 6 production bases complying with GMP standards. In the future, 3S Pharmaceutical Group will continue to uphold the concept of "Care for Life, Cherish Life, Create Life" to create a world's leading bio-pharmaceutical company in China.

3T is an immunotherapy company developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases in broad patient populations. By leveraging the power of the immune system to recognize, target, and destroy cancer cells, 3T's technology is advancing the development of next-generation therapies that have the potential to be safer, more effective, and even curative for difficult-to-treat cancers.

4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases. Our vector discovery platform Therapeutic Vector Evolution harnesses the power of directed evolution, a Nobel Prize-winning technology, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors with improved therapeutic profiles compared to wild-type vectors. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies. We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials for seven patient populations. We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our 4 Guiding Principles drive the way we work together: - Dare to Cure - Break Boundaries - Beyond Yourself - Prepare & Execute Relentlessly Join us in creating the future of genetic medicine.

Cardiogenic Shock: the primary circulatory shock in ICUs with a mortality rate over 70%. Triggered by acute myocardial injuries like heart attacks, it leads to severe left-ventricular dysfunction. Despite advancements in care and treatment for up to 200,000 affected U.S. patients annually, the first 30 days after diagnosis see persistently high mortality rates of 50-70%. Understand its pathophysiology, including the critical role of Dipeptidyl Peptidase 3, and the latest interventions.

A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the world’s largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/

Aarvik Therapeutics is pursuing exciting, novel molecules with an improved therapeutic index for several oncology targets by combining a novel modular antibody platform with multiple target mechanisms.

AAT Bioquest®, Inc. (formerly ABD Bioquest, Inc.) develops, manufactures and markets bioanalytical research reagents and kits to life sciences research, diagnostic R&D and drug discovery. We specialize in photometric detections including absorption (color), fluorescence and luminescence technologies. The Company's superior products enable life science researchers to better understand biochemistry, immunology, cell biology and molecular biology. AAT Bioquest offers a rapidly expanding list of enabling products. Besides the standard catalog products, we also offer custom services to meet the distinct needs of each customer. Our current services include custom synthesis of biological detection probes, custom development of biochemical, cell-based and diagnostic assays and custom high throughput screening of drug discovery targets. AAT Bioquest® is committed to constantly meet or exceed its customer’s requirements by providing consistently high quality products and services, and by encouraging continuous improvements in its long-term and daily operations. While we continue to rapidly expand, our core value remains the same: Innovation and Customer Satisfaction. We are committed to being the leading provider of novel biological detection solutions. We promise to extend these values to our customers during the course of our service and to continue to support our customers with new products and services.

AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs in antibody-based medicine development. We aim to be a leading partner for the global biopharmaceutical industry focusing on a broad range of diseases including cancer, autoimmune disorders, and neurological conditions. We are committed to providing unparalleled expertise and innovative technologies that contribute to the advancement of novel antibody therapeutics. Technologies: Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics. Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.

Abacus Bioscience is developing a new class of immunotherapy that unleashes the power of a novel CD180 platform technology. Our Antigen-Specific Immune Accelerants (ASIA) are POTENT, SPECIFIC and DURABLE, with broad applications across infectious disease and oncology.

The remarkable specificity and safety of antibody drugs have been limited to blocking inactivators for the largest class of drug targets. Abalone Bio develops antibody drugs that activate, enabling us to turn on previously inaccessible biological activities like anti-cancer or anti-inflammatory actions.

AbBC is a next generation ADC company that utilizes a biological conjugation process to target and deliver Granzyme B to cells for internalization and irreversible toxicity without the requirement of cleavage. Our pipeline of 7 fully human fusion proteins in ongoing preclinical development demonstrate inhibition and regression of tumor growth without toxicity. The platform enables the opportunity to methodically select ADC targets for development of new Granzyme B fusion proteins with major focus in oncology.

Our Mission To create best niche antibody-based biologics for fulfilling the research and development needs in biomedical and biopharmaceutical communities. Our long range goal is to develop therapeutic and diagnostic entities. Core Competence ABB's core competence is in protein designs of biologics for diagnostic and therapeutic applications of immuno-oncological disorders. Specifically, our R&D for therapeutics is focused on biologics that are capable of modulating activities associated with antigenic targets and effector molecules. In addition, ABB has designed and produced a panel of immune related protein reagents that are available to biomedical researchers as investigational tools. History Founded in 2007, AB Biosciences (ABB) has been dedicated to the engineering of therapeutic biologics and research protein reagents. With decades of combined experience in research and development, ABB's scientists have built an efficient platform for the development of these two protein classes. The recombinant replacement of the traditional IVIG (PRIM program) is a great example of our engineering expertise in R&D of an unique protein drug for replacing the traditional serum-derived IVIG. Our Community Massachusetts provides a vibrant and nurturing environment for life science ventures like ABB, in terms of training grants and tax benefits, as well as an abundant talent pool possessing a wide range of expertise. Discovering breakthrough biotechnology and exploring biologics for biomedical study is our mission at AB Biosciences. As part of our commitment to science education, we open our doors to intern students, who can experience firsthand the R&D employment possibilities in the Biotech Industry. More than 15 students/interns have visited our laboratory since 2009.

As researchers are focusing their efforts on determining the biological functions, interactions and regulation of the human proteome, Abbiotec is dedicated to developing cell biology-based research tools that assist scientific discoveries. Besides custom services, Abbiotec offers over 12,000 antibodies, proteins, peptides, lysates and kits to assist researchers in understanding human biology and diseases at the cellular and molecular levels.

AbboMax is a biotechnology company that offers high quality, diagnostic-grade products and professional custom services for research purposes.

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottCareers, on Instagram @AbbottGlobal, and on X @AbbottNews. We invite you to explore opportunities at Abbott, to see if your talents and career aspirations may fit with our openings. An equal opportunity employer, Abbott welcomes and encourages diversity in our workforce. Terms of Use: https://www.abbott.com/social-media-terms-of-use.htm

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

At Abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That's why we're constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders. Abcam is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. Abcam is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

Abcentra develops oxidized LDL blocking therapeutics to treat cardiovascular inflammation. Many patients worldwide live with substantial risk of a major cardiovascular event because of chronic inflammation. This includes patients who have recently had a heart attack, and patients with calcific aortic valve disease. It also includes patients with chronic inflammatory diseases such as psoriasis, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). Abcentra is developing a potential solution for patients with cardiovascular inflammation – therapeutics that target oxidized low-density lipoprotein (LDL). Oxidized LDL is a well-described pro-inflammatory mediator that is strongly implicated in atherosclerotic cardiovascular disease, type 2 diabetes, calcific aortic valve disease and several inflammatory diseases. Oxidized LDL blockade offers a promising new way to treat cardiovascular inflammation and meet large unmet medical needs in cardiovascular disease. Our pipeline focuses on developing oxLDL-blocking therapeutics for patients who have significant residual risk of major a cardiovascular event from chronic inflammation (see Pipeline). Our lead candidate, orticumab, is a fully-human, first-in-class antibody that targets a specific oxidized LDL epitope. Orticumab is currently in phase 2 in psoriasis patients with cardiometabolic risk factors. Several additional indications are also being pursued. Abcentra has offices in Los Angeles. The Company’s ownership includes world-renowned Los Angeles hospital, Cedar-Sinai. Our team includes experienced drug developers and founding scientists that pioneered our approach to oxidized LDL blockade.

AbCheck discovers and optimizes human therapeutic antibodies with one of the industry’s most versatile technology platforms. Tailored to specific needs and desired Target Product Profiles, AbCheck leverages both cutting-edge (e.g., microfluidics, rabbit mass humanization) and state-of-the-art (e.g., phage/yeast display libraries) technologies to provide high quality leads. The company has proven its capabilities in multiple partnerships throughout the U.S. and Europe. AbCheck is a wholly-owned subsidiary of Ampersand Biomedicines, a Flagship Pioneering Company.

AbClon was founded in 2010 by a consortium of Korean and Swedish experts in antibody development. Our mission is to cure once incurable diseases such as cancer.

Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies. IBM is a progressive and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. Abcuro has received FDA orphan drug designation for ABC008 in IBM. The company is also advancing ABC015, an anti-KLRG1 blocking antibody capable of reactivating inhibited cytotoxic T and NK cells in the tumor microenvironment.

Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options. Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation. Come join us and be a part of the ground-breaking team set to unlock the power of targeted radiotherapy!

Abeomics Inc. is founded by scientists for the scientists. Our immunologists, cell biologists and business professionals have contributed for over 25 years to the growth and success of global companies including BD Biosciences, eBioscience and IMGENEX Corporation. We bring our experiences to develop well-validated and specific antibodies by traditional hybridoma technology and by genetic engineering to produce recombinant mouse and rabbit monoclonal antibodies.

Abcepta is a biotechnology company that specializes in developing primary antibodies and custom services for research and drug discovery.

Abilita Therapeutics is a biotechnology company focused on redefining the druggable landscape for multi-span membrane proteins, including G Protein Coupled Receptors (GPCRs), transporters and ion channels. We are building a rich pipeline of high-value assets for such targets, with the goal of becoming the leader in discovering and developing first- and best-in-class antibody therapeutics.

Ability Biologics is dedicated to developing innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases. The company utilizes its powerful AbiLeap™ discovery engine, which combines massively parallel, continuously learning AI with advanced cell targeting technology, to develop the most potent and selective antibody therapeutics for areas of great unmet need.

With a 60+ year history as a service provider to the life sciences industry, Advanced BioScience Laboratories (ABL) provides a strong core of product development expertise, GMP manufacturing, and analytical testing capabilities. Founded in 1961 as a biomedical research contractor for the federal government, ABL has made major contributions to the development and evaluation of a wide range of life-saving diagnostics, vaccines, and therapeutics designed to combat the world's most challenging diseases. We partner with our clients to support advancement of their candidate vaccines and therapeutics through preclinical and clinical development. With facilities located in the United States, ABL aims to be a seamless extension of our clients' team – helping them advance today's ideas into tomorrow's medicines. ABL's CDMO service division specializes in the development and manufacturing of GMP cell banks and viral vectors from the bench to Phase I/II clinical trials. We aim to contributes to the success of our clients' ground-breaking innovations, including gene therapies, immunotherapies, viral vaccines, oncolytic viruses, and more. ABL's CDMO services include bulk drug substance production, fill/finish of drug products, process development, assay development and release testing.

ABL Bio Inc. (Kosdaq: 298380) is a South Korean biotechnology company dedicated to the development of bispecific antibody therapeutics to improve and save people's lives. With our BsAb platforms ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B,’ we have built a robust pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated excellent efficacy and safety. We also created a next-generation antibody drug conjugate program to treat various cancers. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. We continue to actively expand and advance our pipeline through global strategic partnerships. For more information, please visit http://ablbio.com

Ablexis offers the AlivaMab® Mouse platform, a suite of transgenic mouse strains for human therapeutic antibody discovery. AlivaMab Mouse strains are uniquely designed to be better for human therapeutic antibody discovery and development, for applications across antibody drug discovery including highest quality IgGs, singe-domain VH, multispecifics, ADCs, CARs, TCRm, and other modalities. The AlivaMab Mouse strains are well-documented for generating drug-like antibodies with broad combinatorial and somatic diversities, high affinities, specificity, and excellent developability properties. Users of AlivaMab Mouse include the world’s largest pharmas, public and private biotechs, and leading academic institutions. AlivaMab Mouse-derived antibodies in clinical development span formats including IgG, multispecific, ADC, and CAR. Many partners use AlivaMab Mouse at Ablexis’ sister company, AlivaMab Biologics, a leading provider of services in antibody drug discovery, engineering, and protein sciences. Visit us at www.ablexis.com to learn more. For inquiries about licensing the AlivaMab Mouse, contact us at info@ablexis.com.

Abnova is the first biotech company successfully integrated the IT-style management and industrial-scale antibody manufacturing. Our goal is to have at least one antibody to every human expressed gene in human genome. In Phase I of our business plans, we vastly expand the scope and availability of antibody reagents for the research market by taking a genome-wide approach to the high throughput production of human protein and antibody. There products are marketed through a combination of E-commerce based direct sales and a multi-tiered, sales network of over 49 distributors around the world. Starting from Year 2009 to 2013, in Phase II of the business plans, we have diversified into the systems arena focusing on antibody pairs, ELISA kits and instrumentation for rare cell isolation. In Phase III, we focus on in vitro diagnostics development concentrating on non-invasive, liquid biopsies of circulating tumor cells, ctDNA, and exosomes for precision medicine. Now in Phase IV (Year 2017 and later), we have focused on drug development specializing on immunotherapy. The value-added business has set the path of company's future growth and provided opportunity for Abnova to contribute to the biotech industry at large. We welcome researchers, biotech, and pharmaceutical companies to work with us and succeed together!

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance, AbolerIS Pharma is developing novel and unique therapeutic approaches to finely regulate the immune system by inducing immune tolerance and preserving useful immune responses in inflammatory, autoimmune, and degenerative diseases.

Abologix is a biopharmaceutical company based in Geneva, Switzerland. The company is a spin out from the laboratories of Prof. Beat Imhof and Thomas Matthes at the University of Geneva and the Geneva University Hospitals. The company is developing two monoclonal antibodies that selectively block two novel pharmacological targets. Several oncological medical indications are being pursued.

Abound Bio was acquired by Galapagos. Abound Bio is a US company whose mission is to generate novel antibody-based biological therapeutics to meet unmet medical needs in the fields of cancer and infectious disease. Galapagos acquired Abound Bio in 2022.

Abpro Corporation is a biotech company developing next-generation antibody therapies. Established in 1897, Abpro offers competitive salaries and generous benefits with the opportunity to learn and grow in an employee-driven culture. They are focused on developing antibody therapies to improve the lives of patients facing severe and life-threatening diseases.

Antibody-based therapeutics for tissue repair applications

Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.

Absolute Antibody Ltd is a UK-based biotechnology company founded in Oxford in August 2012. It specializes in recombinant antibody technology and operates from an ISO 9001:2015 certified facility in Redcar, England. The company focuses on improving antibody reproducibility through genetically defined production methods. The core services include recombinant antibody production using mammalian HEK and CHO cell lines, allowing for animal-free and serum-free manufacturing. They also offer custom engineering, providing antibody sequencing and reformatting into over 180 formats, as well as bespoke projects for pharmaceutical, diagnostic, and academic clients. Their product range features over 21,000 defined recombinant antibodies, ensuring consistency across batches, and includes specialized formats for various applications. Absolute Antibody serves a diverse clientele, including 14 of the top 15 pharmaceutical companies by R&D expenditure, biotechnology firms, and academic institutions. The company emphasizes collaboration in therapeutic antibody development and assay standardization.

Absolute Biotech specializes in antibody reagents, kits and services, adding value to existing antibodies through annotation, validation, sequencing, engineering and recombinant manufacturing. Our company unites multiple antibody-centric brands to offer customers worldwide the full breadth of antibody-related products, services and expertise for research, diagnostic and therapeutic applications. Our mission is to serve as “antibody curators” for customers worldwide, treating each antibody like a work of art to deliver unique and absolutely defined reagents that empower scientists. Brands within the Absolute Biotech family include: - Absolute Antibody, experts in antibody engineering and recombinant antibody technology - LSBio, leaders in IHC validation with a comprehensive catalog of antibodies, proteins and ELISAs - Kerafast, which makes unique laboratory-made research tools easily accessible to the global scientific community - Nordic Mubio, which develops antibody and flow cytometry reagents according to ISO 9001 guidelines - Everest Biotech, specialists in anti-peptide and antigen affinity purified goat polyclonal antibodies - Exalpha, which offers cutting-edge antibodies, reagents, kits and custom IgY services

Ab Studio Inc. is a biotech company in the San Francisco Bay Area. We have extensive knowledge and expertise in the discovery, optimization, and development of therapeutic antibodies with complex designs, and combine conventional approaches with computer-aided antibody design in this process. Ab Studio believes in 'Quality by design' and aims to address current limitations in the field of therapeutic antibodies with novel technology platforms including multi-specific and internalization antibodies. Please visit our website for more details and partnership/service opportunities http://www.antibodystudio.com

Abterra Biosciences is reimagining antibody discovery and sequencing by harnessing the latest next-generation sequencing, mass spec, machine learning. Abterra Biosciences is enabling the next-generation of antibody therapeutics. Our technologies use the latest in next-generation sequencing.

AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive partnership with Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and FTO. For over 20 years, AbTherx’s passionate, innovative, and collaborative team has pushed the boundaries of antibody discovery technologies, leading to over 1,000 successful antibody discovery campaigns and 13 marketed therapeutics. AbTherx’s industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes.

Abveris is a world leader in in vivo antibody discovery and a division of Twist Bioscience. We partner with leading biopharmaceutical scientists across diverse organizations to discover and develop antibodies for diverse pharmaceutical and industrial applications.

Abzyme Therapeutics is a biopharmaceutical company focused on developing modular single domain VHH antibody fragments for immunotherapy using proprietary antibody generation platforms. The company is located in the Eastern Pennsylvania biotechnology/pharmaceutical hub 30-miles west of Philadelphia. Unique to Abzyme is our proprietary and highly engineered eukaryotic in vitro antibody discovery/optimization platform based on yeast display self-diversifying libraries, rapid target-directed antibody affinity maturation in combination with a FACS single cell sorting approach to identify desired antibodies. Abzyme’s modular antibody discovery platform incorporates a real-time screening ability to select for key properties such as epitopic diversity, binding affinity, expressibility, solubility, developability, broad-reactivity and target-specificity. Today, the Company has over 60 proprietary and partnered programs in development in therapeutic and diagnostic areas including infectious diseases, immuno-oncology, ophthalmology, inflammation and central nervous system disorders.

AcceGen Biotech proudly develops innovative technologies for the pharmaceutical, biotech and specialty ingredients markets. We are committed to supplying the best products and services with global manufacturing, development expertise and advanced technologies to enhance the overall quality of life. AcceGen Biotech developed significant expertise in cell and genomic research. We provide a variety of high-quality human/animal cells, cell media/kits, cell-derived molecular biology products, gene-based assay kits, Clones, Fish probes and Sequencing products for research use. AcceGen Biotech offers custom cell line generation, microRNA sponges and microRNA Agomir/Antagomir services to simplify the gene research. The aim is to accelerate scientific discovery related to genetic analysis available to academic researchers as well as commercial enterprises. AcceGen Biotech has permanent facilities in Fairfield (New Jersey). We take care of our customers and their global, regional or local requirements. We welcome potential partners and distributors to explore our business all over the world.

The company providesmolecular biology services includingproduction of antibodies, GPCRs, kinases, nuclear receptors, and many other classes of drug targets and therapeutic proteins

Accel Diagnostics is medical diagnostic company developing proprietary point-of-care diagnostic assay for the diagnosis, monitoring and management of a wide variety of medical conditions. We are dedicated to making a difference in the quality of life of millions of patients through technology and innovation. AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests anytime and anywhere. The Company's patented platform technology transforms the patient blood testing paradigm, from lab-centered to near-patient. The technology bringing significant advantages in terms of simplicity, time to result, care delivery, and cost over current standard lab-based diagnostics. During COVID-19 pademic Accel Diagnostics began to operate the ADX Diagnostic Lab to provide high quality COVID testing in Houston, TX.

Accelerated Biosciences Corp. is commercializing human trophoblast stem cells isolated from the trophectoderm of embryos from women with ectopic pregnancies. hTSCs are ethically sourced and have immune-privileged characteristics. It is an abundant and dynamic pluripotent stem cell platform for basic research, disease modeling, toxicology, drug discovery, and cell therapy.

Accu Reference Medical Lab is a state-of-the-art medical testing laboratory service that provides a complete range of tests for diagnosis, screening or evaluation of diseases and health conditions. We are certified under the federal government’s Clinical Laboratory Improvement Amendments (CLIA) and operate in compliance with all governmental regulations. We use the latest diagnostic technology. As new medical tests become available, we update our list of services. Our laboratory technicians are well trained and have many years of experience, providing the most accurate and precise testing results. We also continuously strive to improve the quality of our testing, data handling and reporting through integrating robust technique and technological advancements. Accu Reference Medical Lab is an equal opportunity employer.

ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising product candidates. ACELYRIN is embedding a corporate culture of Courageous Caring™ -- placing patients first and embracing the concept that all of us are better than any one of us -- as we seek to addresses the most basic human needs: to live a productive life free from diseases.

Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics. ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics. Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.

Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains. This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France. The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies.

Acumen is forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic soluble amyloid-beta oligomers. Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the on cusp of realizing the therapeutic potential of Aβo targeted drugs.

Development of antibodies from phage display discovery

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of metastatic solid tumors. The company was founded in 2011 and is headquartered in Suzhou, China.

AdAlta (ASX:1AD) is the pioneer of a novel technology platform that mimics the shape and engineers key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease. AdAlta is utilising the power of its i-body technology platform to develop a pipeline of i-bodies (drugs), with an initial focus on treating fibrotic diseases.

Adaptin Bio, is a pioneering biotechnology company dedicated to revolutionizing drug delivery. Our focus is on developing innovative technologies that enhance how medications and other therapeutic compounds reach their target destinations within the body. Our core mission is to overcome a major hurdle in medicine: ensuring effective delivery of drugs to specific tissues.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has a translational collaboration with AstraZeneca to investigate the use of immunoSEQ T-MAP. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.

AdaptVac is a joint-venture between NASDAQ First North listed ExpreS2ion Biotech and University of Copenhagen spin-out NextGen Vaccines. The goal of the Joint Venture is to create a world class unit for the development of highly competitive vaccines and therapeutics against infectious diseases, cancer, and immunological disorders. The combination of ExpreS2ion’s proprietary insect cell expression technology, ExpreS2, and NextGen’s unique expertise in proprietary Virus-Like Particle (VLP) technology makes us a strong and versatile player in the field of new vaccines and immune therapy.

Adcendo is a Danish clinical-stage biotech company headquartered in Copenhagen, dedicated to the development of highly differentiated First-In-Class Antibody-drug conjugates (ADCs) for treatment of solid tumors. In November of 2024, the company announced the closing of a USD 135m series B financing round. With a total sum of USD 240m raised since 2021 and under the leadership of a highly experienced management team, Adcendo is moving forward a growing and highly differentiated pipeline of drug candidates into the clinic. Read more at www.adcendo.com

Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies for improving patient treatment options.

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors. Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer. For more information, please visit https://www.adctherapeutics.com/.

Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases.

Adecto is a pre-clinical stage, cancer therapeutics company, developing the first targeted therapy against ADAM8-expressing cancers and a companion diagnostic to identify patients who can benefit from it. ADAM8 is a critical driver of the growth and spread of many aggressive tumors, including those of the breast, stomach, colon, lungs, liver and pancreas, and is associated with poor patient survival. Adecto’s current focus is on breast cancer with a plan to expand to other oncology indications in the future.

ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs.

Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast-based platform is a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. Our partners range from some of the biggest pharma to biotech companies at all stages to leading academic institutions. We're committed to staying at the cutting edge of protein-based therapeutic discovery to enable the highest quality IgGs, multispecifics, CARs and other modalities to allow our partners to have the most successful therapeutic programs possible.

We are a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with our R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, we have built a global pipeline through collaborations and internal discovery with more than 10 drug candidates in development. We have assembled a world-class management team, built our unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation. We are committed to becoming an innovative biopharmaceutical company with global vision and strives to benefit patients worldwide. Our ultimate goal is to transform cancer into manageable conditions.

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

"Innovative medicine for everyone, everywhere"​ Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia is specialized in diabetes and obesity. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. For more information, visit our website: www.adocia.com For careers offers, please click to the following link : https://www.adocia.com/careers/adocia-careers/

Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Enibarcimab is a first-in-class monoclonal antibody. Enibarcimab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Enibarcimab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock.

AdvanBio Inc., www.Advabio.com, a subsidiary of Autobio Diagnostics in the U.S is a fast-growing biotechnological company based in Irvine, CA. Established in 2021. We specialize in providing cutting-edge IVD Quality Control products & Reagents designed for a diverse range of analytes. In addition, we are committed to providing global partners with high-performance IVD Critical Raw Materials and services such as: • FDA Submission • Assay Development • Product Sales • New Technology/Biomarker Development We are committed to the advancement of medical laboratory technology and dedicated to the promotion of human health. We empower medical providers in making pivotal biomarker & diagnostic decisions with our portfolio of innovative technologies. #Advanbio#ADLM

Personalised therapies for the heart and vasculature Innovative, independent, close to the patient. We are a biotech company that independently develops innovative drugs and diagnostics for personalised treatment of cardiovascular diseases. We have a unique product pipeline that we are consistently moving into clinical trials. Our lead compound has been successfully tested in two Phase II studies. We work closely together with excellent academic and clinical teams in basic and clinical research. We use state-of-the-art analytical methods, and we develop our products according to the highest quality standards (GLP, GMP and GCP). Revacept is a therapeutic agent for the prevention and treatment of acute arterial thrombosis, which can lead to heart attack, acute limb ischemia and stroke. A Phase II clinical trial in 160 patients with stroke or transient ischaemic attack (TIA) has been completed. It showed beneficial effects in patients treated with 120 milligrams (mg) of Revacept. Another Phase II clinical trial investigated Revacept in 332 patients with stable coronary artery disease (ISAR-PLASTER) has been completed. This study conducted by the German Centre for Cardiovascular Research (DZHK) confirmed the very good tolerability of Revacept. Overall, Revacept did not lead to increased bleeding despite of its additional platelet aggregation inhibition on top of conventional standard therapy. It decreased ischemic strokes in NMR and improved the net clinical benefit of MACE and bleeding. Recently, the FDA has approved the preclinical and clinical development and the further phase 3 protocol until market approval. Antibody therapeutic In collaboration with Morphosys an anti-GPVI Fab antibody has been discovered. The candidate is currently in preclinical evaluation for the treatment of acute coronary syndrome and stroke. Imprint: https://www.advancecor.de/imprint/ privacy policy: https://www.advancecor.de/privacy-policy/

With a 60+ year history as a service provider to the life sciences industry, Advanced BioScience Laboratories (ABL) provides a strong core of product development expertise, GMP manufacturing, and analytical testing capabilities. Founded in 1961 as a biomedical research contractor for the federal government, ABL has made major contributions to the development and evaluation of a wide range of life-saving diagnostics, vaccines, and therapeutics designed to combat the world’s most challenging diseases. We partner with our clients to support advancement of their candidate vaccines and therapeutics through preclinical and clinical development. With facilities located in the United States, ABL aims to be a seamless extension of our clients’ team – helping them advance today’s ideas into tomorrow’s medicines. ABL's CDMO service division specializes in the development and manufacturing of GMP cell banks and viral vectors from the bench to Phase I/II clinical trials. We aim to contributes to the success of our clients' ground-breaking innovations, including gene therapies, immunotherapies, viral vaccines, oncolytic viruses, and more. ABL's CDMO services include bulk drug substance production, fill/finish of drug products, process development, assay development and release testing.

Aegis Life, Inc. is a biotechnology company founded in early 2020 with a mission to prevent and treat existing, emerging, and future contagions. Our nucleic acid delivery technology Fusogenix PLV stems from more than a decade of research and development in gene delivery. We actively leverage the Fusogenix PLV platform to accelerate the discovery, clinical development, and manufacture of vaccines and therapeutics for infectious diseases.

We are a research-oriented provider of innovative, efficient products and services for early detection, diagnosis and prognosis of autoimmune and infectious diseases, allergies and food intolerances. We strive to improve the diagnosis and management of different diseases as a provider of innovative in-vitro diagnostic products that really work. Built on a tradition of innovation and an interdisciplinary knowledge network, AESKU.DIAGNOSTICS offers unique diagnostic options: faster, more efficient and reliable test systems designed to improve clinical outcomes for the benefit of patients and physicians. Follow us on our other Social Media Profiles. https://www.linkedin.com/company/dst-diagnostische-systeme-&-technologien-gmbh/about/ instagram: https://www.instagram.com/aesku.group/ Contact us: Website: www.aesku.com⁠ E-Mail: socialmedia@aesku.com⁠

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Aethon takes a novel approach to fighting cancer, creating custom antibody therapeutics that unite immunotherapy and targeted therapy.

Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. The company operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that targets psoriasis, and B-cell driven autoimmune diseases respectively. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. Affibody has ongoing commercial relationships with several companies such as AbClon, Alexion, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum. Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Affibody AB is a holding of Patricia Industries.

At Affimed, we are committed to improving outcomes for patients with cancer. Our scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unique approach to fighting cancer. With our unparalleled expertise in innate immunity and innate cell engager-based medicines, we aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Affinity Biologicals Inc. is a biotechnology company based in Ancaster, Ontario, Canada, specializing in hemostasis diagnostics and research. Founded in 1987, the company develops, manufactures, and markets over 250 high-quality reagents and kits used in coagulation and thrombosis studies. Their product offerings include coagulation-related antibodies, matched-pair antibody sets for ELISA, depleted/deficient plasmas, and a line of complete ELISA kits. The company also provides tailored services such as research and development, custom manufacturing, and contract services to support clients in the biotechnology and healthcare sectors. Affinity Biologicals maintains a strong commitment to quality, operating under an ISO 13485:2003 registered Quality System and holding licenses from regulatory authorities like the US FDA and Health Canada. With a dedicated team of around 30 employees, Affinity Biologicals serves a global market through a network of distributors.

Founded in 2006, Affinity Biosciences is a pioneering Life Science and High-Tech company whose biochemical products and services are mainly applied in biotechnology, medical research and pharmaceutical development. Dedicating to advancing customer success through innovation, Affinity Biosciences has established R&D affiliates in the United Kingdom and United States with the aim of providing outstanding service around the globe.Our customers include scientists and technologists in life science companies, university and government institutions, hospitals and industry. To underline our commitment to our customers and enhance our standards of service, we have opened packaging and quality control facilities in the People’s Republic of China. Our goal is to develop high-quality antibody that focuses on Cell Signaling Transduction research, including Akt,AMPK,NF-KappaB,TGF-beta,etc,as well as inhibitors and related reagents.

AffinityImmuno Inc. is a provider of R&D support services for your biological drug research and discovery. We specialize in antibodies, antibody lead discovery, protein engineering, and assay development for targets in cancer, autoimmune, and endocrine disorder therapeutics. Our goal is to help you advance your life science research through innovation and creative problem solving. Let us put our experience to work for you.

Affinity Life Sciences for over 10 years providing the highest quality services for Lyophilization, Reagent Manufacturing, Immunoassay test and more.

We are a clinical-stage biotechnology company that strives to challenge established treatment options for neurodegenerative diseases in order to preserve the quality of life of patients.

AGADA Biosciences is a biotechnology company that specializes in providing expert assistance with drug development programs in neuromuscular disease, offering pre-clinical trials in mouse models and human clinical trial support.

Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFS TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

agilvax.com is your first and best source for all of the information you’re looking for. From general topics to more of what you would expect to find here, agilvax.com has it all. We hope you find what you are searching for!

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

AgonOx, Inc.is a spin-off company from the Providence Cancer Center located in Portland, Oregon. We are developing immune system activators for use in cancer therapy. Research in the field of T-cell modulation conducted worldwide with OX40 and other agents has demonstrated that the use of T-cell modulating therapies in combination with specific anti-tumor therapies have the potential for yielding therapeutic benefits for patients with cancer. AgonOx is focused on the development of immune system modulators in combination with other promising agents in the immune oncology space.

-Artificial Intelligence powered Drug Discovery. -a Biopharma company specialized in medicinal chemistry research of preclinical drug candidates. Ai-biopharma has in-silico solutions of Chemoinformatics, Molecular Modeling, Docking, Data analysis, SAR formatting/interpretation and also an Artificial Intelligence platform for the accelerated drug design towards the selection of new preclinical candidate drugs .

We aim to advance current state-of-the-art AI drug discovery technologies and transform high-cost, low-efficiency drug discovery practices into rapid, efficient discovery, ultimately leading to high success rates in the clinical phase. Our award-winning AI drug discovery platform enables the direct discovery of high potency drugs that induce desired cellular-level activity with minimal off-target effects and toxicity. AIGEN Sciences will revolutionize AI-based drug discovery.

Akamis is a clinical-stage oncology company whose mission is to leverage its groundbreaking T-SIGn® platform to positively impact the lives of people living with cancer. We are developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis’ growing pipeline of T-SIGn® therapeutics is anchored by its lead clinical-stage program, NG-350A, which is being investigated in an ongoing Phase 1 clinical study in patients with metastatic or advanced epithelial tumors. Akamis has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI)

Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing innovative medicines that address global medical needs. Since our inception, we have established a distinctive and integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the fundamental components, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode. Akeso is actively developing a diverse pipeline of over 50 innovative assets in cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields. Among these, 19 assets have entered the clinical stage, with 3 innovative drugs already approved, and 13 pivotal/phase III trials ongoing. Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug for the market. Additionally, the company has five other innovative bispecific antibody drugs in the clinical stage, including ivonescimab (PD-1/VEGF), PD-1/LAG-3, TIGIT/TGF-Beta, PD-1/CD73, and claudin18.2/CD47 bispecific antibodies.

Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.

Albatroz Therapeutics is a pre-clinical stage biotech company developing therapeutic antibodies and ADCs to treat solid tumours and arthritis, based on its proprietary position over a novel target critical to ECM degradation.

Alcala Labs was founded by a partnership between a healthcare attorney specializing in the defense of individual and institutional healthcare providers and a physician with one of the largest pain management practices in Southern California. The lab grew out of frustration with existing laboratory providers and the conviction that Alcala Labs could do better. Smaller labs were not scientifically up to the task and, in many cases, were simply dishonest about the services they provided. Larger labs were either unresponsive or subcontracted critical complex lab services to unaccountable third-party labs . Alcala Labs was built to react quickly to the needs of physicians who need to understand drug use and efficacy in their practices. The Alcala difference is accessibility to its physician customers, responsiveness to their needs and inquiries, and customizable lab testing. If a physician has a medical-legal question that arises from testing, he can immediately reach the company's healthcare attorney President. If a physician requires insight into how a particular test affects the course of a patient's care, she can engage in a dialogue directly with the lab's Medical Director. If there are questions about science and the development of new tests, our highly credentialed scientific team can be reached directly. Widely in demand among a variety of specialties, Alcala Labs is of especial importance to drug rehabilitation, pain management, and psychiatry practices. We're able to add assays as illicit "designer" drugs begin to appear, and our new pharmacogenetic department gives physicians the power to anticipate the right drugs and dosages to best treat their patients. Located in San Diego, Alcala is a laboratory of national reach and reputation. It is among the fastest growing labs in the country, dedicated to state-of-the-art science and the highest quality service.

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

Founded in 2017 and headquartered in Paris, France, Alderaan Biotechnology works with world-class teams in the fields of immunomodulation and immunotherapy of cancer focusing on the development of monoclonal antibodies with technologies aiming at Treg depletion in solid tumours. The company raised €1.5M ($1.7M) in 2017 from co-founder AdBio partners and €18.5M ($20.7M) in 2019 from AdBio partners and Medicxi. Alderaan Biotechnology works in partnership with the French national Institute for health and medical research (INSERM) and with the Institut Paoli Calmettes, Marseille, France.

Aldevron is proud to be part of Danaher. Aldevron is a leader in advancing biological science. Our custom development and manufacturing services have provided scientists around the world with the tools to make significant scientific advances. We provide high-quality plasmid DNA, proteins, enzymes, and other biologicals to help our partners achieve ground-breaking science.

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company that focuses on developing first-in-class breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors. In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).

Privately-held Montreal-based biotechnology company Engaged in the discovery and development of therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. Currently having one clinical-stage program with phase I data. Portfolio of highly-specific, novel and clinically-relevant targets using the proprietary STAR technology. Exploiting a powerful a proprietary target discovery technology with the potential to expand pipeline. Established strategic partnerships to access mAb generation, humanization, antibody-drug conjugates, and CHO production technologies

Our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. By continuing to deepen our understanding of rare disease, which began with our pioneering work in complement biology, we are able to innovate and evolve into new areas where there is great unmet need and opportunity to help patients and families fully live their best lives. Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work. We invest in and value people who believe in the importance of our purpose and understand what it takes to deliver on it. Alexion has over 3,000 talented colleagues dedicated to serving people living with rare diseases in more than 50 countries around the world. Our global headquarters are based in Boston, Massachusetts and our EMEA headquarters are in Zürich, Switzerland. We also have a Research Center of Excellence in New Haven, Connecticut, global supply chain and operations headquarters in Ireland, as well as local and regional operations in countries around the world. At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people living with rare diseases, and the communities we serve. Every day.

AlivaMab Biologics is a biotechnology company based in San Diego, California, focused on therapeutic antibody discovery and development. The company provides integrated solutions to accelerate the creation of biologics, delivering fully human antibodies with a commitment to speed and reduced development risks. Their mission is to create efficient pathways for partners in the pharmaceutical and biotechnology sectors. The team at AlivaMab includes experienced professionals from leading global pharmaceutical companies, contributing to over 500 discovery programs and 35 clinical candidates. They utilize advanced technologies, such as the AlivaMab® Mouse platform, to generate high-quality antibodies and offer a range of services, including antibody engineering and target validation. AlivaMab collaborates with numerous top-tier pharmaceutical companies, with several of their antibodies currently in clinical trials.

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.

Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical researchers. The company was founded by scientists and other professionals with the goal of advancing discovery and innovation. Our mission is to increase accessibility to innovative molecular biology research tools by offering cutting edge products at a reasonable cost, and providing excellent customer service in addition to the technical knowledge needed to facilitate their use. Our knowledgeable scientists and technicians are available to answer questions regarding any of our products. Over the past decade, Allele has become a reliable source for a wide variety of Molecular Biology reagents, superior fluorescent proteins, camelid derived nano antibodies (nAb), cellular reprogramming services and reagents, and immundiagnostic kits and various other products and custom services.

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator´s technology platform comprises the proprietary technologies ALLIGATOR-GOLD® and FIND®. ALLIGATOR-GOLD® is a human antibody library containing more than 60 billion unique antibody fragments. FIND® (Fragment Induced Diversity) is a molecular evolution technology for optimization of antibodies and other proteins. Immunotherapy of cancer: The immune system protects the body from attacks by pathogenic microorganisms (e.g. viruses and bacteria) and by cancer cells. Cancer cells usually evade the immune system, for example by producing immunosuppressive substances. Thus, although tumors often contain a large number of immune cells that should be able to attack the cancer cells, they are unable to do so due to the immunosuppression caused by the tumor. With immunotherapy, the ability of the immune system to fight cancer cells is improved in an effective manner, and the defense mechanisms used by the tumor are blocked or weakened. In addition, immune cells capable of destroying the cancer cells will survive in the body and thus protect it from metastases that may arise after treatment has ended. This "vaccination effect" is unique for immunotherapy.

Allinaire is developing humanized anti-endothelial monocyte activating polypeptide II (EMAP II) monoclonal antibodies, which are currently being progressed as a potential disease-modifying treatment for PAH. Allinaire was founded in 2016 by BioMotiv (www.biomotiv.com; now managed by Advent Life Sciences, www.adventls.com), with the licensed technology from Indiana University. EMAP II is a non-classical cytokine which impacts apoptosis, cell injury, endothelial cell function and inflammation. Based on the pioneering work by the scientific founders, Matthias Clauss, PhD and Irina Petrache, MD, and their colleagues at Indiana University and National Jewish Health, Allinaire Therapeutics and their network of preclinical and clinical scientists, have demonstrated a pivotal pathogenic role of EMAP II in cardiopulmonary diseases, including pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease (COPD), and viral-induced acute lung injury.

Founded in 2023 and based in Shanghai, China, Allink Biotherapeutics is a biotech company dedicated to expediting the development of a diverse pipeline of FIC/BIC therapeutic candidates for oncology and immune diseases. Our goal is to harness our proprietary bispecific antibody and ADC technology platforms, along with efficient execution and business collaboration , to address critical unmet clinical needs.

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. From academics and biotechs of every size to large pharma, we democratize access to foundational, pre-competitive biologics discovery technologies and services to enable drug discovery across six biologic modalities. When you partner with Alloy, you can: • Access our ever-growing stable of services and cutting-edge technology platforms to help you discover the best therapeutic antibodies against your targets • Unlock the therapeutic potential of T cell receptor (TCR) modalities through our fully integrated Keyway™ TCR Discovery service offering • Reach intracellular disease targets at the nucleic acid level with our novel AntiClastic™ ASO Format, which enhances the drug-like properties of antisense • Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA, with labs in Cambridge, U.K.; Basel, CH; San Francisco, CA; and Athens, GA. We reinvest 100% of our revenue into innovation and access to continuously develop new groundbreaking platforms and protocols to make our collaborators more successful.

Allterum Therapeutics is a biopharmaceutical company developing an immunotherapy for pediatric acute lymphoblastic leukemia.

Alopexx Enterprises works with scientists and entrepreneurs to build successful new companies. We invest in novel health care technologies at all stages of development and can serve as a lead investor or collaborate with a group of investors to advance important science. We also have the capabilities to provide management and development expertise where needed. To date, our initial investments have ranged from $1-20M. The Alopexx team consists of experts who have deep industry knowledge and technical expertise in all areas of drug development including, pharmacology, CMC, toxicology, medical and clinical operations, quality and regulatory affairs. We form collaborations with academic institutions, biotech and pharmaceutical companies to advance our portfolio companies to deliver breakthrough therapies to patients in need. Our business model is to invest and develop to an important inflection point and then partner the asset for further development and/or commercialization. Portfolio companies include: -Alopexx Pharmaceuticals -Alopexx Oncology -Alopexx Vaccine -Valerion Therapeutics -Janus Biotherapeutics -Cognoptix

We are a leading global developer and provider of innovative molecular and immunodiagnostic products focused on Infectious and Gastroenterological Diseases. We are a trusted partner creating value for research and clinical laboratories with high-quality, user-friendly, reliable and accurate solutions. We achieve this through a culture of respect, dedication, empowerment and creativity.

Alphageneron Pharmaceuticals, Inc., is a privately-held clinical stage biotechnology company, developing Antibody Drug Conjugates (ADCs) and natural killer (NK) cell therapies, supported by Companion Diagnostics. Our team are industry veterans with experience in both large pharma and biotechnology startups committed to transforming the lives of cancer patients.

Alphamab Oncology (Stock code: 9966.HK) is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment. With multiple in-house proprietary platforms in bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/ immunology, and we are striving to develop next-generation or best-in-class medicines to address unmet medical needs globally.

ALTEOGEN Inc., Daejeon(fifth-largest metropolis)-based in South Korea, is a leading biopharmaceutical company with a leading edge pipeline of novel biologics such as next generation biobetters including long-acting therapeutic proteins, Antibody-Drug Conjugate (ADC) therapeutic antibodies and monoclonal antibody biosimilars. The company was founded in 2008 and listed in KOSDAQ stock market (KRX:196170). Our innovative NexP™ fusion technology is applied to various proteins and peptides to allow longer activities in human beings. Long-acting human Growth Hormone, long-acting exenatide (for diabetes) and long-acting Factor VIIa (for hemophilia) are developed with the NexP™ fusion technology. Our proprietary ADC technology, NexMab™ ADC technology is well suited for the targeted therapy for the cancer drugs with lower side effect and better efficacy. With this NexMab™ ADC technology, we are developing ADC therapeutics for breast/gastric cancer and ovarian cancer. Alteogen's mostly distinguished Hybrozyme™ technology to a human hyaluronidase, which has been widely used to improve the absorption of drug biologics delivered via subcutaneous injection. The novel human hyaluronidase based on Hybrozyme™ technology showed improved enzymatic activity and thermal stability. Based on long and rich experiences, Alteogen has quickly developed its own cell lines with high expression, efficient process (upstream and downstream), and optimized analysis methods for monoclonal antibody biosimilars including Herceptin preparing for the phase 3 trials upon completion of global phase 2 testing, SC formulation of Herceptin biosimilar as well as working on Eylea biosimilar.

At Altratech, we are moving serology and the monitoring of viral contagious diseases out of the laboratory to the point-of-care and community clinics. We are a team of twenty scientists and engineers, including nine PhDs, from cross-functional backgrounds of molecular biology, organic and synthetic chemistry, microfluidics, engineering and CMOS semiconductor technologies. With over 200 years of combined experience, our vision is to create portable high-performance diagnostics which will enable the next generation of decentralised connected healthcare and wellbeing.

AltruBio is developing first-in-class immunomodulators to target diseases of the immune system. Our world-class global team brings a breadth of expertise in immunology and drug development to bring our biologic treatments to patients.

Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.

Launched in February 2024, Alys Pharmaceuticals is an innovation leader in immuno-dermatology, co-founded by Medixci and world-leading dermatology and scientific experts. Originating from the aggregation of six asset-centric Medixci compannies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications. With a vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet medical need, Alys aspires to redefine the landscape of dermatological treatments.

Alyssum Therapeutics, a biotechnology company which is developing next-generation immunotherapies to modulate B cells

Alzinova AB is a Swedish clinical-stage biopharma company developing treatments for Alzheimer’s disease by specifically targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that has unique ability and precision to target the toxic amyloid-beta oligomers involved in the onset and progression of the disease. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further.

AmberGen® is a biotechnology company and producer of Miralys™ spatial biology imaging solutions. Miralys™, also known as MALDI HiPLEX-IHC, is a new breakthrough method for targeted intact protein imaging that has unique multimodal imaging capabilities. First introduced in 2022, it has gained significant traction, including 8 of the top 10 pharma companies, as well as many of the world's premier research institutions. It is currently being used to study tissues for a wide range of diseases including cancers, Alzheimer's and Parkinson's diseases; and even COVID. Benefits include: - Drug/target co-localization on the same sample, same instrument - The ability to produce images that co-register small molecule lipids and metabolites as well as the intact targeted proteins. - The product's combination of fast, targeted, protein imaging (scan time as short as 45 min and 1cm2), ultra-high plex (10 to 100+), wide viewing area (up to 25 x 75 mm), and multi-modal capability make it an ideal technology for doing initial scans to identify regions of interest for later deep-dive analysis. - Miralys™ requires no dedicated instrument, and minimal investment to start using. It is used on MALDI Mass Spec Imaging instruments that your institution most likely already owns, such as the industry-leading instruments from our partner, Bruker Corporation.

Focusing on generating innovative biological respondents with a unique mode of action coupled with conditionally activated characteristics, we handle high-value disease targets with huge upside potential, which are otherwise intractable for traditional targeting approaches.

At Ambient Biosciences, we are dedicated to being a true partner in your success. We bring the same spirit of versatility, transparency, and innovation to our customer relationships as we do to our technology. Our approach is to take the mystery out of biomolecule stabilization, making it an accessible and collaborative process that empowers you to feel confident about your products and assays.

Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient’s own immune system by targeting the ß and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. Ambrx Biopharma Inc. has collaborations with various pharmaceutical companies, which include Bristol Myers Squibb Company; AbbVie Inc.; Astellas Pharma Inc.; and Elanco Animal Health. The company was founded in 2003 and is based in La Jolla, California.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

AmMax is a private biotechnology company focused on the clinical development of innovative cancer therapeutics. The Company strategically acquires oncology assets to develop into innovative and clinically meaningful products. It leverages its expertise in translational science to pursues first-in-class or best-in-class therapeutics with significant market opportunity. The company is focused on leveraging its CSF1R mAb platform licensed from Amgen, to launch multiple oncology products that address colorectal cancer with minimal residual disease (CRC MRD), tenosynovial giant cell tumors (TGCT), and an antibody-drug-conjugate construction for acute myeloid leukemia (AML) and solid tumors. AmMax has a very experienced management team, led by Dr. Larry Hsu, co-founder and former CEO of Impax Laboratories, Inc., which he successfully built into a fully integrated multi-billion dollar publicly traded pharmaceutical company. With broad experience across therapeutic areas and therapeutic modalities, the AmMax team is strong in execution and has collectively brought multiple BLAs, NDAs and MAAs to approval and commercialization. With a seasoned management team, a versatile technology platform and a robust pipeline, AmMax is poised to grow into a leading biotech company. For more on AmMax Bio and its pipeline, please visit the Company’s website at: www.AmMaxBio.com.

Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

Amplitude Ventures is a capital catalyst for highly innovative companies at the point of value acceleration. We work with Canada's most promising healthcare companies that share our vision of bringing groundbreaking technologies to patients. Amplitude is focused on building world-class Canadian companies in precision medicine and next-generation medical devices. Since 2012, the Amplitude team has deployed a venture growth model used to build Canadian companies with world-class management teams and scale companies to breakout potential. This model has been used by the team to create, build, and grow companies, resulting in over $1 billion in company value. Our offices are in Montreal, Toronto, and Vancouver.

Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis. Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.

AnaptysBio ($ANAB) is a clinical-stage biotechnology company focused on transforming patient health by discovering and developing innovative immunology therapeutics. Our broad portfolio of immune cell modulators includes two checkpoint agonists in clinical-stage development. We are dedicated to making a difference in the lives of people living with autoimmune and inflammatory diseases.

AnaSpec, a subsidiary of Kaneka Eurogentec, is a globally recognized biotechnology company that manufactures and sells custom and catalog Peptides, Fluorogenic and FRET Assay Kits, Fluorescent Dyes, Amino Acids and more, for research use, drug discovery and diagnostic use. We also manufacture custom Peptide based starting materials for GMP applications. As a trusted and long-standing provider to the biopharmaceutical and diagnostic industries, academia, and governmental institutions, we aim to empower the scientific community in their endeavors to elucidate diseases and enhance health and well-being, through our quality proteomic products and services. Our team of experts strive for excellence with honesty and transparency on behalf of our customers. AnaSpec established in 1993 is certified to ISO 9001:2015.

A start up based in Switzerland that develops biologics to modulate the functions of cytokines and provide substantial therapeutic benefits to cancer patients.

Ancora Biotech LLC is a privately held company supporting the clinical development of three multi-specific antibodies. These three antibodies are held in separate spin-offs, namely: 1) TeneoTwo holds our clinical stage TNB-486 (anti-CD19xCD3) T cell engager for the safe and effective treatment of B cell cancers, 2) TeneoFour holds our preclinical TNB-738 (anti-CD38) enzyme inhibitor for the treatment of inflammatory and metabolic disorders in the elderly, and 3) TeneoTen holds our preclinical T cell engager (anti-HBVxCD3) for the curative treatment of chronic hepatitis B infections (CHB). TNB-738 is poised to enter Phase I clinical studies by early 2022 and we anticipate to select a clinical lead for CHB by mid-2022. Certain former executives and former shareholders of Teneobio, including Lightspeed Venture Partners and Sutter Hill Ventures, have formed Ancora Biotech to oversee all manufacturing and clinical development of these assets.

Andson Biotech is dedicated to advancing mass spectrometry workflows by enabling simple and fast sample-to-analysis workflows. Andson's DynaChip platform leverages advanced microfluidics packaged into an easy-to-use system to make sample prep for mass spec faster (and easier) for everyone. Our platforms are designed to be flexible - they couple with any commercial MS system for on-demand mass spec analysis with no expert training required. Our focus today is on improving sample preparation and workflow integration so that everyone can get more out of their mass spec.

Angeles Therapeutics is a next generation cell and immune therapy company based on the technology licensed from the laboratory of its founder @PreetChaudhary. Angeles has developed a novel CAR-T and CAR-NK platforms that provide physiological TCR signaling and overcomes most of the limitations of current generation CAR-T. Most importantly, our platform is highly effective against solid tumors. Angeles has also developed one of the largest portfolio of CAR-T and CAR-NK in the world targeting more than 130 antigens covering cancer, infection and immune disorders. Our platform is fully compatible with autologous, allogeneic, universal and bispecific approaches. Angeles has recently entered a partnership with a global major pharmaceutical company and is looking for additional partnership opportunities for further development of its portfolio.

Angel Pharmaceuticals was founded in 2020, focusing on develop, produce and sale of innovative oncology drugs. We develop four innovative drugs in China and build a platform for new drugs, aiming at the unmet medical needs of China's cancer drug market, and build China's first-class innovative drug company. Our management team has decades of clinical and drug research and development experience, which lays a solid foundation for the development of new drugs.

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located.

Angios is a biotechnology company, specializing in vascular research to improve patients' lives all over the world. We are based in the beautiful city of Innsbruck. We strive to develop new treatments for challenging diabetic vascular diseases by pursuing pre-identified targets for diabetic retinopathy and by leveraging the vascular organoid model developed in the laboratories of our founders.

Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key unmet medical needs of serious musculoskeletal diseases. With the team’s experience and scientific expertise in new drug development, Angitia is dedicated to bringing innovative therapeutics to help patients in need.

Animab is a new venture designed to address the changing needs of animal production. Using proprietary research discoveries, Animab targets the emerging science and new possibilities in the gut. The interdisciplinary team integrates cutting-edge research, animal science, and biotechnology for product breakthroughs in animal health, cost-efficiencies and sustainability. Led by an experienced group of experts with expertise in a range of relevant domains from vaccines, biotechnology, business management and international marketing, Animab is dedicated to offering a safe and sustainable way to ensure animal performance. More information: www.animab.com.

Ankyra is developing a novel approach for cancer treatment called Anchored Immunotherapy, promoting prolonged immune activation locally while limiting systemic toxicity.

Annexon Biosciences is a clinical-stage biopharmaceutical company developing novel therapies for autoimmune and neurodegenerative diseases, including ophthalmic diseases.

At Annovis Bio, Inc., we are pioneering a novel approach to fighting chronic and acute neurodegeneration, offering new hope against the largest unmet need of our aging population - Alzheimer’s and Parkinson’s diseases. Our diverse pipeline also targets such neurodegenerative conditions as traumatic brain injury (TBI), stroke, Down Syndrome, Huntington disease, and mental illnesses. Our lead compound, buntanetap, is a small, once-daily, orally administered, brain-penetrant inhibitor of neurotoxic proteins. The biological activity of buntanetap has been evaluated in 19 animal studies conducted in leading institutions such as the Karolinska Institute, Columbia University, and Harvard University. We have also conducted seven clinical studies in over 1,000 people, which consistently showed that buntanetap is safe and well-tolerated. Moreover, buntanetap has shown the ability to normalize levels of several neurotoxic proteins – APP, tau, aSYN – to those seen in healthy volunteers. In our late-stage trials, buntanetap significantly improved cognitive functions (ADAS-Cog11) in patients with mild Alzheimer’s disease, halted cognitive decline in Parkinson’s patients, and improved motor and non-motor Parkinson’s-related functions (MDS-UPDRS) in several disease subpopulations. We are currently in the process of submitting our latest data to the FDA and planning two pivotal Phase 3 studies—one for Alzheimer’s and one for Parkinson’s. We believe that buntanetap holds the potential to be the first drug to address the underlying mechanisms of neurodegeneration, heralding a new era in the treatment of these debilitating diseases.

Anogen-Yes Biotech Laboratories Ltd. is a biotech company located in Mississauga, Canada. Founded in 1989, we have been a proud supplier of high quality antibody-based products for 30 years. We offer more than 300 monoclonal and polyclonal antibodies and more than 60 types of ELISA kits for research, diagnostic and therapeutic applications. As a research-focused company, we have also developed many a number of proprietary diagnostic and therapeutic products. Our product Abcream, an effective anti-IL-8 (CXCL8) monoclonal antibody topical treatment for psoriasis, had received approval by State Food & Drug Administration (SFDA) of China in 2001 and many international patents. Our neonatal TSH ELISA kit for diagnostic purposes has also been licensed by Health Canada. We also initiated research and developed products for inflammation, Alzheimer’s disease, and cancer. Learn more about our R&D projects under the “R&D Projects” tab. We have been ISO certified since 2000. We guarantee that every product delivered to our customers is of the best quality. With our in-house cell bank of more than 1000 hybridomas, we are able to monitor and control the entire manufacturing progress to ensure that our antibodies and ELISA kits are the best on the market. We provide antibodies, ELISA kits, and other lab reagents to major biotechnology and pharmaceutical companies, laboratories, hospitals, and academic and government research institutions around the world. We also work with distributors across the globe to make our product more accessible. At Anogen, we devote ourselves to produce high-quality and reliable antibody products for biomedical research, and hope that our contributions to the field can benefit patients, and improve the future of medicine.

Founded in 2002, ANP Technologies, Inc. is an emerging nanobiotechnology company with a major focus on design, development, and marketing of innovative technologies. ANP Technologies, Inc. is a nanobiotechnology company with cutting-edge technology platforms focused on: • Specialty CRO for biological drug R&D • Biodefense and homeland security • Home/point-of-care diagnostic systems • Nanoencapsulation and targeted drug delivery and therapy

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of Treating Patients Beyond Borders. Since 2017, Antengene has built a pipeline of 9 oncology programs at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. We have successfully obtained marketing authorizations for selinexor, Antengene’s lead asset, in multiple Asia Pacific counties and regions including mainland China, Taiwan,China, South Korea, Singapore, and Australia.

Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases. Anthos Therapeutics aims to combine the agility of a biotech with the rigor of a large pharmaceutical company. Anthos Therapeutics was launched by Blackstone Life Sciences in 2019.

Antibodies Incorporated is a biotechnology company that specializes in manufacturing and distributing monoclonal and polyclonal antibodies, diagnostic reagents, diagnostic kits, and developing ImmunoAssays.

Antibody Research Corporation is a biotechnology company that specializes in offering custom antibody and protein services including monoclonal and polyclonal antibody development, gene cloning, in vitro antibody production, cell line engineering, and assay development.

Antibody Solutions is a privately held American contract research organization that helps biopharmaceutical companies advance their discovery of better diagnostics and therapeutics by delivering fit-for-purpose antibodies. The company provides comprehensive project management and technical support in a fee-for-service model. Antibody Solutions has expertise in immunology, immunochemistry, biochemistry, molecular biology, cell biology, transgenic animal platforms, flow cytometry, recombinant expression, and bioreactor technology. Antibody Solutions has served more than 500 clients, including all of the top 10 global pharmaceutical companies. Founded in 1995, the company is headquartered in Santa Clara, Calif. and works with clients worldwide. A leading developer of therapeutic, biomarker and critical reagent antibodies, Antibody Solutions provides elements vital for successful antibody discovery, including: Antigen design and generation Monoclonal and polyclonal antibody generation Monoclonal and polyclonal antibody production and purification Biological characterization (sensitivity, specificity, agonist/antagonist activity, internalization) Physico-chemical characterization (affinity, amino acid sequence, purity) Conjugation of antibodies and proteins Antibody engineering and recombinant expression Analytical methods development (ELISA, Flow Cytometry, PK/PD, ADA, Flourescence-Activated Cell Sorting) The company offers 24/7/365 online project management and tracking service.

Antigen Targeting & Consulting Service Incorporated (ATCS Inc), a biotech company formed in 2009, is dedicated in providing top-quality custom services for the development of vaccines and immunotherapies. The company specializes in targeting antigens to cell surface molecules on dendritic cells for vaccine development, as well as the development of PSMA-targeted PET imaging agents for improved diagnosis of prostate cancer. ATCS Inc also focuses on the translation of multi-antigen targeted off-the-shelf therapies for various medical conditions.

Antikor is a privately-held biotechnology company originally spun-out from Imperial College. We specialise in the discovery and development of small-format Antibody (Fragment) Drug Conjugates, known as FDCs. FDCs are a form of targeted cytotoxic chemotherapy combining the specificity of antibodies with the potency of small-molecule chemotherapy drugs. Specifically, FDCs are smaller than conventional Antibody Drug Conjugates (ADCs) meaning better tumour penetration and more rapid systemic clearance, potentially leading to a higher clinical therapeutic index. Antikor are developing the next-generation of solid tumour therapies, with a major interest in gastro-intestinal cancers.

ANTITOXIN GmbH is a biotechnology company that specializes in producing Blood Typing Antisera and Rare Sera for various blood groups.

Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics.

Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company headquartered in the San Francisco Bay Area. We are advancing our product pipeline of improved cytokines (Exenokines, Mableukins etc) and tumor-targeting antibody drug conjugates. Our lead product, Exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies. Our mission is to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases. We specialize in the discovery and development of optimized immunotherapeutics, leveraging our core expertise in cancer immunotherapy, bioinformatics, and target-based protein evolution.

APEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies.A drug candidate developed by APEIRON Biologics named APN01 is being tested in China in a phase one pilot trial as a treatment for Covid-19. APN01 is based on research conducted by a professor at the University of British Columbia for treating SARS. The research revealed that the ACE2 protein was the main receptor for the SARS virus.

Apertura is a biotechnology company opening opportunities in gene therapy for treating debilitating diseases with limited options. We are pioneering next-generation AAV gene therapies by simultaneously engineering capsids, regulatory elements, and payloads to overcome current limitations in genetic medicine. Founded on technologies from the Broad Institute and Harvard University, and with support from Deerfield Management Company, we are located at the Cure in New York City.

Apeximmune's mission is to harness the power of the immune system to treat cancer and autoimmune disease. We focus on discovering and pioneering powerful therapeutic antibodies against innovative targets that shift the balance of immune cell activity and deliver lasting, transformative medicines.

Apheon Bioscience specializes in research and development to support life sciences research through recombinant molecular biology technologies. Apheon Bioscience is committed to helping large and small organizations identify novel disease biomarkers to advance first-in-class immunotherapies. Apheon Bioscience offers affinity-based tumor antigen and biomarker discovery services that simultaneously provide therapeutic lead compounds. Other areas of research include the development of recombinant immune-particles to enhance complex immunoselection procedures and for precision diagnostics. We are also utilizing our platform for synthetic biology applications by creating novel abzyme (antibody-enzymes) capable of boosting catalytic enzymatic activity. We offer all our goods and services to assist academic laboratories and life sciences companies. Our mission is to streamline and boost research productivity in a cost-effective manner to help drive discovery. We welcome partnerships to develop immunotherapies for diseases with unmet medical needs. Our affinity-based antibody development platform profiles disease states based on antigenicity and provides both the biomarker target and corresponding therapeutic lead all-in-one. Lead compounds can be reversed engineered into recombinant human monoclonal antibodies, CAR-T therapy, or converted into antibody drug conjugates (ADC). The platform can also be deployed for precision medicine serving as a diagnostic to guide combination treatment decisions. Please visit us today to see how we can help propel your research and development needs in a more cost-effective manner.

APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutic assets into clinical utility. APIS has deep expertise and capabilities in IVD development of molecular & immune assays for ultimate product realisation as diagnostic tests. In addition, APIS' expertise in bioinformatics and software development is offered as an agile service to our clients, to develop bespoke, end-to-end multi-OMICs solutions and platform development. APIS has also developed a broad breast oncology product portfolio: The APIS Breast Cancer Subtyping Kit is a reproducible RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. The APIS ESR1 Mutations Kit is a qPCR assay for the sensitive detection of eleven key mutations within the oestrogen receptor gene. Coming soon - the new APIS PIK3CA Mutations Kit is a qPCR assay for the sensitive detection of key mutations in the PIK3CA gene.

APITBIO is a biotech company that specializes in antibody therapeutics research and development.

Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders.

Apogenix develops innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby reducing lymphopenia and inflammatory cell death in patients with viral infections and restoring the anti-tumor immune response in cancer patients.

Applied Biomics is a proteomics service company that provides top-quality, cost-effective, and full-line proteomics services to meet customers' research and discovery needs.

Advancing Gene and Cell Product Development Through iPSC and Genome Editing Technologies Applied StemCell strives to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry to assist in the development of breakthrough therapeutic approaches to cure intractable diseases. ASC is a trailblazing CRO/CDMO committed to building a complete iPSC-Gene Editing platform for the production of iPSC-derived products for gene and cell therapy research and development. With the integration of our unique iPSC approach and IP-based site-specific large cargo insertion technology, TARGATT™, we (1) develop immune-compatible master iPS cell lines and (2) deliver large DNA fragments to pluripotent cells that have proven differentiation capabilities. We stand at the forefront of the iPSC-based therapy revolution delivering research- and GMP-grade iPSC solutions along with various downstream assay services. Current Offerings: • iPSC Cell Line Models: iPSC generation, CRISPR & TARGATT™ genome editing, differentiation • Cell Gene Product CDMO: TARGATT™ iPSC Platform for allogeneic cell therapy products/GMP iPSC reprogramming, cell banking, gene editing, and differentiation • Bioproduction: TARGATT™ CHO cell system for antibody screening and bioproduction/TARGATT™ HEK293 cell system for library/antibody screening • Animal Models: Custom and off-the-shelf CRISPR & TARGATT™ mouse models For patent licensing, business development, and investment inquiries, please contact us at info@appliedstemcell.com.

Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants. Apriori was founded in 2020 in Flagship Labs, a unit of Flagship Pioneering.

Biopharmaceutical company focused on developing and manufacturing biosimilar products, new protein drugs and bispecific antibodies

APTAGEN Labs is a biotechnology company offering aptamer and aptabody custom-based services to replace antibodies in research, diagnostic platforms, drug discovery and therapeutics. Aptagen was formed in 2004. Operations began in 2006. Aptagen is located in Jacobus, PA, a suburb of York, beautifully surrounded by Lake Redman and conveniently situated off of Interstate 83. The facility is a forty minute drive from Johns Hopkins University and Hershey Medical Center.

Aptahem AB is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in patients diagnosed with a septic condition, among others. The company holds patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.

AptaMatrix is a privately held, start-up biotechnology company headquartered in Syracuse, New York. The company's focus is to accelerate the rate of aptamer discovery using its patent pending High Throughput Screening of Aptamers (HTSA) approach in addition to developing its novel AlloSwitch™ sensor technology capable of a) creating rapid diagnostic tools for detection of chemical and biological targets, and b) leveraging this diagnostic platform for drug discovery applications. AlloSwitches™, have demonstrated the ability to transduce molecular recognition of biological targets into a real-time (seconds) optical signal for identifying environmental and terrorist released contaminants in liquid systems. HTSA and AlloSwitch solutions are built on patented biotechnology based on years of leading-edge biological research and industry partnerships at Syracuse University. The HTSA approach leverages the high throughput capabilities of deep-sequencing technology. All sequencing activity is managed by our Genomics Division and conducted on our Illumina GAIIx platforms. Data analysis is supported by our in-house bioinformatics team. In addition to supporting internal research and development, our genomics division actively supports both academic and commercial deep-sequencing projects.

Aptarion is dedicated to leveraging the strengths of biostable L-aptamers (highly specific "chemical antibodies") across the biomedical spectrum. Besides the discovery of new L-aptamers for the functionalization of sensors with its powerful platform technology, Aptarion pursues the development of its proprietary existing L-aptamers as therapeutics in areas of high medical need.

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Based in Seattle, Washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. As a result, Aptevo has been able to attract some of the most innovative minds in the field. Many of our team members have notable experience with other pioneering biotech companies including Trubion, ZymoGenetics, Immunex, Dendreon, and VLST.

Aptitude Vision is a biotechnology company that specializes in developing next-generation synthetic biomolecules for treating vision-threatening diseases by simultaneously targeting multiple pathological processes.

Drug discovery remains an expensive and time-consuming process. Promising compounds proceed through clinical trials only to have many fail before FDA approval. Aracari Biosciences aims to simplify this process by more accurately and efficiently evaluating promising drug compounds in a human tissue-on-a-chip model prior to clinical trials. Our​ proprietary, Vascularized Micro-Organ (VMO) platform is the first to contain a 3D, perfused network of living, dynamic human blood vessels that deliver nutrients and drugs directly to tissues just as in the body. Ask about our oncology models that incorporate multiple human tumor types within the vascularized tissue or our blood-brain barrier model for testing trans-barrier transport of drug compounds targeting the brain.

Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

Arbele is a locally grown pharmaceutical biotech focused on immunotherapy of cancers, immune disorders and neurological diseases. The company founding team has a strong combination of business development and pharmaceutical R&D, with an accumulation of >30 year experience in multinational drug companies. Our motto is to excel patient healthcare through innovation and breakthrough. Our mission is to deliver innovative and cost-effective therapeutics to treat diseases of unmet needs. We focus on antibody-based therapeutic platforms, including chimeric antigen receptor (CAR)-T and Bi-specific antibody technology, while leveraging new technology on CRISPR genome editing. Our culture ingredients are “integrity and social values”.

Arbor Assays is the first employee-owned life sciences company and is dedicated to advancing scientific discovery by providing innovative and reliable assay solutions. Our mission is to equip researchers and scientists worldwide with high-quality scientific tools and support their objectives with unparalleled customer service. Arbor Assays strives to be a trusted partner to our customers through our commitment to quality, integrity, and collaboration. As employee-owners, we are driven not by investor demand, but rather by a shared sense of responsibility to each other, our customers, our community, and our planet.

Arbor Vita Corporation (AVC) is a privately held company committed to making a difference by enabling early and accurate diagnosis and treatment of disease. The company has products on the market or in clinical studies to address global health challenges in the areas of HPV-induced cancer and infectious disease. AVC also has a pipeline of products in development.

Arch works closely with the scientific community, universities and research institutions to advance and build the value of select medical innovations, develop the most promising intellectual property, and create value for its investors. The company holds a strong patent portfolio of new drug candidates to prevent inflammation and organ injury. Arch’s Phase I and Phase II clinical trials led to LSALT peptide (Metablok), being the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial involving fifty-five hospitals across Canada. • Arch scientists described a novel mechanism of action for organ inflammation in the journal Cell. • Arch scientists identified the enzyme dipeptidase-1 (DPEP1) as a major neutrophil (white blood cell) adhesion receptor in the lungs, kidneys and liver. • DPEP1 was shown to be the target of LSALT peptide (Metablok), the Company’s lead drug candidate targeting inflammation in the lungs and kidneys. Arch is currently working to advance LSALT peptide through the production of additional human safety and efficacy data in a Phase II trial to prevent IRI-acute kidney injury (AKI). Please follow the company on LinkedIn, and subscribe at the website for the latest science and investor news.

Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.

Arcus Biosciences is an exciting growth company founded on the vision of creating best-in-class cancer therapies. We are an oncology-focused biopharmaceutical company leveraging its deep cross-discipline expertise to discover highly differentiated therapies and develop a broad portfolio of novel combinations addressing significant unmet needs. We are located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub. Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus is an ambitious undertaking, and we fully expect our company to become a force in the discovery, development and commercialization of novel therapies for the treatment of cancer. Our employees enjoy operating in an exceptionally dynamic and cooperative environment in which the “rule book” has not yet been written.

Arda is taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions.

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and Japan.

ArgusEye provides innovative sensor systems based on nanoplasmonic detection for real-time monitoring of biological systems and processes.

We now know that immune cells – not only in the body’s periphery but especially in the brain – can produce autoantibodies that cause severe neurological and psychiatric diseases. Founded to explore the latest discoveries in autoimmune neuropsychiatry, Arialys Therapeutics is developing new precision medicines to specifically block pathogenic autoantibodies in the brain and meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease.

Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR).

ArkeaBio is a company focused on developing technology to reduce greenhouse gas emissions from the agricultural industry, specifically targeting livestock methane emissions. The company was founded on the premise that a simple vaccine could be a powerful tool in fighting climate change.

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

Aronora is a translational biotechnology company (aronorabio.com) engaged in the development of proprietary biologic therapeutics, including recombinant monolconal antibodies and enzymes. Rational design of our innovative therapeutic agents is expected to result in drug products that reduce the progression and growth of life-threatening blood clots without the detrimental bleeding side effects that characterize all currently marketed antithrombotic drugs. Our products are intended to be used in difficult-to-treat, severe, rapidly progressing, or catastrophic thrombotic blood clotting diseases.

Arrayjet Ltd is accredited to ISO13485 and providesCRO/CMO liquid handling solutions to support a variety of microarray applications. Their high-speed microarray spotters utilize a patented, non-contact, inkjet technologyfor printing multiplex array-based assays onto slides, Point-Of-Care devices, biochips and microplates.COVID-19: Re-purposed its in-house antibody screening technology to create a population-scale diagnostic program that will help scientists better understand the behavior of the COVID-19 virus and further the rapidity of a global vaccination program.

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.

Art Blood Co., Ltd. is a company that is building/developing a cell-based in vitro blood production system to solve the problem of blood for transfusion that is in short supply worldwide and has side effects. In addition, we are developing a platform to provide reagent red blood cells used to detect transfusion-related antibodies and therapeutic red blood cells that transport and express various therapeutic agents and immunostimulants.

At Artiva, our mission is to deliver to cancer patients highly effective cellular immunotherapies that are also safe and immediately accessible. Towards this end, Artiva is advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, including CAR-NK cell therapies, that leverage the company’s unique manufacturing and engineering capabilities. Artiva is headquartered in San Diego.

Arvada Therapeutics is a biotechnology company working to develop innovative large-molecule therapeutics for a rare cardiac arrhythmic syndrome.

ARVYS Proteins Inc. is a Contract Research Organization (CRO) that Specializes in Custom Protein Services for Drug Discovery and Life Science Research. Our strong integrated expertise in protein biochemistry, working experience with various recombinant expression systems and protein classes, up-to-date knowledge in protein technologies, enable us to become a reliable and resourceful partner for our clients. We help at any stage of a protein project. Our goal is to become your preferred outsourcing choice for Protein Services and we will work hard to earn your business. Maximize Project Success with Our Expert Protein Services! Protein Expression - generation of heterologous recombinant proteins in multiple expression systems. Fermentation & Cell Culture - bacterial, yeast, insect and mammalian biomass production for scale up processes. Protein Purification - homogeneous and well-characterized preparations save time, effort and resources. Protein Characterization - Customized design to address specific protein characterization goals. Functional Assays & Assay Development - Protocols with detection by UV-Vis, fluorescence or luminescence spectroscopy. ELISA Development - from selection of assay components to development of a working protocol. Protein Labeling & Conjugation - development of strategies to maximize functionality of modified proteins. Endotoxin Removal & Testing - expert service in less than 1 week. Antibody Development & Production - from generation of antigen to characterization of antibodies.

AscentGene is a biotechnology company that provides high-quality cell lines and protein services to the life sciences community.

Ascletis is an innovative R&D driven biotech listed on Hong Kong Stock Exchange (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of NASH, cancer lipid metabolism and oral checkpoint inhibitors, viral hepatitis and HIV/AIDS for unmet medical needs in China and globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Gannex, a wholly-owned company of Ascletis, is fully dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets – FASN, THR-beta and FXR, and three combination therapies.

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio is backed by Third Rock Ventures and is located in South San Francisco.

āshibio is developing novel therapies for patients with rare bone and connective tissue disorders that have the potential to prevent the onset of symptoms or slow the progression of disease.

Since our inception in January of 2006, Assay Biotechnology has been a worldwide contributor of industry-leading antibody and assay technologies, fluorescent dyes, quenchers, recombinant proteins and synthetic peptides. Located in the heart of California's San Francisco Bay Area, we have strived to answer the global need for high quality assay kits and immunological reagents used in academic and pharmaceutical research that formulate the basis of healthcare. For the first couple years after our founding, Assay Biotech established itself as an antibody manufacturer, catering specifically to large corporations through OEM partnerships. Since then, we have been emerging as a prominent assay and antibody source, expanding our reach to millions of researchers in over 50 countries around the world. We are determined to become one of the world's leading assay development and manufacturing companies, providing a multitude of ready-to-use assays, immunological reagents, molecular detection modules and biomarkers to support the most arduous academic and pharmaceutical research endeavors.

Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the Americas and around the world. All content developed by Astellas Pharma US, Inc. and intended for U.S. audiences.

Driven by innovative science and our entrepreneurial culture, we are focused on the delivery of life-changing medicines that are fuelling growth and contributing value to patients and society.

At Astria Therapeutics, our team is focused on bringing therapies with the potential to improve the quality of life to patients and families affected by Hereditary Angioedema (HAE) and rare allergic and immunological diseases. Our name originates from the Greek word for star, and patients are guiding stars who guide us in the development of life-changing therapies. Learn more at www.astriatx.com

Asylia Therapeutics is a private development stage biotechnology company committed to transforming scientific advances into safe and effective medicines for cancer and other immune-related diseases.

Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.

ATB Therapeutics is a pioneering biopharmaceutical company building a new line of attack against cancer. atbtherapeutics has developed the atbody; a game-changer biologic format designed to broaden the therapeutic window of antibody-based therapies. Only our proprietary and versatile plant-based atbiofarm technology enables single-step manufacturing of our novel class of therapeutic atbodies. The resulting therapeutics offer a novel mechanism of action, avoiding major cancer cell resistance, and provide a promising, life-changing therapy for hard-to-treat and refractory cancer.

Atengen is developing drugs that specifically target the tumor blood vessels of most solid tumors. The long-term goal is to develop a new generation of drugs that can be used in combination with existing cancer therapies to improve patient outcomes.

aTen Therapeutics is an innovative biotechnology company developing novel therapeutic antibodies to target a fundamental control pathway associated with cancer and several other major diseases. Their technology is focused on antibody discovery and cutting-edge technology development.

Athena Discovery is a contract research organization (CRO) for biotech and pharmaceutical companies specializing in non GLP drug discovery services with a focus on virology and immunology.

At Aton, we're building a team of expert companies dedicated to accelerating the progress of tomorrow's therapies. To help deliver the right treatment, to the right patient, at the right time. Aton's Ecosystem – Lifescience platforms united to transform therapies Our platforms are driving a fundamental shift in how medicines are developed. Toward products and services adapted to the patient's biology. Complimentary cutting-edge businesses, with unique technologies and diverse teams of experts. One goal. To accelerate discoveries for the good of patients, medicine, and society. Aton's platforms guide and support life-science businesses to achieve their goals with greater efficiency. Our Strategy We're driven by our ambition to develop tomorrow's therapies. We invest in, guide, support, and develop lifesciences companies with unique technologies. Our strategic investments focus on advancing personalized medicine. We collaborate with the brightest entrepreneurs, to provide flexible and longterm support. To ensure they reach their full potential — to help advance today's and tomorrow's medicines. To transform patient outcomes for good. Many specialists, working as one team, we're constantly moving forward, to take our place at the cutting-edge of medical advancements. We see the future of health. It's safer, targeted and more effective. We understand what it takes to deliver to health and regulatory requirements. Helping make this future a reality.

Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches. By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.

Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Our proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in all systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.

ATUM is an industry-leading provider of life science tools and solutions. Founded as DNA2.0 in 2003, we were a pioneer in the application of machine learning to synthetic biology and currently hold multiple patents covering several technologies, including our first-to-market Leap-In Transposase® platform. Our integrated offerings include Gene Design & Synthesis, Protein Production, Cell Line Development, and Master Cell Banking — all powered by our Leap-In Transposase® and machine learning platform. This means a streamlined path from sequence to Master Cell Bank (MCB) with just a click, ensuring efficiency, regulatory compliance, and innovative solutions tailored to our clients' needs. ATUM is privately held and is headquartered in Newark, CA.

Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems toward killing tumor cells. Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors. The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.

Aurigene Pharmaceutical Services is leading contract research, development, and manufacturing organization (CDMO). Built on the legacy of accelerating innovation and backed by a vast experience in drug discovery and development our mission is to relentlessly work for the success of our clients and to build long term relationships through a holistic approach to accelerate the journey of a molecule from laboratory to market. By providing access to our resources, knowledge and experience, we create success for our clients and ultimately patients. We offer integrated and standalone services for medicinal chemistry, biology, preclinical services, DMPK studies, development and manufacturing for clinical phase I-III programs, regulatory submission batches and commercial manufacturing. A differentiating factor is the integrated API and formulations service that spans from key starting material, advanced intermediates, APIs to finished products such as oral solids, sterile products, nasal solutions etc. Our development services in India are complemented by cGMP commercial manufacturing facilities in the UK, Mexico, USA and India.

Auron Therapeutics is a privately held patient-centered, platform-powered, product-driven oncology company. We are the leaders in identifying and targeting cell state to treat a range of solid tumors and hematological malignancies.

Research product distributor, Contract Services

Austrianni GmbH is a pharmaceutical company with the mission to develop therapeutics for the prevention and treatment of tuberculosis.

Autonomous Medical Devices Incorporated (AMDI), with its principal place of business in California, employs a world class team of engineers, scientists, clinicians, and manufacturing experts dedicated to the development and manufacture of point-of-care diagnostic devices using breakthrough microfluidics, protein engineering, and data/cloud connectivity. AMDI will launch its first products from its ISO:13485 certified 110,000 square foot facility in Santa Ana, CA.

Auven Therapeutics is a private equity firm pursuing an innovative life science investment strategy. Although it utilizes a fund structure, it also has an internal drug development company that allows it to more effectively manage drug development and grow the value of its therapeutic assets.

Our mission is to shape the future of medicine by developing safe and efficacious drugs, and high performing diagnostics, based on our proprietary Affimer® and pre|CISIONᵀᴹ platforms. The Affimer® platform is a novel class of biotherapeutic based on a naturally occurring human protein. It is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families. Avacta’s proprietary pre|CISIONᵀᴹ targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta expects to take its first pre|CISIONᵀᴹ drug candidate, AVA6000, a targeted form of the standard-of-care Doxorubicin, into the clinic by the second half of 2021. By combining these two platforms the Company is building a pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta’s diagnostics division, based in Wetherby, UK., utilises it’s proprietary Affimer® platform to develop high performing diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty bearing license deals.

Avalo Therapeutics Inc. (Name changed from Cerecor Inc.) is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain. We are a Delaware corporation, organized in April 2011 in partnership with various laboratories and research institutes at Johns Hopkins Medical Institute ("JHMI"​). Cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. We acquire rights to early stage therapeutic technologies ("assets"​) from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset.

AvantGen is a biotechnology company dedicated in accelerating antibody-based therapeutics for their scientific partners by using innovative platforms. Based in San Diego, the fun and collaborative team is steadfast in this pursuit.

AvenCell - Based on our deep science and focused on patients in need, we develop next generation immunotherapies for hard-to-treat cancers.

Aves Labs produces high-affinity, custom chicken IgY and other immunoreagents for biomedical research and antibody manufacturing.

Avid Bioservices (NASDAQ:CDMO), is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology, biopharmaceutical, and cell & gene therapy industries. With over 30 years of experience, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Avid Bioservices positions are accessible via the Avid Bio Careers page at https://avidbio.com/careers/.

At Avidicure, we invent and develop entirely new antibody therapies, called "AVC-Boosters". Our first-in-class product platform is designed to deliver targeted and potent immune-modulating treatments for patients with cancer or auto-immune diseases.

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company’s lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases.

Aviva Systems Biology specializes in providing polyclonal and monoclonal antibodies, ELISA kits, proteins, and custom services for research needs. We manufacture 24,000 validated polyclonal antibodies and offer nearly 20,000 ELISA kits. Our custom laboratory services include protein expression and purification, antibody development, and ELISA development, validation, and production. Our head office is in San Diego, CA, we also have an office in Beijing, China. Both locations provide scientific support assisting researchers with a variety of proteomic objectives. Aviva provides unique tools for research associated to unique species and targets. The company's products are relevant to 10,000 unique species, 10,000 cellular processes, and 5,000 protein pathways. Research Areas Transcription factors, cancer, cardiovascular, cell biology, DNA damage and repair, epigenetics, signal transduction, cell differentiation, stem cell biology , and many more. Specialties Western blot, immunohistochemistry, ELISA, custom protein expression

Avotres Inc. is a private biotechnology company developing breakthrough therapeutic solutions for incurable immunologically mediated disorders. Targeting these therapeutic areas with significant unmet medical needs, we apply innovative science to unveil potentially paradigm shifting immunological pathways in the hope to transform the treatment for millions of patients. We consider it our mission to tackle these diseases from their root cause(s) and aim to reach the goal of relieving patients from the disease burden.

Axcynsis Therapeutics is at the forefront of developing cutting-edge Antibody Drug Conjugate (ADC) therapies. Our team's profound expertise, pioneering and proprietary ADC technology platform, enduring IP and know-how, substantial market opportunities, and strategic and effective execution position us as industry leaders in innovative cancer treatment solutions. At Axcynsis, our groundbreaking Matrix Optimization Platform is the cornerstone of our research and development efforts. This cutting-edge platform empowers us to swiftly explore numerous linker and payload combinations alongside our proprietary antibodies. We further harness state-of-the-art technologies, including an exclusive payload library derived from an FDA-approved drug and site-specific conjugation methods. These innovations are strategically employed to enhance the safety and quality of our ADCs. With two potential best-in-class programs on track for clinical trials by 2025 and a third program making headway toward IND status, we are poised for significant value creation and breakthroughs in cancer therapeutics. Based in Singapore, we plan to expand our clinical development operations to the United States by 2024. Join us on our journey to transform cancer treatment and make a meaningful impact in biotechnology. Axcynsis is at the forefront of developing life-changing ADC therapies, and we invite you to be a part of our innovative and dedicated team as we pioneer the future of cancer therapeutics.

AxisPharm is a San Diego based antibody drug conjugate (ADC) linker product and service provider. At AxisPharm, we focus on manufacturing novel ADC linkers, site specific molecular probes and advanced biochemical reagents. We also provide a variety of bio/chemical services worldwide, including custom synthesis and integrated drug discovery services.

AXON Neuroscience is a clinical-stage biotech company founded in 1999 with a specialized team of researchers focused exclusively on tau immunotherapies and tau diagnostic platforms. AXON has identified and wholly owns several compounds which are being investigated as potentially disease-modifying therapies for the treatment of Alzheimer's disease and other tauopathies. The two lead compounds are the active vaccine AADvac1 and the monoclonal antibody AADvac2. The tau vaccine AADvac1 has potential to be the first breakthrough therapy to address Alzheimer's disease and help millions of people suffering from the devastating disease. Axon is also developing a suite of diagnostic assays to more accurately identify patients with potential tau-derived brain diseases that can benefit from its novel therapeutic candidates.

Badrilla is a biological reagents company focused on providing effective, well validated research antibodies to cardiac proteins, chemistry kits for the study of S-palmitoylation and standards for precise and accurate quantification of immunoassay data. Do you need reagents for your research project that are not currently available? We work with researchers to develop new probes in emerging areas of research, bringing them to the whole community after prompt and thorough characterisation. Approach us with your ideas, we'd like to work together.

四川百利天恒药业股份有限公司 百利药业是一家集研发、生产、营销为一体的现代化高新技术企业。拥有2个新药研发中心、1个抗体及ADC药物生产企业、1个化学中间体生产企业及1个化学原料药生产企业、2个化学。

Baliopharm was acquired by Promethera Biosciences on April 10, 2018. Baliopharm was founded in 2006 as Celonic AG, a service company for the contract development and manufacturing of biopharmaceutical compounds, based on the...

Bambusa Therapeutics is a rapidly growing biotechnology company specializing in developing transformative inflammatory and immunological therapeutics. Based in the vibrant Boston Seaport area, our mission is to advance the field of immunology with cutting-edge solutions.

BA Sciences is a cGMP compliant, FDA/DEA registered, ISO/IEC-17025:2017 certified analytical laboratory located in Salem, NH. BA provides testing services to Pharmaceutical, Biopharmaceutical and Medical Device companies worldwide including: Analytical Testing and Method Development, Microbiological Testing and Environmental Monitoring Services, Biologics, Stability Testing & ICH-compliant Storage, Impurities Testing, Advanced Therapeutics and Extractables & Leachables Studies.

Base Pair Biotechnologies, Inc. offers rapid discovery of high quality aptamer (DNA- and RNA-based) affinity ligands. Aptamers have been successfully employed in virtually every application where antibodies are typically used. Aptamers have a number of potential advantages over antibodies, however, in a variety of applications. Base Pair Bio's aptamer discovery is powered by a patented, multiplexed approach to aptamer identification. This and other chemical enhancements result in better DNA affinity ligands. For more information, please visit www.basepairbio.com.

Batavia Biosciences is a science-based CDMO that offers personalized services that fully support all the stages of biopharmaceutical development, from cloning to GMP manufacture and release of clinical material for phase I/II studies. We are not your standard CDMO - our customers regularly refer to us as their product development partner and thought partner. We focus on the early stages of product development with services ranging from DNA cloning, mammalian cell line generation, upstream process development, purification development, product characterization to clinical manufacturing. Headquartered in Leiden, The Netherlands, Batavia Biosciences is privileged to have strong strategic partners in both the EU and US. Batavia Biosciences aims to significantly contribute to ease human suffering from infectious disease and cancer.

The company providesservices inbioanalytic, molecular and cellbiology, in vitro and in vivo pharmacology.The company's capabilities include assay development and in vitro/in vivo pharmacologystudies forantibodies, small molecules, siRNAs, proteins, and gene therapy products.

BBI Solutions - Serving the Science of Diagnostics BBI Solutions is a leading expert in immunoassay development and manufacturing services, and provides an extensive portfolio of products and technologies to the global research and diagnostic markets. The contribution that the BBI Group makes towards achieving this is by adhering to our Mission; ‘To deliver exceptional products and technologies that people rely on to enjoy a better quality of life. Through innovation, partnership, effective delivery and the collaboration of our people, we constantly strive to help set industry standards, engender trust and build our reputation for excellence

BCN Biosciences is a privately held pharmaceutical company with core competency in oncology drug development. BCN is currently developing novel small molecule drugs for the treatment of cancer.

BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com. See community guidelines here: https://tinyurl.com/yunjmzkx.

Be Bio is pioneering Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies.

Bectas Therapeutics is a preclinical-stage biotech company developing monoclonal antibody therapies for cancer accompanied by biomarkers to identify patients that will most benefit from each Bectas therapeutic antibody. Our programs combine monoclonal antibodies that exhibit best-in-class pre-clinical activity with precision insights that enable first-in-class therapies to serve patients across multiple cancer indications

Bedrock Therapeutics is an AAV gene therapy research and development company developing platform and disease specific technologies for the treatment of ocular, hematologic, and other diseases. Drs. Matt Hirsch, Chenwen Li, Bryan Sutton, and Brian Gilger are co-founders of Bedrock. Drs. Gilger and Hirsch oversee the de novo design and validation of ocular assets, and Drs. Li and Sutton oversee basics aspects of the various host immune responses to AAV vectors and protein engineering and design.

Beech Biotech is unlocking novel biology to create breakthrough treatments for preeclampsia and other complications of pregnancy. Each year, preeclampsia causes the deaths of 70,000 mothers, 500,000 babies worldwide. Beyond that, long-term health consequences affect 300 million surviving mothers and their preterm infants. A key unmet need are medicines that treat only the mother without exposing the fetus to additional risk. We are addressing this need by developing “Mother only” monoclonals, achieved by a patented modification that blocks antibodies from crossing the placenta. Our lead asset, MOm303, binds and eliminates maternal sFlt-1, a known cause of vascular breakdown in preeclampsia, and releases placental growth factor, thus restoring the healthy balance of these factors. This has the potential to prolong pregnancy and reduce the consequences of preterm birth

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. On November 14, 2024, the company announced its intent to change the Company’s name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible.

TheBEI ResourcesRepository is a central repository, established by the National Institute of Allergy and Infectious Disease, that supplies organisms and reagents, such asSARS-CoV-2, to the broad community of microbiology and infectious diseases researchers.

BenchSci is a biotechnology company that offers an AI-powered platform to accelerate biomedical research by providing researchers with antibody search and selection tools.

BENTEN BIOTECH is committed to strengthening the R&D+i capabilities of the global animal vaccines laboratories. BIOTECH BENTEN designs new products and optimizes processes to ensure effectiveness and quality of final products under quality standards of US and EU pharmacopoeia, covering the specific R&D+i needs of the veterinary industry.

3/21/23- Acquired IsoPlexis Corporation (Nasdaq: ISO) then renamed to create PhenomeX. On Aug. 17, 2023, PhenomeX and Bruker entered into a merger agreement. Berkeley Lights is a leading functional cell biology company focused on enabling and accelerating the rapid development and commercialization of bio-therapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain. Berkeley Lights’ Beacon® and Lightning™ systems and Culture Station™ instrument are for research use only. Not for use in diagnostic procedures.

Berlin Cures was first to follow up on the scientific finding that there are a large number of diseases associated with pathological functional autoantibodies directed against G protein-couples receptors. Heart failure and Long Covid belong to this group of diseases. Our aptamer BC 007 can neutralize these autoantibodies and this is the reason why Berlin Cures has been working for decades to develop a product based on scientific findings that may help many suffering patients.

Beroni Group is an international biotechnological company listed on the National Stock Exchange (Australia) and traded on the OTC markets in the U.S.A. with business presence in Australia, China, Japan and the USA. It currently has four core businesses – cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases. Beroni Group’s overall strategic goal is to become a world’s leading enterprise in the biotechnology, life sciences, and environmental science industries.

BeyondSpring Pharmaceuticals is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes. The Company is developing treatments in two of the world’s largest markets, China and the United States. BeyondSpring’s first-in-class lead asset plinabulin, a selective immunomodulating microtubule-binding agent, is being developed as a “pipeline in a drug” with potential to be an anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). In the DUBLIN-3 Phase 3 study, the plinabulin and docetaxel combination met the primary endpoint of extending overall survival, compared to docetaxel alone in 2nd/3rd line non-small cell lung cancer (EGFR wild type). In addition, the plinabulin and G-CSF combination for the prevention of CIN has demonstrated positive Phase 3 data, for which it received Breakthrough status in the U.S. and China. Plinabulin is also currently being studied as part of other immuno-oncology (IO) combination regimens that include radiation and/or checkpoint inhibitors for the treatment of a number of cancers. Lastly, BeyondSpring also has three preclinical IO assets and majority ownership in its subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

Bharat Serums And Vaccines Limited (BSV) is one of the fastest growing biopharmaceutical companies in India. For 50 years now, BSV has used its scientific resources to develop a range of biological, biotech and pharmaceutical products. Today, as we influence patient outcomes in the therapeutic areas of Women’s health and Critical Care and IUI-IVF, we have the privilege of being a partner of choice. BSV's product portfolio includes plasma derivatives, monoclonals, fertility hormones, antifungals, anaesthetics, cardiovascular drugs, and equine immunoglobulin /antitoxins. In addition, BSV offers products in the areas of gynaecology, assisted reproductive technology, critical care, emergency medicine, neurology, nephrology, haematology, and urology. The company provides its products to retail outlets and hospitals through distributors primarily in India, as well as in the Asia Pacific, the Russian Federation, CIS countries, Latin America, Africa. BSV is amongst the top 10 Biotech companies in India. The Company has in its portfolio over 145 brands. The company has over 1000 employees selling its products across the country. Our brands are marketed all over India and exported to over 70 countries across the world We have an open and entrepreneurial culture, with each of our employees taking on significant responsibility in each activity of our value chain, be it in terms of research & development, manufacturing, quality, sales & marketing, distribution, business development or organisation building. Advent International, a global private equity firm has endorsed its faith in our commitment towards bringing life to life

Onychomycosis is a pervasive, disfiguring, and often painful infection of the nail, surface of the nail bed, and/or nail matrix caused by fungi that are ubiquitous in the environment Over 35 million patients in the US suffer from this type of infection, including approximately 1 in 3 diabetic patients. Research demonstrates an increased risk of other foot disorders and amputations in diabetic patients with onychomycosis. There are no current treatments that effectively treat this type of infection. Our patented TherawaveTM 100 technology delivers a safe and effective High Frequency Energy (HFE) precisely to the infected nail plate and surface nail bed to eliminate the fungal infection while sparing surrounding tissue.

Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA.

BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is backed by Section 32, ‍Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids Capital, AME Cloud Ventures, Innovation Endeavors and Gaingels.

Bilthoven Biologicals is a biopharmaceutical company which produces Inactivated Polio Vaccines (IPV), Tetanus Vaccines, Diphtheria-Tetanus-Polio Vaccines (DT-PV) and Bacillus Calmette-Guérin (BCG) for the treatment of bladder cancer. We deliver our vaccines to UNICEF, with which we support the World Health Organisation (WHO) to eradicate polio. Bilthoven Biologicals has been part of the Cyrus Poonawalla Group since 2012, the world’s largest vaccine producer and employs more than 500 employees.

BIMINI Biotech BV is an innovative biotech start-up that is developing unique compounds for oncology.

Bio4t2 is a clinical stage bio pharmaceutical company developing novel single-target and combo-therapeutic CAR based cell therapies against solid cancers through its proprietary PrismCore platform that are fine-tuned to comprehensively target self-antigens in patients with solid tumors.

A small, agile CRO. The primary function of the scientists at BioAnalysis, LLC is to provide a collaborative workspace that enables productive and effective solutions to the client’s problems. The traditional CRO model works well, however, at BioAnalysis, LLC we believe that collaborative interactions, communication and robust experimental design along with gold-standard quality results are the true value-added. The scientists of BioAnalysis, LLC possess a wealth of experience in characterization of therapeutic proteins, mAbs, and ADC (DARs), non-biologics (Polymers, PEO/PLA, nanoparticles), ICH/FDA regulatory applications, process development, and assessment of final biologic product formulations. Our subject matter expertise in the areas of Biophysics and Proteomics is showcased in over 70 peer reviewed publications.

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential.

BioAtla is a leading San Diego-based biopharmaceutical company developing safer and more effective drugs for cancer. Its Conditionally Active Biologics™ (CAB) are designed to target and treat cancer with greater precision and fewer side effects.

Bio Bench co. ltd (www.bio-bench.com, Belgium and China) is aCRO (Contract Research Organization) that develops functionalantibodiesand bio-active proteins for drug discovery, in-vitro diagnostickits and biologicalresearch.

BIOCAD is Russia's leading innovative biotechnology company; it combines a world-class research and development center, ultra-modern pharmaceutical and biotechnological manufacturing facilities, as well as preclinical and clinical research infrastructure compliant with international standards. BIOCAD is one of the world`s few full-cycle drug development and manufacturing companies, from new molecule discovery and genetic engineering to large-scale commercial production and marketing support. BIOCAD`s medicines are dedicated to treat complex health conditions such as cancer, HIV and Hepatitis C infections, multiple sclerosis and other disorders.

Biocare Medical LLC is an innovator in automated immunohistochemistry (IHC) instrumentation, and the full range of reagents for IHC and in situ hybridization (ISH; RISH) testing. Biocare pioneered multiplex IHC detection which accelerates turnaround time, increases instrument productivity and reduces reagent consumption and cost by 50% or more. Multiplex IHC allows pathologists to visualize more than one marker on a tissue at a time, allowing higher confidence for critical differentiation. Biocare's intelliPATH FLX is the only completely open, continuous random access IHC instrument available. The company’s customers come from clinical and research environments that do tissue based testing and include histology laboratories, pharmaceutical and biotechnology companies; CROs; and academic, government and military labs. Biocare Medical offers an expanding portfolio of products for the rapidly growing cancer and infectious disease diagnostic and research markets. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network. See biocare.net and slidestainer.com for more information. NOTE: Biocare Medical, the Biocare Medical logo, and intelliPATH are trademarks of Biocare Medical LLC.

We develop novel and sustainable products and technologies in bio-therapeutics, vaccines and personalized diagnostics of cancer and infectious diseases. Most of the company's efforts have been directed toward in-house innovation in drug development and diagnostics; biotechnology consulting to pharmaceutical companies interested in technologies related to biosimilar and biologics development; and specialized contract research services to clinical and academic research institutions in order to design solutions based on novel methods and protocols useful in clinical validation of biopharmaceutical molecules and vaccines.

BioCheck develops and manufactures high-quality immunoassay kits for the worldwide healthcare markets in their cGMP and ISO 13485 certified facility in the San Francisco Bay Area. BioCheck also provides custom immunoassay development and contract manufacturing services to the diagnostic and research industries.

BioCity was established in December 2017. It is an innovative drug company created by local entrepreneurs who have a deep understanding of the Chinese pharmaceutical market and young returned scientists relying on the world's leading open drug innovation platform. The company is committed to the discovery, development and commercialization of novel or highly differentiated candidates (with no modality limitation) to treat diseases with significant unmet medical needs, particularly cancers and Nephropathy. Through internal research, open innovation platform and collaborations, BioCity has established a pipeline of more than 10 innovative programs including small molecules, monoclonal and bispecific antibodies as well as antibody-drug conjugate (ADCs).

Biocon: Enhancing Global Healthcare Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high. The early anticipation of the increasing dominance of biologics in global development pipelines helped us to be ahead of the curve in crafting a differentiated product portfolio based on fermentation and recombinant technologies, which straddles fermentation-derived small molecules and biologics, both novel as well as biosimilars. The significant brand equity that we have built worldwide for our small molecule APIs across statins, immunosuppresants and other specialty products has made us a leading global supplier of these products. We have also built one of the largest and most diverse biosimilar pipelines, spanning insulins, monoclonal antibodies and other recombinant proteins that address critical chronic diseases such as diabetes, cancer and autoimmune disorders. Ranked among the Top 3 biosimilar players globally for rh-insulin and insulin glargine in volume terms, we are the first Indian company to launch a biosimilar in Japan with Insulin Glargine, which also has been approved for sale in EU and Australia. Our insulin products have made a difference to the lives of millions of people with diabetes across the globe. We now aim to provide our insulin products to ‘one in five’ people with diabetes in need of insulin-based therapy anywhere in the world within the next 10 years. We are also making a huge impact in the area of cancer care. Our biosimilar Trastuzumab, which was the first to be approved anywhere in the world and launched in India in 2014, has helped treat several thousand HER2-positive metastatic breast cancer patients. We are also the first company from India to get its biosimilar approved by the USFDA; Ogivri™, co-developed by Biocon and Mylan, is the first biosimilar Trastuzumab to be approved in the US. In addition to Trastuzumab, several of our biosimilar assets are on track for anticipated regulatory approvals in developed markets. We are also developing a pipeline of patented biologics to address global unmet medical needs. We have successfully launched a couple of novel biologics in India: Nimotuzumab for the treatment of head and neck cancer and Itolizumab to tackle psoriasis. Besides these, we have a basket of novel assets are under various stages of clinical development, including a high potential oral insulin. Through our subsidiary, Syngene, we offer a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) to the global life sciences sector. Ranked by the prestigious Science magazine among the Top 10 Best employers in the biotech industry, Biocon is passionately pursuing a mission to rationalize healthcare spends, enhance access to life-saving therapies and make a significant impact to global healthcare through ‘blockbuster’ drugs with the potential to benefit a billion patients.

BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and develop-ment time of next-generation biotherapeutics from approx. 3 years to 12 months. It will save valuable time in the fight against cancer and significantly reduce the cost of cancer therapeutics. In the long term, BioCopy will expand its efforts beyond cancer and develop biotherapeutics for immunological and neurological diseases. The company is managed by Dr Matthias Wiedenfels, a proven expert and industry insider in the pharmaceutical and biotechnology industry, not least through his time as CEO of STADA Arzneimittel AG.

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ mice), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with more than 70% of the top 50 pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world.

BioFactura develops and commercializes biodefense drugs, novel drugs, and high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast™ Biomanufacturing Platform, the optimal choice for bringing these products to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.

The heart of BioFluidica's CTC (Circulating Tumor Cells) system, is a highly efficient CTC capture bed, comprised of 50 to 500 sinusoidally-shaped channels. These channels are coated with antibodies, which isolate specific CTCs from whole blood. The antibodies are chemically immobilized onto the surfaces of the capture bed using BioFluidicas patented technology.

Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. With approximately 7000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.

BioGenes is a full-service provider of customized immunoassay and antibody development, with a strong commitment to quality and service. Founded in 1992 and headquartered in Berlin, Germany, BioGenes is a recognized partner serving more than 600 customers in 40 countries. The company maintains long-term relationships with global pharmaceutical, biotech companies, CMOs and in vitro diagnostic firms. BioGenes provides highly customized solutions for the quality control of biological products, from drug discovery and drug development to the manufacturing of biologicals, as well as for diagnostic purposes.

 The company specializes in sophisticated custom monoclonal, polyclonal and anti-idiotypic antibody development and has a proven track record in the development, optimization, pre-validation and production of highly sensitive and robust ELISAs and host cell protein (HCP) assays. Furthermore, BioGenes offers the enhanced generic 360-HCP ELISA kits and supports customers with a comprehensive range of analytical services.

BioGeometry is an AI-driven biotech dedicated to developing next-generation, programmable protein medicines. We aim to solve the high cost, long lead time, low success rate problems for traditional macromolecular theraputics through the combination of geometric deep learning, structural biology, immunology, and synthetic biology. We enjoy talents from renowned pharmaceutical companies, top-tier AI and bio labs worldwide.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

BioLegend develops antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA.

Biologics Resources, LLC (BRLLC) is a Vaccines, immunotherapeutics and Biopharmaceuticals technology company.

Biolojic Design makes developable, active human antibodies directed against functional epitopes, including targets for which existing technologies fail.

BioLoomics is a preclinical stage biotechnology company leveraging directed evolution of antibodies in human cells to create ADCs with improved internalization and trafficking. Our proprietary tech combines single-cell bioassay engineering, robotics, and ML.

BioMap is an AI for life sciences company, unmasking nature’s rules to generate proteins for a wide range of therapeutic and industrial applications. We build super-scale Foundation models supported by access to unrivaled computational power through our strategic collaboration with Baidu, with whom we share our Founder and Chairman, Robin Li. We supplement our AI capabilities with a leading team of scientists, disease experts and cutting-edge high-throughput labs which generate large volumes of high quality proprietary data for our AI models. We partner with pharma, biotechs and industry to enable their discovery ambitions across a wide range of therapeutic and synthetic biology modalities through access to our AI technology platform, with a variety of flexible collaboration models. Our mission is to leverage AI to radically improve lives.

Welcome to Biomatik - Your Quality Source of Integrated Products & Services for Life Sciences and Drug Discovery! ​Biomatik has been proudly serving the life sciences and drug discovery industry since 2002. In the first 10 years, Biomatik had been primarily focusing on Biochemicals, Gene Synthesis, and Peptide Synthesis. In the past 5 years, Biomatik has largely outgrown the above product lines and is rapidly expanding its new product lines: ELISA Kits, Proteins, and Antibodies. Offered Products: 22,000+ ELISA Kits, 26,000+ Antibodies, 15,000+ Proteins, 300+ Biochemicals Offered Services: Gene Synthesis, Peptide Synthesis, Protein Expression and Antibody Production Services To date, in addition to our catalog products, Biomatik has delivered 52,000+ custom-made products to our researchers worldwide. You can count on the quality products and tech support from Biomatik for your research needs. Please​ view our customer testimonials and some of the well-respected publications citing our fine products at Google Scholar​. Biomatik works closely with its partners at the R&D and production levels, along with 35+ distributors all over the world. Our goal is to provide worldwide researchers with high-quality research products and customized solutions at highly competitive prices - to be a truly valuable partner in unveiling the mysteries of the life sciences. We sincerely invite you to join our list of satisfied customers worldwide.

OUR COMPANY BioMed Valley Discoveries, Inc., is a clinical stage biotechnology company with a mission to address unmet patient needs across a wide spectrum of diseases. Operating since 2007, BioMed Valley Discoveries advances its mission with commercial capabilities and resources typically unavailable to academic institutions. As a member of the Stowers Group of Companies, our stable long-term funding allows us to advance programs that may not fit within the model of more traditional clinical development groups. OUR APPROACH BioMed Valley Discoveries leverage several hundred experts at leading academic and clinical institutions to move projects forward in the early stages of clinical development. Our partners have a proven track record of scientific rigor and experience in efficient study execution. Our selection of development partners is based on our desire to address unmet patient needs and achieve critical development milestones as swiftly as possible. Through this approach, we endeavor to quickly answer scientific questions and determine next steps in the development process. OUR TEAM BioMed Valley Discoveries calls on the talents of a core leadership team of scientists who are focused, passionate, and committed to advancing new medical innovations to improve the lives of patients with difficult-to-treat diseases. Our team brings extensive experience from pharma, biotech, and academia. By utilizing unique advantages from each of these settings, BioMed Valley Discoveries creates a highly creative and functional drug development environment. We take a nimble and thoughtful approach to advancing programs with a focused sense of urgency, allowing for the most efficient path forward.

Develops antibody-based therapeutics

Biomissile is a biopharmaceutical company that focuses on the drug development.

Antibodies, Immunoassays, Small Molecule

BIOMUNEX Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough immunotherapies using its Unique BiXAb® technology to create next generation bi- and multi-specific antibodies. Our disruptive biological approaches target a number of cancer types, in particular where there are unmet medical needs. We are committed to provide oncologists and patients with immunotherapies that are novel, efficacious and prolong life expectancy.

Bionamic was founded by researchers to address the frustrating challenge of implementing digitalization in biopharma R&D. Our software platform can serve as a single source of truth for all your antibody related discovery and development data and offers an easy way to navigate it. We have put an incredible amount of thought and effort into making sure the data can be represented in a way that makes sense and helps to solve real problems.

Biond Biologics is an Israeli clinical-stage biopharmaceutical company Biond is an innovative biotech company developing breakthrough immunotherapies and a pioneering intracellular drug delivery platform for the treatment of cancer patients. Our innovation: Biologics targeting novel immune evasion mechanisms, discovered through in-house research utilizing real-world patient and tumor samples A transformative intracellular delivery platform for biologics, e.g., antibodies or enzymes, inside cells, allowing to drug intracellular targets currently considered "undruggable". Biond Biologics – Novel and innovative immunotherapies for cancer and auto-immune diseases.

BiOneCure Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative ADC drugs for the treatment of cancers. The company was founded in 2017 by a group of industry veterans who have worked in global biopharmaceutical companies. Their research focuses on creating innovative technology platforms and adopting a multifaceted approach to develop new medicines that exceed current standards. The current pipeline covers classic ADCs, bispecific ADCs, and bifunctional ADCs, aiming to be the first-in-class or the best-in-class products.

Bionor Holding is a privately held biopharmaceutical company focused on advancing its proprietary therapeutic vaccines toward HIV cure.

BioNova Pharmaceuticals Ltd is an innovative biotech company engaged primarily in the discovery, development and commercialization of breakthrough therapies for the treatment of diseases with high unmet medical need, with a focus on the Greater China market Our talent, scientific knowledge and research capabilities help us accelerate drug development in China and bring innovative medicines to the Chinese patients

Bionova Scientific is a dynamic, full service, biologics Contract Development and Manufacturing Organization (CDMO) on a mission to deliver the highest quality process development and manufacturing services to biologic drug development companies around the world. Bionova's renowned scientific expertise and dedication to its customers helps life changing therapies arrive to the market faster and more efficiently. At the heart of Bionova is a team of highly dedicated experts combining strong experience in cGMP biologics manufacturing and process development, with a technology-focused approach and a deep knowledge of the industry. From early stage research material generation to Process Development and GMP manufacturing, Bionova's teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients.

BioNTech is a global next generation immunotherapy company aspiring to translate science into survival. Around 6.100 pioneers currently work with us, employing a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules.   Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. To learn more about us, please visit www.BioNTech.com. Our privacy statement can be found here:  https://www.biontech.com/int/en/home/data-privacy-statement.html Our imprint can be found: https://www.biontech.com/int/en/home/imprint.html

Biopharma PEG Scientific Inc. is a fast-growing worldwide company dedicated to developing and manufacturing of high-quality polyethylene glycol (PEG) products and derivatives, like Biotinylated PEGS, Monofunctional PEGS, Heterbifunctional PEGS, Homobifunctional_PEGS, Multi-arm PEGS, Fluorescent PEGS, Lipid PEGS,etc. Based on proprietary technologies, Biochempeg scientific Inc. is capable of supplying small to large quantities of high quality PEGs for customers worldwide, such as PEG Amine, PEG NHS ester, PEG Maleimide, PEG Azide, PEG DSPE, PEG DBCO, etc. Biochempeg scientific Inc. also provides custom synthesis of PEGs of various molecular weights (MW) and functionalities to facilitate and enhance growing industrial and academic uses. Biochempeg scientific Inc. is ready to help keep your projects on track with our high quality products and technical services.

BioPharm International® covers all aspects of biopharmaceutical development, analysis, processing, and packaging, as well as business strategies and regulatory issues. The print and digital editorial coverage provides technical and business insight and analysis for all biologic-based therapies including monoclonal antibodies, vaccines, biosimilars, protein therapeutics, cell therapies, gene therapies, antibody-drug conjugates, and other emerging therapies.

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, clinicians can identify patients potentially at risk of AKI more rapidly than is possible with the current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark, and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com. To learn more about our products and their availability in your country, please visit https://bioporto.com/products/. Posts are not intended for a U.S. audience. If you are from the United States, you are encouraged to visit https://www.linkedin.com/company/bioporto-diagnostics-inc-us/ Social Media Community Guidelines: https://bioporto.com/social-media/

Research & Diagnostic Products. Bio-Rad is partnering with Biodesix on a test for SARS-CoV-2.EUA (05/2020) for a digital PCR molecular diagnostic test for SARS-CoV-2, the virus that causes coronavirus disease COVID-19. The 2019-nCoV CDC ddPCR Triplex Probe Assay is now authorized for use on the firm's QX200 and QXDx Droplet Digital PCR systems.

BioRay is a commercial-stage biopharmaceutical company with a full suite of end-to-end capabilities in China. We focus on discovering, developing, manufacturing and commercializing medicines for immune-mediated diseases. Leveraging our expertise in immunology and diverse portfolio covering different therapeutic targets and cellular pathways, we are committed to delivering life-changing medicines and other treatment solutions for patients living with autoimmune diseases and cancer. BioRay has full-spectrum R&D expertise from drug discovery to late-stage development, industry-leading commercial-scale manufacturing and quality management systems, and a robust pipeline with more than 20 preclinical candidates and over 10 ongoing clinical projects. In addition, our well-established nationwide commercial operations support four marketed products in mainland China. Currently, we operate four R&D and manufacturing centers in Taizhou, Hangzhou and Shanghai, China and San Diego, US, and have over 1,300 employees worldwide dedicated to building a pre-eminent biopharmaceutical company by offering medicines of the highest quality while pushing the boundaries of scientific discovery.

Biosceptre is developing a multi-targeted universal CAR-T system, designed to incorporate our nfP2X7 technology, to be capable of treating a range of cancers.

Bioserv Corporation located in San Diego, California is a boutique cGMP contract manufacturing organization (CMO) serving the pharmaceutical, biotechnology, life sciences, medical device, and diagnostic industries since 1988. Bioserv’s core competency is manual filling which allows us to be very flexible and capable of handling small to medium batches effortlessly. Bioserv has a broad range of manufacturing suites to meet your production needs. Bioserv’s manufacturing facilities include certified Class 10,000 (Class 7 or Class C), Class 100 (Class 5 or Class A) areas, and Uncontrolled laboratory rooms. Whether a client is looking to move a drug product candidate into the pre-clinical setting, Phase I, Phase II clinic, or looking for basic reagent formulation and filling expertise, Bioserv has the experience and capabilities to get our clients there on time. We have filled a significant number of cGMP finished drug product lots for our clients to support their Phase I and Phase II clinical trial needs. We have a broad level of highly skilled production experts that have worked with very complex formulations, including liposomes, emulsions, nano-particles, small molecules, conjugates, and adjuvants. We understand that each product has its own unique set of manufacturing requirements. Bioserv is committed to making sure that those products are made with the highest Quality Standards each and every time. Work-From-Home Job Scam Alert It has been brought to our attention that job seekers are being contacted by scammers misrepresenting themselves as Bioserv recruiters. These scammers are contacting job seekers on LinkedIn or other job sites asking job seekers to apply for fake work-from-home positions. Please be advised that Bioserv does not generally offer work-from-home positions and all job listings are available here: https://sorrentotherapeutics.com/careers/. Any communication regarding recruitment will be done via email domain ending in @sorrentotherapeutics.co

Biosion is a global R&D biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived technologies including the H³ antibody discovery, SynTracer™ HT-endocytosis and Flexibody™ bispecific platforms. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in phase 1 clinical trials for atopic dermatitis and severe asthma. Biosion and partners have plans to progress additional assets into the clinic for oncology indications over the next year. Biosion has operations in the US, Australia, and China.

BioSourcing is developing a New Generation of Biotherapeutics, in particular Monoclonal Antibodies for Global Unmet Medical Needs : Available, Affordable, Sustainable. BioSourcing changes the design paradigm of these new biotherapeutics thanks to the mastery of several breakthrough technologies including genome editing (CRISPR). The BioSourcing disruptive approach leads to a drastic reduction in capital requirements and production costs, especially for large volumes, as well as an improvement in the quality/efficiency of biopharmaceuticals through better glycosylation. BioSourcing strongly contributes to sustainable development, in particular in drasticly reducing the carbon footprint. BioSourcing is a fully operational biotechnology company, based in Liège, Belgium. Its team is made up of the best scientists, international experts in their field and has developed strategic partnerships with leaders in the pharmaceutical and biotechnology industry.

Biosyngen is a cell therapy company focusing on unmet needs with technology targeting solid tumors and lymphoproliferative diseases. The company’s first-in-class products have entered into Phase I/II clinical trials for nasopharyngeal cancer (ODD and Fast-Track), lymphoproliferative disease and lung cancer. The company continues to enrich its pipeline with further IND submissions. Biosyngen drives its global strategy from the dual HQ in Singapore and Guangzhou. Leverages on the public-private biopharma ecosystem for the better cause. Committed to giving cancer patients a better chance to survive, our pipeline is enriched, covering other major indications which are on track for regulatory registration. Biosyngen seeks breakthrough in collaborations, particularly in translational R&D and clinical development. The company has positioned GMP cell therapy manufacturing facilities in two locations - in Singapore and Guangzhou covering global needs. To quicken drug development from bench-to-bedside, a parallel effort in the form of the Translational Medicine Centre is set up. It is public-private-partnership connecting stakeholders in R&D, Clinical Development, Hospitals, Pharma, Enterprises and Venture Capital.

Critical Raw Materials and Services for Diagnostics, Vaccines and Pharmaceuticals. Where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. Biosynth's mission is to supply critical raw materials and services to the pharmaceutical and diagnostic industries. Biosynth strives to de-risk its customer's supply chains. Our expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Biosynth is a life sciences reagents, custom synthesis and manufacturing services company. We are by scientists, for scientists, securing supply chains with consistent quality, across the globe. We manufacture and source a vast range of chemical and biochemical products, and take pride in delivering products that others cannot. We are experts in complex chemistry, peptides and key biological raw materials. We provide a full range of products and services to support life science research and development, with more than a million products in our research catalog and hundreds of complex manufacturing service projects. The trusted supplier, manufacturer and partner for the pharmaceutical, life science and diagnostic sectors, along with customers across food, agrochemistry and cosmetics, we have facilities across three continents and a rapid global distribution network. We produce chemicals on the milligram to ton scale, and at ISO 9001 and GMP, with peptides at mg to multikilogram scale. Biosynth's services and products include enzyme development and biocatalysis, reagents for in vitro diagnostics and bioconjugation chemistry. Biosynth is owned, among others by KKR, Ampersand and Senior Management.

Biotest is a specialist supplier of plasma proteins and biotherapeutic drugs used to treat diseases of the immune system or the haematopoietic system. The value chain of the medium-sized company, which was founded in 1946 as a family business, ranges from pre-clinical and clinical development to worldwide marketing. Biotest specialises primarily in the fields of clinical immunology, haematology as well as intensive care and emergency medicine. As the world market leader in hyperimmunoglobulins and the only manufacturer of IgM-enriched immunoglobulins, Biotest sees itself as an expert for innovative products for the prevention and therapy of life-threatening and rare infections. In addition, Biotest supports doctors and patients with coagulation factors that are also produced on the basis of human blood plasma. Among other things, the company has state-of-the-art plasmatic factor VIII and factor IX concentrates for the treatment of the congenital coagulation disorders haemophilia A and haemophilia B. Since 2019, the product portfolio also includes a first recombinant FVIII preparation from a human cell line. Biotest currently employs more than 2,000 people worldwide, the majority of whom are based at the company's headquarters in Dreieich near Frankfurt. The internationally active specialist supplier has subsidiaries in eight countries and sells its products in more than 80 countries. The plasma used is mainly obtained in the company's 22 plasma collection centres in Europe and meets the strictest official safety and quality requirements. Biotest manufactures all products exclusively in Germany.

Bio-Thera Solutions is a clinical-stage pharmaceutical company focused on biologic therapeutics. Bio-Thera is developing a pipeline on innovative enhanced monoclonal antibodies and antibody-drug conjugates for the treatment of a broad range of cancers and other diseases as well as a pipeline of biosimilars in the autoimmune and oncology therapeutic areas. The company is headquartered in Guangzhou, China.

Biotheus (普米斯生物技术) aims to discover and develop effective therapeutic biologics for patients with cancer and inflammatory disease. We believe in creative scientific and industrial/academic collaborations in order to reach this common goal.

BioVision is now part of Abcam. BioVision is a privately held Life Science company headquartered in the beautiful San Francisco Bay area. Founded in 1995, BioVision specializes in the supply and integration of high quality imaging technologies to support research. In August 2021, Abcam acquired BioVision for $340 million, and it is now part of Abcam.

Our company was Founded in 2007, Minnesota Bioworld Biotech., a company (Bioworld) is a private enterprise. We are committed to providing customers with innovative research tools, used to help determine the mechanisms of cell function and disease. Company since its establishment, has become the Bioworld antibody of cellular signal transduction pathways of the world's leading manufacturers. We are the world research, diagnosis and treatment to provide quality products, to contribute the biological world.

Accelerate your research from pilot to pre-clinical phases. Rely on us to deliver the largest catalog of monoclonal antibodies formulated specifically for in vivo use and provide customizable antibody production services - backed by 25 years of experience.

Bio-Xtal is historically a provider of structural biology services. Since twelve years, our know-how in structural biology allowed us to perform projects ranging from domain definition to the structure resolution of protein/ligand or protein/protein interactions by Xray crystallography and NMR. We put an emphasis on monitoring the activity of our targets to ensure the relevance of the structural data we deliver. Our policy is to systematically develop home designed activity assays during our structural biology projects. Mastering eukaryotic and prokaryotic expression systems allows us to supply high quality protein for the needs of your compound screening as well as for structural studies of the selected compound’s complexes, guarantying the coherence of the results obtained on both sides A new key service from of Bio-Xtal is the cytosoluble single chain antibody fragment selection (Cytobody™). These can be raised against any antigen within a very short delay (4 weeks) and are very well expressed in either mammalian or bacteria cells. This allows their expression in Coli for large scale production and expression within mammalian cells for cellular biology applications. The applications of the Cytobodies ranges from the discovery of new druggable sites in multi-domain proteins to immuno-detection, cell imaging, protein purification, and protein stabilisation.

BiVictriX is an emerging drug discovery and development company generating a pioneering new class of next-generation anti-cancer therapeutics which exhibit superior selectivity towards the cancer. Existing antibody-based approaches have shown considerable therapeutic benefit in a number of cancer indications, however the wider application of these drugs to more challenging settings is limited by the shared expression of the targeted antigens on healthy tissues. Thus leading to debilitating and sometimes fatal toxic side-effects associated with treatment. The lack of true cancer specificity seen with existing platforms has resulted in many antibody-based therapeutics being removed from the clinic and is one of the major factors limiting the development of this otherwise promising therapeutic class. BiVictriX's Bi-Cygni therapeutics are engineered to selectively target unique cancer-specific twin antigen fingerprints, which are largely absent from healthy cells. The Bi-Cygni approach links the Company's in-house panel of cancer-restricted twin antigen fingerprints to generate the next generation of bispecific ADC therapeutics with enhanced therapeutic index, across a broad range of malignant indications. The Company's initial focus is on the generation of Bi-Cygni Antibody Drug Conjugates (ADCs), with future plans to expand the technology to other therapeutic modalities (Cell engagers and CAR-T).

Bliss Biopharmaceutical (Hangzhou) Co., Ltd. is a clinical-stage biotech company dedicated to the discovery, development, and commercialization of anti-tumor biotherapeutics. With the core value of 'Together, We Improve Human Health,' the company focuses on multi-level collaborations and developments to advance its mission.

Founded in 2016, Bluefin BioMedicine is a privately held company focused on the detection of novel cancer antigens and the development of next-generation medicines for the treatment of cancer. We are using proprietary, cutting-edge protein detection methods to interrogate complex tumor specimens and discover differentially expressed cancer antigens that can be targeted with antibody therapies. Our focus is on cancers with clear unmet medical need and building a robust portfolio of therapeutic candidates that address those needs.

Blue Heron has been collaborating with some of the most brilliant minds in the industry to create millions of complex genes using our proprietary GeneMaker® multi-technology platform. We are the first gene synthesis company founded and solely operated in the USA. Our only location in Bothell, Washington subjects us to strict U.S. standards for Intellectual Property (IP) Policy and ensures every contract for each customer is confidential. Because of our simple flat rate pricing, we deliver what no other company can provide — the assurance your project will proceed as quoted. Utilizing high grade reagents and proprietary technology we produce DNA of the utmost quality. Our aptitude for projects involving unusually long or difficult sequences allows clients to eliminate errors, risk, and costs that are simply no longer a necessary part of the research process. Blue Heron Provides: - Dedicated Customer Service - Simple Pricing - Easy Ordering - Strict Client Confidentiality - Guaranteed Turnaround Time - Sequence Design - Synthesis of Genes up to 50KB - Complex Genes (hairpins, repeats) - 100+ IP free Expression Vectors - Free Codon Optimization - Free Archiving Publications Citing Blue Heron Biotech Gene Synthesis: http://www.blueheronbio.com/assets/documents/citations/BlueHeronBiotechCitations.pdf

The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HBV infection. Bluejay has exclusively licensed global rights to advance several HBV programs, including a best-in-class anti-HBsAg monoclonal antibody.

BlueWillow Biologics® is developing and enabling a new generation of safe and effective nasal vaccines to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. Our novel intranasal NanoVax® adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including Peanut Allergy, HSV-2, Covid-19, Anthrax, Pandemic Flu and RSV.

Boditech Med Inc. has been developing products for in-vitro diagnostics and diagnostic reagents for the past 20 years by pursuing the value of a company called "Respect for Life"​. In particular, about 60,000 units of ichroma ™ readers are installed and operated world wide, and ichroma™ CRP (C-Reactive Protein) has secured its largest market share in China, showing a unique competitiveness. Boditech Med Inc. is leading the way in exploring new markets through the automation of on-site diagnosed immunodiagnostic devices and the development of new high-sensitive diagnostic reagents. We have built up our reputation successfully by carrying out various national R & D projects based on solid technology, experience, and human resources accumulated over the years. In addition, Boditech Med Inc. is developing a smart production system that integrates digital technology and IT technology to flexibly manage the production scale. All employees of Boditech Med Inc. is making every effort with pride that we are the top leader of BT-IT convergence industry in Korea.

Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.

Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.

With 30 years of expertise, Boster Bio is committed to producing high-quality antibodies and ELISA kits at the best value for researchers worldwide. Our global distributor network extends beyond 30+ countries and delivers rigorously validated antibodies, ready-to-use kits, and reagents that have received over 60,000 citations. At Boster, our customers' research is our priority. Our mission is to help customers achieve their research goals so that they can stay on the cutting edge of research. To honor our customers' goals, we choose to uphold high quality standards by manufacturing our antibodies and ELISA kits in our very own facilities from start to finish for strict monitoring, efficiency, and optimization. Let us become your partner in research. Get better results with Boster. For more information, please visit www.bosterbio.com.

BITT’s dominant antibody antagonist antibody platform (DOMabTM) is a proprietary discovery platform for the development of antagonist monoclonal antibodies to the TNF superfamily. DOMab antibodies create unique surface stabilization of anti-parallel dimers for altering intracellular signaling. For TNF superfamily proliferative pathways (such as TNFR2, TRAIL and HVEM), antagonism causes cell death. For death receptors (such as CD40, CD27 and OX40), antagonism permits cell growth. Our technology’s ability to create antibodies that target only rapidly proliferating cells opens the door to TNF superfamily targets that were previously considered undruggable or limited by toxicology.

Transforming the right molecules into the best medicines™ Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for our diverse pipeline.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in combination with a PD-1 inhibitor, retifanlimab (provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for advanced breast cancer.

BrickBio's engineered RNA and protein-chemistry platform technology enables custom tailoring of any protein with homogenous, site-specific and site-selective bioconjugation modifications, enabling novel classes of biologics with superior therapeutic windows and characteristics such as half-life, dosage, and efficacy. Having validated its precise and unrestricted conjugation capabilities through pharmaceutical co-development partnerships, the company is building its internal oncology and immunology pipeline by creating unique antibody and bispecific-conjugates while additionally pioneering spatial protein assembly for Precise Protein Origami™.

Bright Peak are developing a portfolio of first-in-class and best-in-class cytokines with optimized biological properties for the treatment of cancer and autoimmune diseases. Through a variety of proprietary technology platforms, Bright Peak is uniquely abled to conjugate its cytokines as payloads to antibodies, creating bespoke, novel and proprietary “Bright Peak Immunocytokines”, and to other cytokines as “duokines”. The Bright Peak Immunocytokines allow tissue- and cell-specific targeting of the cytokine payload with the added potential for significantly enhanced efficacy. One of the many advantages of our approach is its "off-the-shelf" feature. Using a pioneering site-specific ADC-like chemical conjugation technology, any therapeutic antibody at any stage of development can be conjugated with Bright Peak’s cytokine payloads of choice, eliminating the current complexities of antibody engineering and cell line development. Bright Peak’s team works with a passion for innovation and bold science. We are an international research-driven organization dedicated to discovering and developing cutting edge therapies that will make a difference in the lives of patients. We aim to create a vibrant and international corporate culture and are currently hiring in our Basel, Switzerland and Southern California locations.

Brii Biosciences is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice. Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline. Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.

Brise Pharma is a clinical stage biopharmaceutical company with a major focus on the development of innovative and highly differentiated treatments for chronic pain.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

BroadPharm is a leading customer-focused biotech company. We are dedicated to manufacturing and supplying high-purity PEG Linkers, Click Chemistry Tools, ADC Linkers, PROTAC Linkers, Drug Delivery Lipids, and Labeling Reagents to our clients worldwide. Founded in 2009, BroadPharm takes our customer needs as our highest priority. We have over 8,000 PEG Linkers, Click Chemistry tools, ADC Linkers, Lipids, Fluorescent Dyes, and Nucleosides. In addition to our broad catalog selection, we also offer IP-protected custom synthesis and bio-conjugation services for our clients in the pharmaceutical and biotech industries. We provide timely technical support to address our client's needs and offer technical advice for the best use of our new products. With our strong expertise in modern chemistry along with innovative and novel Lipid & PEG technology supported by state-of-the-art equipment, BroadPharm can help our customers accelerate their research through cost-effective and efficient solutions.

Broadwing Bio is advancing antibody therapies to treat common causes of vision loss. Focused on genetically validated targets, our goal is to develop best-in-disease therapies to meaningfully preserve eyesight for glaucoma and geographic atrophy patients.

Bryllan is a contract manufacturing company that specializes in producing potent and cytotoxic compounds meeting US FDA and global regulatory standards.

With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.

Calder Biosciences, Inc. is a nano-scale molecular engineering company that is applying its platform technology to develop novel respiratory syncytial virus (RSV) and universal Influenza vaccines that both represent multi-billion dollar market opportunities with mitigated clinical risk.

Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

Cambridge Protein Arrays Ltd. is a SME founded in 2010 and located in Cambridge, United Kingdom. We offer products and customised services in the area of protein microarrays and related areas. We are the distributors of HuProt™ arrays, the largest human protein arrays available, with more than 23,000 human proteins, representing 80% of the human protein coding genome, on a single slide. HuProt™ arrays have been successfully used for antibody and small molecule specificity screening, autoimmune antibody profiling, and interactomics. Cambridge Protein Arrays Ltd. also offers customised protein array services for high throughput screening, autoimmune biomarker validation, and tailored consulting services in the microarrays and antibody area.

Cambridge Research Biochemicals is a biotechnology company that specializes in custom-made peptide and antibody tools.

CanariaBio is a biopharmaceutical company that focuses on developing and commercializing immunotherapies for cancer, utilizing a technology platform of tumor antigen specific monoclonal immunoglobulins targeting CA-125, MUC1, PSA and Her2/neu.

CANbridge Pharmaceuticals is a pharmaceutical company that focuses on developing and commercializing innovative medicines to address unmet medical needs.

Developing innovative therapeutics to materially improve the lives of patients. We strive to be transparent and open in our goals, plans, and progress.

Cantargia develops antibody based therapy against the target IL1RAP. The lead candidate CAN04 is for treatment of solid tumors and hematoligacal cancers, entering phase I/IIa clinical development.

CARBOGEN AMCIS leverages its world-class chemistry skills to provide seamless drug substance, drug products development and commercialization services for leading pharmaceutical and biopharmaceutical companies. We help customers create a better world by becoming the partner of choice thanks to our innovative solutions. We offer an array of integrated and customized services operating in a fully cGMP-compliant infrastructure, including dedicated Highly Potent API facilities and a clean room for Antibody Drug Conjugates. Beyond our services, we also provide high-quality Cholesterol and Vitamin D analogs. CARBOGEN AMCIS is owned by Dishman Carbogen Amcis Limited, (India). Learn more about us: www.carbogen-amcis.com

CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.

Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra's high throughput LSA, LSA-XT, and Ultra platforms for monoclonal antibody (mAb) and small molecule screening and characterization combine patented microfluidics technology with real-time High-Throughput Surface Plasmon Resonance (HT-SPR) and industry-leading analysis and visualization software. These systems deliver up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing label-free platforms. The LSA-XT and Ultra instruments introduce enhancements to Carterra’s flagship product, the LSA, increasing sensitivity and enabling new applications in biotherapeutic discovery and small molecule analysis. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity. For additional information, please visit www.carterra-bio.com.

Building a smarter roadmap for precision therapeutics.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company’s product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited; Juventas Cell Therapy Ltd.; Pharmathen Global BV; and Cleave Therapeutics, Inc. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.

CatalYm is a Germany-based biotechnology company that researches and develops gene therapies for the treatment of cancer.

Catapult Therapeutics is a privately held Dutch biotech company developing CAP-100 – an innovative first-in-class humanized anti-CCR7 antibody.

CD ComputaBio is a professional computational biology service company. Our service spans across different areas in computational biology, providing access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. We are committed to providing high-quality data and customer service to various industrial and academic customers.

CDI Labs combines proteomic libraries and synthetic biology to create Monomabs™, proteome-validated monospecific monoclonal antibodies, and the immunoprofiling service Antygen™.

CDR-Life is a biotherapeutics company developing novel therapies harnessing the power of the immune system. Today’s cancer immunotherapies are powerful but are not tumor targeted, which compromises both efficacy and safety. We are developing a next generation of highly tumor-selective immunotherapies to truly empower the immune system to eradicate malignant cells without the off-tumor-related limitations of current immunotherapies. CDR-Life has developed the unique M-gager® technology to generate MHC-specific antibody-based T cell engagers that target highly tumor-specific intracellular antigens with unparalleled specificity. Our dual-MHC binding molecule format based on antibody fragments has the promise of developing new immunotherapies with high tumor cell killing potency, longer duration of effect, and lower risk of immune-related adverse effects. CDR-Life is advancing a growing portfolio of novel and highly tumor-selective immunotherapies based on the M-gager® technology.

Celemics is a Next Generation Sequencing (NGS) full solution provider based on target enrichment technology. We confidently offer custom target enrichment panels and high-quality pre-set panels, covering fields such as Inherited Diseases, Oncology, Immunology, and Pathogen Diagnostics. With 13 years of experience, we will provide the best solution for your Targeted Sequencing. [Products/Services] OncoRisk (Hereditary Cancer) | CancerScreen (Somatic Cancer) | Custom Target Enrichment Panel | Whole Exome Sequencing | Clinical Exome Sequencing | BRCA 1/2 | PharmacoScreen | Comprehensive Respiratory Virus | Agrigenomics

Celetrix is the leader in electroporation with our new high efficiency electroporation technologies for delivering DNA, RNA and proteins to cells. Celetrix provides technology and support for CAR-T manufacturing by transposon mediated expression and RNP mediated gene editing for T cells, stem cells and CD34+ HSC.

Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody-drug conjugates, immune system modulators and other protein-based therapeutics that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications.

Celldom is developing next generation, high throughput single cell analysis technology to advance research, drug discovery, and drug development by illuminating diversity in cell populations. The company's cloneXplorer and proprietary nanowell plates uniquely integrates both phenotypic and genomic data at massive scale (up to 100,000s of cells per experiment) to identify and characterize rare cells that play critical roles in biological pathways and disease. Celldom is developing initial applications of the platform in the areas of oncology, immunology and stem cell biology. Learn more at www.celldom.com and follow the company's growth @celldominc on Twitter.

Cellenion offers solutions and technologies for controlled cell dispensing with applications in the fields of single-cell isolation and bioprinting : Ability to manipulate single-cell has long been a challenge for the scientific community due to their micrometric size and delicate nature. Cellenion has developed and patented CellenONE, a breakthrough single cell isolation and dispensing technology. CellenONE provides outstanding single cell precision, high throughput, and unmatched recovery. Bioprinting is the process of generating spatially-controlled cell patterns using 3D printing technologies. Cellenion will aim toward both miniaturization and automation in order to produce reproducible models of different complexities.

Cellex has developed a rapid test for IgG and IgM antibodies to SARS-CoV-2. The company hastests that detect antibodies to multiple kinds of pathogens including HIV, HCV, Syphilis, HSV, and also makes tests for diabetes.Cellex received emergency use authorization (EUA) for its COVID-19 antibody test from the FDA for qSARS-CoV-2 IgG/IgM Rapid Test in 3/2020

Born in 2005 as a biotech company, Anagenics (ASX: AN1) has evolved into a growing beauty, health and wellness business with a strong portfolio of functional skin, hair and wellness brands. We own a beauty distribution company, BLC Cosmetics, which distributes some of the leading names in the beauty and skincare sector. We also develop, manufacture and market two beauty and wellness brands; Uspa and evolis. To learn more, please visit anagenics.com

Founded by research scientists in 1999, Cell Signaling Technology (CST) is a private, family-owned company that prides itself on operating as a research institute developing quality products for other researchers. Active in the field of applied systems biology research, particularly as it relates to cancer, CST understands the importance of using antibodies. That's why all of our antibodies are painstakingly validated for multiple applications by our Ph.D. level scientists. And the same CST scientists who helped produce your antibody will also provide technical support, methods, and guidance needed to achieve the most reliable results. Check out our website! For Research Use Only. Not for Use in Diagnostic Procedures.

Celltrion is a leading biopharmaceutical company that specializes in research, development and manufacturing of innovative therapeutics. We are committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. We have been at the forefront of biotherapeutic development uncovering new ways of targeting the drivers of disease by creating next-generation biologics and small molecule products. For additional information on our guidelines, please visit: http://tinyurl.com/bdh9bxs9

Celonic is a "Pure Play" Biologics Contract Development Manufacturing Organization (CDMO). Celonic's mission is to help its customers, primarily small to large Biotech Companies, bring life-saving and improving drugs effectively to the market using innovative, "next generation" bioprocessing technologies such as, process intensification and full-perfusion. Celonic has a state-of-the-art Development and Innovation Center in Basel, Switzerland (headquarters), and clinical and commercial GMP manufacturing facilities in Heidelberg, Germany. At present, more than 500 highly qualified employees work at Celonic. Due to the expansion of the company, Celonic is looking for committed and qualified employees. Our job is to make a difference!

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases.

Cenna Biosciences is revolutionizing Alzheimer's treatment with proprietary small peptides and molecules that inhibit beta amyloid production. The company is focused on developing disease-modifying drugs for Alzheimer's disease using a proprietary novel mechanism.

Centauri Therapeutics Limited is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity"​ in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ assets include specific leads and platform chemistry that is protected by strong IP and a family of granted patents and applications.

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company’s preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.

Centivax’s mission is to accelerate the world’s transition to a post-pathogen humanity.

Centrose is a biopharmaceutical company that develops and commercializes small molecular drug therapeutics for the treatment of cancer.

CentryMed is a biopharmaceutical company located in Frederick, Maryland, neighboring the National Cancer Institute (NCI) and numerous pioneering biotechnology companies and supporting entities. Since its founding in 2018, CentryMed has been dedicated to discovering and developing safer and more effective biotherapeutics for the treatment of various diseases.

Cerberus Therapeutics utilizes nanobody-based platform to create novel therapeutics for modulating the immune system. The COVID-19 pandemic highlights the need for safe and accessible therapies to modulate our immune responses. We have developed strategies that allows for precise turning on/off the immune system in response to debilitating diseases. Our pilot programs focus on autoimmune disorders and infectious diseases, that are based on novel biological discoveries originating from decades of work by our three founders: Dr. Novalia Pishesha, Prof. Hidde Ploegh, and Prof. Harvey Lodish.

With more than 45 years’ experience in the pharmaceutical industry, Swiss-based CERBIOS is specialized in the manufacturing of Generic APIs&HPAPIs alongside with finished formulations based on its own probiotic strain and exclusive CDMO services for HPAPIs, ADCs and recombinant proteins. 𝐏𝐡𝐚𝐫𝐦𝐚 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐬 Cerbios portfolio covers a wide range of drug substances including reduced folates such as Calcium Folinate (Leucovorin Calcium), Calcium Levofolinate, Folinic Acid, 5-Methyl-Tetrahydrofolic Acid Calcium Salt, Sodium Folinate, as well as other folates manufactured exclusively for customers. Starting from 1993 Cerbios specialized further in the commercial manufacturing of HPAPIs, with a particular focus on Vitamin D Derivatives, (analogues). Cerbios has also a long standing experience in the probiotics field. For more than 40 years Cerbios produces its finished pharmaceutical drug based on proprietary strain Enterococcus faecium SF68®, for treatment of diarrhea and dysbiosis by antibiotics. Due to the unique characteristics of SF68®, Cerbios recently marketed two new Food Supplements for the management of ACNE & Seborrheic dermatitis and to boost immune response; other new formulations/application are in development phase. 𝐂𝐃𝐌𝐎 Services Cerbios is the ideal partner from clinical to commercial supply of API, HPAPIs, Payloads, ADCs, Proteins and Antibodies. Services offered include Process & Analytical Development, Scale-up and Clinical Supply, Industrial Validation, Commercial Supply, Full CMC Regulatory Support. Within its ADC dedicated division -Proveo (TM)- Cerbios has leveraged the combined experience in Payloads and recombinant proteins to offer an end-to-end solution for Antibody Drug Conjugates (ADCs). 𝐀𝐧𝐢𝐦𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 Products CERBIOS offers a range of products for animal feed or veterinary application including probiotic feed additives Cernivet® LBC G35, Cernivet® LBC ME5 PET, Cernivet® LBC M10, Cernivet® LBC M20 plus.

Highly specialized and customer-oriented, Certest Biotec consists of four divisions, including Raw Materials, Immunodiagnostics (Rapid Tests, Turbidimetry, and CLIA), Molecular Biology under the VIASURE brand, and Pharma. Certest Raw Materials provides high quality solutions for developing and manufacturing your IVD assays. Our expertise in protein expresión & purification, monoclonal antibodies develoment & manufacturing and primers & probes manufacturing offer to our customers a priceless support in their challenging proyects. Certest Immunodiagnostic -Rapid Test, Turbidimetry, CLIA- is committed to providing a comprehensive portfolio of diagnostic reagents for detecting infectious diseases and different markers, covering different needs of formats, types of use, throughput, precision and time from sample to result. VIASURE offers a reliable molecular diagnostic solution, from sample to intepretation of results, covering a wide range portfolio of products and enabling laboratories to better inform clinical decissions. The objective of Certest Pharma is to contribute with its technology to obtain better therapeutic products based on RNA. It is focused on three main áreas: RNAs, Delivery and Vaccines. Additionally, the expertise of our highly qualified personnel, currently numbering over 300 employees, is at the disposal of our customers, offering development and manufacturing services for the production of their own materials.

Resident company JLabs San Diego focused on the development of immunotherapy for substance abuse.

CG Oncology, Inc. (Nasdaq: CGON), is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life. Our lead candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. Cretostimogene grenadenorepvec is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with cretostimogene grenadenorepvec in combination with OPDIVO® (nivolumab).

Our flagship methylarginine-specific antibody, anti-mRG, is specifically designed to recognize the greatest number of methylproteins currently known. The immunizing antigen is based on a site of methylation found in a minimally required peptide sequence of consensus for arginine methylation.This tool provides a fundamental advantage for research that is exploring the importance of protein methylation in biological systems.

Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today's needs and innovating for tomorrow's challenges. At the core of our services is the Champions TumorGraft® (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts® PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations. Champions TumorGraft® PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the company's Personalized Oncology Solutions business. Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients' cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patient's tumor, enabling them to better select treatment regimens.

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe.

CharlestonPharma is a biopharmaceutical company that develops a lead IgG1 monoclonal antibody targeting nucleolin transporter on tumor cells to induce apoptosis and cell death in various cancer cell lines.

Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, in a Phase 1/2 clinical trial for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (“NSCLC”). In addition, Checkpoint is currently evaluating its lead antibody product candidate, CK-301, an anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in a Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers. Checkpoint plans to develop CK-301 as a treatment for patients with NSCLC and other solid tumors. Checkpoint is a majority-controlled subsidiary of Fortress Biotech, Inc., and is headquartered in New York City.

About Chembio Diagnostics: Chembio is a leading point-of-care diagnostics company focused on creating fast actionable tests to diagnose diseases quickly and accurately, including STIs and COVID-19, enabling expedited treatment. Chembio tests are easy to use and provide results in approximately 15 minutes using some of the smallest sample sizes of fingertip blood, nasal swabs and other sample types. Chembio recently received FDA CLIA Waiver for the first rapid point-of-care combination test for HIV & Syphilis. Coupled with Chembio's extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com. About the DPP Rapid Test Platform: Chembio's proprietary DPP® technology platform provides high-quality, rapid diagnostic results in 15 to 20 minutes using a small drop of blood from the fingertip or alternative samples. Through advanced multiplexing, the DPP platform can detect up to eight, distinct test results from a single patient sample, delivering greater clinical value than other rapid tests. For certain applications, Chembio's easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzer then reports accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on-site. Objective results produced by the DPP Micro Reader reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.

Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe and well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. The company has reported encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing.

Pharmaceutical Services

who are we : Chempartner is an innovative company adhering to the principle of "Science First, Technology Leads," providing integrated services for pharmaceutical research and production (CRO+CDMO). It has developed advanced technological capabilities, assembled top-tier scientists, and equipped itself with state-of-the-art research, animal testing, and pharmaceutical intermediate production facilities. Vision Statement： We strive to ensure that all drugs can be produced and every disease can be addressed by creating an open-access platform equipped with the most advanced capabilities and technologies in the global pharmaceutical sector. Mission Statement Our goal is to revolutionize and expedite the discovery, development, and manufacturing of pharmaceuticals. By providing a comprehensive open-access platform, we empower our global healthcare partners and improve patient outcomes around the world. Our PROUD Culture Passion: Committed to customer satisfaction, continuous innovation, and a vibrant, energetic workplace. Responsibility: Embracing accountability, handling challenging tasks with integrity, and contributing to the community. Open Culture: Promoting teamwork, diversity, inclusion, and transparent communication. R&D Focus: Prioritizing research and development, advancing scientific excellence, and fostering innovation.

Chiome Bioscience Inc. designs, develops, and sells monoclonal antibody products for medicine, diagnosis, testing, and life sciences. Chiome Bioscience is a clinical stage biotechnology company. Chiome's focus is on discovery and development of antibody-based therapeutics.

Chondrex, Inc. has been shaping the landscape of arthritis and inflammation research worldwide since 1996. Chondrex was initially focused on providing scientists with the tools necessary to study the pathogenesis of Rheumatoid Arthritis (RA) as well as to develop and screen potential therapeutics for RA. Over the past 20 years however, our scope has expanded beyond just RA research. We now offer a plethora of products ranging from collagen and monoclonal antibody reagents to a wide variety of assay kits for use in allergy, arthritis, connective tissue, and nephritis related research. One such product line, the Collagen Antibody-Induced Arthritis (CAIA) cocktails, allows for faster and more consistent dosage dependent induction of arthritis in mice than the Collagen Induced Arthritis (CIA) model. Furthermore, the CAIA model can be induced in almost all strains of mice, (including CIA-resistant, T-cell deficient, gene knockout, and transgenic mice) whereas the CIA model requires a restricted haplotype. Chondrex is committed to providing the highest quality and most reliable products in order to accelerate the rate of discovery in arthritis and inflammation research.

CHO Plus is creating regulatory compliant genetically engineered mammalian cells to be used by biopharmaceutical companies for therapeutic protein manufacturing. Early proof of concept experiments demonstrate CHO Plus cells to be 4.5-fold more productive than parent cells in model system. The CHO Plus approach includes patented methods for genetically engineering mammalian cells; proprietary and patented targeted transfection technology; and efficient clone screening technology.

Chromocyte is a FREE impartial and innovative online resource for designing complex multi-parameter flow cytometry antibody panels and finding the reagents and antibodies that are required for these and other related techniques. Chromocyte includes intuitive interfaces which highlight the latest flow cytometry products and services and will be an invaluable sales and marketing vehicle for those supplying flow cytometry related products and antibodies. Users can input the configuration of their own flow cytometry instruments and search for antibodies in the context of these. We also have a Core Facility Administration Area which allows flow cytometry configurations to be shared by Users in the same facility. We also offer a unique interface for generating antibody search panels - a great time saver! Chromocyte is somewhat unique in that is is based on the solid and developing academic background in flow cytometry of its Founder. We can therefore provide invaluable insights into current developments and the specific needs of the academic and research communities.

Chugai’s strength in R&D and antibody technologies continues on in global efforts for products and services for the benefit of patients. Chugai Pharma USA, Inc. (CPUSA), located in Berkeley Heights, NJ, is a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai). CPUSA supports the planning and execution of global and U.S. clinical programs for Chugai-originated, innovative new drug candidates. Chugai is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs in Chugai’s strategic fields of oncology, bone and joint diseases, and renal diseases as well as other therapeutic areas with serious unmet needs. Chugai develops its products independently from Roche until early Proof-of-Concept (PoC) for worldwide market, including U.S. For late stage clinical development and marketing outside of Japan, South Korea, and Taiwan, Chugai seeks for partnership with Roche, which has the first refusal rights to develop/sell Chugai products, or other third parties.

Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform.

CILOA’S CUSTOMIZED EXOSOMES FOR INNOVATIVE THERAPEUTICS Ciloa is the most experienced exosome-based R&D Company dedicated to the development of new high-potential bio-drugs. By overcoming undruggable targets, Ciloa supports your projects to create new therapeutic and new preventive solutions. Ciloa customizes in vivo exosomes to contain i) fully native membrane protein complexes (GPCRs, Kinase Receptors, Ion Channels, Viral Antigens, Transporters…) embedded in their membrane and ii) chosen cargo proteins inside their cytosol. Natural properties of exosomes combined with Ciloa in vivo disruptive technology allow to develop: - VIRUS-FREE candidate THERAPEUTIC VECTORS able to deliver specifically chosen cargos to any diseased organ. - ANTIBODIES AGAINST UNDRUGGABLE MEMBRANE PROTEIN COMPLEX TARGETS by unlocking all bottlenecks of the antibody development process. - ADJUVANT & VIRUS-FREE candidate VACCINES, thanks to the combination of perfect antigens with the potent natural adjuvant properties of exosomes. Ciloa works through Licensing and Partnerships.

CimCure’s solution is a vaccination based immunotherapy directed to the tumor blood vessels that are common to most solid tumors.

Cimeio Therapeutics is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs for patients with serious and life-threatening diseases. Cimeio’s proprietary technology platform is based on the discovery of protein variants, which when edited into cells allow them to maintain full function while resisting paired immunotherapy depletion. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders.

CinnaGen is an Iranian biotechnology company founded in 1994 and headquartered in Tehran. It is recognized as a leading biopharmaceutical manufacturer and exporter in the Middle East and North Africa (MENA) region. The company adheres to modern quality standards and complies with Good Manufacturing Practice (GMP) regulations for food and pharmaceutical products. CinnaGen offers contract development and manufacturing services, supporting the development of biopharmaceutical products. The company specializes in biosimilars, particularly for immunological diseases, infertility, hormone disorders, and oncology. Notable products include Cinnovex, a biosimilar for multiple sclerosis, as well as therapeutic recombinant proteins, molecular diagnostic kits, and synthetic peptides. CinnaGen's products are exported to various countries, aiming to enhance patient outcomes in the healthcare sector. The company has achieved significant milestones, including being the first in the MENA region to manufacture Taq DNA polymerase and monoclonal antibodies, and it has received GMP certification from the European Medicines Agency for its biologic plant.

CIS Pharma is an independent pharmaceutical research and development company that was established in 1952. It is based in the Basel Area, Switzerland and focuses on developing next-gen immuno-conjugates, ADCs, and radioligand. The company also specializes in novel contact lens coating technology.

CisThera Inc. is a privately owned biopharmaceutical company in the Seattle area. CisThera’s mission is to develop innovative therapeutics to treat cancer, autoimmune diseases, as well as chronic kidney and liver diseases. CisThera is taking a novel approach to identify drugs with greater efficacy that broadly inhibit validated contributors to disease pathogenesis.

Citryll has translated a deep understanding of the neutrophil extracellular trap (NET) pathway to therapeutically address its central role in a broad range of inflammatory diseases. With a unique dual mode of action, the company’s lead antibody, CIT-013, has reached the clinic by demonstrating a precise and powerful ability to control NETs and NETosis. Citryll is initially developing CIT-013 as a novel drug for rheumatoid arthritis and hidradenitis suppurativa, which may serve as enabling indications for a wide spectrum of inflammatory diseases. The initial clinical trials with CIT-013 are expected to provide the foundation for a new treatment paradigm.

Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.

CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company's research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi’s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.

Clarametyx Biosciences Inc. is a clinical stage biotechnology company developing immune-enabling biologic therapies to fight life-threatening infections. Our novel technology platform targets the protective barrier around bacteria, known as biofilms.

Clarus Biologics was launched to increase the availability of safe and effective prophylactic and therapeutic technologies. It’s lead product is a next-generation vaccine Virus Like Particle intended to enhance the effectiveness, efficiency and availability of vaccines.Clarus Biologics is Dedicated to the Discovery and Development of Novel Vaccine and Immunology Technologies

Clasp Therapeutics aims to bring absolute precision to immuno-oncology by developing next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations across hard-to-treat cancers. Clasp is developing T cell engagers to match both the specific characteristics of the patient’s immune system and the specific genetics of their tumor, enabling the creation of exquisitely personalized, yet off-the-shelf, therapeutics. Built upon academic research in the labs of Bert Vogelstein and Drew Pardoll at Johns Hopkins University, Clasp is backed by prominent life sciences investors including Catalio Capital Management, Third Rock Ventures and Novo Holdings. The company was launched in March 2024 and is based in Cambridge, MA and Rockville, MD.

Clean Cells is a GMP-licensed Contract Development and Manufacturing Organization providing R&D, production and quality control testing services to the biopharmaceutical industry. Our two-part site located in Western France holds an innovative process development platform, BSL2 and BSL3 GMP manufacturing laboratories and analytical areas to develop bespoke assays and perform GMP testing. Clean Cells is part of the Clean Biologics group and benefits from the additional experience of sister company Naobios, a CDMO with considerable experience in the development and manufacture of virus-based products.

Clinical Pathology Laboratories (CPL) is a medically-led company dating back to 1948. For over 75 years, we've proudly served the Austin, Texas medical community as their preferred laboratory partner. CPL maintains the largest laboratory presence in Austin with over 2400 laboratory staff and a network of over 150 pathologists throughout the Southwest, serving local communities. Our dedicated staff is committed to delivering top-tier laboratory services through our expansive, full-service facilities, combining local services with nationally-recognized clinical testing services. Discover more about Clinical Pathology Laboratories and our locations at https://www.cpllabs.com/

CliniSciences commercialises reagents (antibodies, recombinants, ELISA kits, RNAi, cDNA clones, probes, PCR/qPCR reagents...) to diagnostic and research labs. As very dynamic company, we do our best to be close to our customers'​ needs in terms of high quality reagents that we propose and in terms of service that we provide (search for a particular antibody, technical support, delivery time, etc.) Our principal assets for better serving you : adaptability, flexibility, reactivity and naturally the competence of the technical specialists at your service.

Biotech services

CLONZ  is a biopharmaceutical firm promoted by a group of young and passionate Biotechnologists, focused on the development, manufacturing and commercialization of Human Therapeutic  biosimilar Monoclonal Antibodies (MAbs).   Clonz got incorporated in 2009  and started its operations in September 2010 at Genome Valley, Hyderabad, India With experienced team coming from recognized leaders in recombinant biosimilar manufacturing, Clonz is committed to delivering quality biologics to make treatment and care affordable to the world population in many disease indications, with special emphasis on Oncology. DSIR (Govt.of India) Recognised R&D unit with fully integrated Mammalian platform to Develop Biosimilar MAbs

Coagulant Therapeutics seeks to address acute bleeding, a significant area of unmet medical need and includes the indications post partum hemorrhage, intracranial hemorrhage, traumatic brain injury and blunt trauma.

COARE Biotechnology is a multidisciplinary drug development company that seeks to advance the current treatment modality of patients with aggressive cancers by coordinately targeting aspects of both the primary tumor and the biological processes that effect metastatic initiation and progression. Our team has garnered worldwide acclaim for their groundbreaking scientific discoveries in support of the novel therapeutic platforms developed here at COARE Biotechnology. We have identified key components within cancer biology that have not been targeted – until now.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) is a biopharmaceutical company developing innovative cell therapy platforms for patients with cancer.

Bio Information is energy! COGNANO, Inc. is a venture to aim for computer-supported drug discovery. The big VHH data obtained from our own alpacas will lead us to a new drug discovery platform. Our goal is to optimize drug designing/development.

Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.

Colorado Serum Company specializesin manufacturingUSDA-licensed large animal biologicals, Colorado Serum Company’s product line includes Serum Antibodies, Bacterins, Toxoids, Bacterin-Toxoids, Antitoxins, Spore, and Modified Live vaccines.

Combotope Therapeutics has developed a proprietary mAb discovery platform designed to target cancer cells without impacting healthy cells. Our platform, known as integrated Design Antibody Libraries (iDEAL), combines glycan and peptide-focused scFv technology, providing antibodies that specifically target the tumor form of a particular protein on cancer cells while leaving healthy cells expressing the same, but correctly glycosylated protein, untouched. Our scFv sequences are of high affinity, making them suitable for easy integration into numerous therapeutic modalities for effective cancer treatment.

Commit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in cancers and autoimmune diseases. Spun out of Aarhus University, and building on more than three decades of research, Commit's Bispecific Complement Engaging (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target. The modular approach of the BiCE™ technology can be used to develop therapeutics across multiple tumor-associated antigens and immune cell targets. Complement is a largely untapped aspect of the body's natural immune system that leverages both the direct cytolytic activity of complement along with its ability to bridge recruitment and activation of both innate and adaptive immune cells – a new approach to killing cells which can be used in combination or on a standalone basis. Commit is backed by major investors including Bioqube Ventures and Novo Holdings, as well as initial funding from the Bio Innovation Institute from Denmark.

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’ scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Complement Pharma is a biotech company developing new therapeutics that target the complement system, an important component of the immune system. With a focus on C6 we aim to fight neurodegeneration in indications like TBI, ALS and MS. Our promising pre-clinical data, shows safety and efficacy of C6 inhibition to modify disease progression in the mentioned indications and beyond. Our first antibody, with excellent characteristics is now getting ready for GMP production and clinical trials. In June 2018 Alexion and Complement Pharma announced their collaboration to develop C6 complement inhibitor CP010 for neurodegenerative disorders.

Compliment Corporationis a start-up biotechnology company developing revolutionary therapeutics in oncology. Ourmission is to improve cancer treatment by dramatically increasing the effectiveness of cancer drugs and by reducing the toxicities associated with standard chemotherapy treatment.

A biotech company dedicated to the discovery and development of protein therapeutics using its proprietary alphabody™ technology. Alphabodies are robust and versatile protein scaffolds, unrelated to immunoglobulins, and inspired by naturally occurring motives. Complix’s proprietary Cell Penetrating Alphabody (CPAB) technology allows it to access a broad range of intracellular disease related targets that are considered “intractable” by currently available drug formats, such as antibodies and small molecules.

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies is licenced to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Conagen is an accomplished biotechnology company located in the greater Boston biotech corridor. We innovate and develop synthetic biology solutions for supporting global partners across a spectrum of current and developing markets. From our proprietary strain development to fermentation and process scale-up, Conagen impacts partners’ abilities to sell and market products in the food, nutrition, flavor and fragrance, pharmaceutical, and renewable materials industries. Our bio-manufacturing capabilities, coupled with extensive platforms of enzymes and microorganisms, gives us the edge in commercial biotechnology. Nature is our inspiration for designing metabolic pathways, improving production organisms, and optimizing production processes. Our discovery and development methods foster sustainability and improve efficiency—from lab to world scale. Plant biology ignited the spark for the creation of Conagen. Today, our bioengineering teams are experts in enzymatic bioconversion and fermentation technology. Nature is our guide for innovating ways to produce natural products and materials. This approach gets us to market faster with better products made competitively and sustainably. Simply, our distinction is creating molecules that are identical to what nature produces. Many of the innovative natural products we make at Conagen are truly proprietary. They are the only ones on the market that are made by natural fermentation which means they are produced biologically and sustainably unlike most chemically synthesized products. As a vertically integrated biotech company, we engage in research and development as well as world-scale production. The advantage at Conagen is our ability to direct the manufacturing of our products. We can rapidly scale our strains to produce what our partners need while maintaining the highest level of quality control throughout the entire process. Scaling up from micrograms to metric tons is our expertise.

ConfometRx is a leader in G protein coupled receptor (GPCR) structural characterization and analysis and GPCR-targeted drug discovery.

Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments. Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies, Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium.

Tianjin Conjustar Biotechnology Co., Ltd. is a researcher and developer of peptide-drug conjugate intended for oncology treatments. The company was established in early 2022 and is located in Tianjin Airport Free Trade Zone. It was founded by Fosun Health Capital and focuses on cooperative development and independent research.

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company’s lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, visit www.contexttherapeutics.com.

Contraria Biotech (formerly AchilleS Vaccines) is a biopharmaceutical development company that aims to create sustainable therapeutic and prophylactic drugs against infectious diseases. We are committed to designing innovative, cost-effective therapeutic and prophylactic products to address some of today's major global health problems, including antibiotic resistance, emerging diseases and pandemics.

Convalife Pharmaceuticals is an innovative pharmaceutical company that specializes in drug research and development for tumor diseases. They are dedicated to developing innovative drugs and focus on antibody biopharmaceuticals and small molecule treatments.

Converge Bio is at the forefront of integrating Generative AI with biological data. Our mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages.

Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.

CORAT develops phage-display derived fully human antibodies into passive vaccines to treat and to protect against COVID-19

Corner is pioneering a new class of immunotherapies. Our versatile dendritic cell hyperactivation (hDC) platform is unique in its ability to address a virtually unbounded range of cancers and infectious diseases. Our platform technology induces exceptional memory T cell responses that provide robust and durable immunity. Corner seeks to transform standard of care, ushering in a new era of robust, rapid, patient-friendly and low-cost immunotherapies – even for the most difficult to treat diseases.

Cortalix is a clinical-stage biopharmaceutical company developing imaging diagnostics and targeted radiotherapeutics based on its proprietary single domain antibodies (nanobodies) platform. Cortalix developed a pipeline of radiopharmaceuticals that target fibrogenesis-related membrane receptors and proteins that appear in early stage fibrotic diseases such as in pulmonary fibrosis, cardiac fibrosis, hepatic fibrosis and several solid cancers with fibrotic stroma, including colon cancer and pancreatic cancer. The Cortalix technology platform is based on the screening and selection of single domain antibodies for myofibroblast-specific membrane proteins and receptors including PDGFRA (CD140a), PDGFRB (CD140b), EGFR, IGF-2R (CD222) and FAP. Our nanobodies do contain a functional group that can chelate a radionuclide suitable for nuclear imaging. Eventually the platform allows for a theranostic approach in cancer using the same single domain antibody for patient identification, targeted therapy and disease monitoring (a combined diagnostic and therapeutic in 1 molecule). Cortalix wants to share its single domain antibodies platform, the selection of new candidate molecules from it and, if appropriate, the development of new radiopharmaceuticals with others and offers this knowledge as a service, whether or not under license.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial.

Couragene believes that delivery of gene and biologic therapies should be safer and more efficient. Delivery of genome modification therapies to brain is further complicated by the physiological barriers. Couragene's STEP (Stimuli-responsive Traceless Engineering Platform) technology has demonstrated great potential to overcome the delivery hurdles for treatment of various diseases, including neurogenetic disorders.

We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to a variety of diseases. By attacking the disease directly with our novel nanoparticle-based technologies and working strategically with our medical and scientific partners we seek to provide treatments and cures previously unavailable to doctors and their patients.

CovalX has been established as the leader in characterizing protein interactions by mass spectrometry. Providing Innovative Technologies and Exclusive Services, CovalX has been doing business with world-renowned Universities, therapeutic companies, and most major pharmaceutical companies worldwide for many years. CovalX AG developed a unique protocol for measuring intact protein complexes using MALDI mass spectrometry. CovalX both sells the tools and/or services for High-Mass MALDI protein-protein interaction analysis. The main applications involve: • epitope mapping (both conformational or linear) • characterizing aggregates from biotherapeutic drugs • analyzing antibody-antigen interactions • rapid characterization of any protein complexes (stoichiometry, inhibition, etc) CovalX also has flexibility and provides services for characterizing any large macro molecules such as PEGylated proteins or polymers. CovalX has recently restructured by moving some of its hardware support facilities and US sales and marketing into the US and establishing an official subsidiary in the Boston area.

Creative Biolabs is specialized in providing custom biotechnology and pharmaceutical services that cover the full scope of biotechnology needs of early drug discovery and drug development. As a trusted provider of the most cost-effective outsourcing solutions, Creative Biolabs has been working for a large number of satisfied clients from biotechnology and pharmaceutical companies as well as government and academic research laboratories all over the world. Creative Biolabs was founded by scientists who are dedicated to the conquering of cancer. We believe to build up a custom-service-centered business model is important for optimizing the drug development process, leveraging accessible resources, and forming a team of various background to conduct drug discovery in future. Our commitment to this long-term goal motivates us to deliver the highest quality results to our clients with speed. Specialties: Protein Production, Hybridoma, Immunoassay, Tissue Array, Antibody Engineering, Other Services Check out our current job openings: https://www.creative-biolabs.com/career/available-positions.aspx

Creative Diagnostics is a biotechnology company based in Shirley, New York, specializing in diagnostic reagents and contract research services. Established in the early 2000s, the company serves global markets in biopharmaceuticals, diagnostics, and academic research. With a team of 25 to 200 employees, Creative Diagnostics generates an estimated annual revenue of $5 million to $25 million. The company offers a range of products, including research-grade and therapeutic antibodies, viral antigens for vaccine development, customizable ELISA kits, rapid test kits, and specialized reagents for gene therapy and bioanalysis. Creative Diagnostics also provides contract assay development, GMP manufacturing for biologics, and custom antibody development through its proprietary Omni-Hybridoma™ platform. Its technical capabilities support rapid commercialization and are particularly relevant for mRNA vaccine development and therapeutic drug monitoring.

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo’s T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody. The Company’s ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications. Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis. Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital.

Cristal Therapeutics focuses on its unique and proprietary copper free click chemistry CliCr®. CliCr® has a higher stability, enables faster reactions, and generates optimal bioconjugate products. Our mission is to offer our CliCr® technology to partners under license agreements in different diagnostic and therapeutic areas.

Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.

CrossBridge Bio is a biotechnology company focused on developing innovative ADC therapeutics using our proprietary stable dual-linker payload technology.

Aberrant functioning of kinases is known to be an important driver in cancer. Targeting hereof has proven to be extremely successful and has already revolutionized the management of numerous types of cancer. At Crossfire Oncology we approach kinases from three different angles: inhibitors, degraders, and degrader antibody conjugates. This tailored approach allows us to design kinase targeting drugs that aim to maximize the therapeutic benefit for cancer patients.

CryptoMedix is a biotech company in the field of Oncology, developing highly innovative treatments for cancer.

CStone (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received ten NDA approvals for four drugs. Multiple late-stage drug candidates are now under pivotal clinical trials or registration. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

CTK Biotech is a biotechnology company that specializes in medical diagnostics for healthcare applications.

Cube Biotech is a contract research organization of membrane protein scientists offering non-GMP services for many applications. We assist in protein preparation, biophysical target characterization, and structure determination by cryo-EM or assay development. Our USP is a vast synthetic copolymer portfolio, enabling more reliable membrane protein research. Copolymers offer, in contrast to detergents, a broad and native picture of your target. Discover endless customization possibilities with our Protein Services – your project, your way, as easy as building with Lego bricks! Build frameworks that are easily incorporated into your own processes. Choose between FTE-based, fee-for-service-based, and milestone-based models. We are looking for long-term collaborations with industrial and academic partners. Contact us to learn more.

Cullinan Oncology is advancing a growing portfolio of innovative, early-stage clinical therapeutic assets by capitalizing on the latest scientific breakthroughs. We combine a unique portfolio model with innovative sourcing techniques and drug development expertise to discover and advance candidates for potentially transformative oncology drugs.

Cullinan Therapeutics is a biopharmaceutical company dedicated to creating new standards of care for patients. They have strategically built a diversified portfolio of clinical-stage assets across oncology and immuno-oncology, as well as autoimmune diseases. The company is focused on developing innovative therapies to address unmet medical needs and improve patient outcomes.

We Focus on Identifying, Acquiring and Developing Disease-Modifying Therapeutic Drug Candidates with Rare Disease Indications

CuraVac is a clinical-stage biotech developing a new class of targeted therapeutic vaccines / immunotherapies for autoimmune diseases. Our first therapeutic vaccine is for myasthenia gravis (MG). Preclinical work is ongoing for other autoimmune diseases including MS and GBS. Future studies will focus on Graves' diease, Hashimoto's disease, Type 1 Diabetes, ...

Curida is a Contract Development and Manufacturing Organization for Pharmaceuticals, based in Norway. We are building on more than 40 years of experience and offer premium quality manufacturing to international pharma companies. Curida has core competency on sterile and aseptic manufacturing of liquid pharmaceuticals. Our core technologies are blow-fill-seal (BFS) and nasal spray. We work with companies ranging from small biotech to Big Pharma. We have a lean and flexible organization that will, enabling a strong partnership with our customers.

Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics or the treatment of cancer. The Company currently has three drug candidates in development: - Emavusertib (CA-4948), an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma and in a separate Phase 1 trial for acute myeloid leukemia and myelodysplastic syndromes. - CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation, or VISTA signaling pathway, being investigated in a Phase 1a/1b trial in patients with solid tumors. - Fimepinostat, an orally available, small molecule inhibitor of HDAC and PI3K enzymes, which is currently being evaluated for future studies. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. We are seeking dedicated, driven, humble, hands-on professionals, from diverse backgrounds, who are passionate about making a difference in the lives of patients and families touched by cancer, and who want to have some fun while doing it. For more information, visit Curis's website at www.curis.com.

Currus Biologics is utilising its proprietary BEAT technology to develop CAR-T cell therapies for the treatment of solid tumour cancers, traditionally difficult to treat with current CAR-T cell therapies. Currus Biologics’ proprietary Bispecific Engagers of Antigen Presenting Cells and T cells (BEAT) technology overcomes many of the challenges presented when treating solid tumours with traditional CAR-T cell therapy, demonstrating CAR-T cell proliferation and persistence, CAR-T cell trafficking to the tumour and immunological memory extending to additional antigens. Currus Biologics is a privately held biotechnology company based in Melbourne, Australia.

Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. In addition, Cygnus now provides innovative viral clearance solutions as well. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. Cygnus provides analytical tools and solutions delivering insights to improve bioprocess development for faster regulatory approval and better clinical outcomes. Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus also offers a unique approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits. Cygnus’ proprietary technology, available through its off-the-shelf and custom analytics programs, sets the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems. Founded by Ken Hoffman in 1997, Cygnus continues to support and advance technology in order to improve biotherapeutic safety and accelerate the movement of new therapeutics through the development and regulatory approval process. Located in Southport, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.

CYTEA BIO is a pre-clinical stage biotech company developing therapeutic products by combining genetically unmodified effector cells and engineered targeting ligands. Its patented Pin™ Platform enables practically limitless combinations of effector mechanisms and targeting ligands for applications in oncology and immunology. CYTEA BIO is the first portfolio company of MedXCell, a European cell therapy venture builder with offices in Switzerland, France and the US. MedXCell focuses on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders, with the aim to turn promising academic ideas into commercially viable propositions.

We at CYTENA strive to empower our customers to serve patients faster and better. To accelerate workflows and bring new insights into biotherapeutic drug development, we provide precise control of individual cells through automation and microtechnology. Our instruments offer automated isolation of single cells with assurance of clonality and selection based on cell morphology. We can isolate many common cell types including bacteria. Our high viability rates make our instruments compatible with cell line development, single cell analysis, and other downstream applications. Most of the top ten largest pharmaceutical companies have successfully integrated cytena instruments into their workflows to quickly produce monoclonal cell lines for antibody development with minimal risk of cross-contamination. cytena instruments are also used for academic research for various topics including cancer, autoimmune disease and genomic research. Our instruments provide many benefits including: Assurance of clonality Every single cell isolated is imaged to provide assurance of clonality. The image sequence is assigned to the well of the deposited cell and stored for documentation. Viability Our instruments gentle handling routinely achieves high cell viability without the need for cell labelling. Purity A disposable cartridge is the only component in contact with the cells ensuring no cross-contamination between samples and no cleaning routines. Easy to use and flexible Our instruments and software are intuitive, user friendly, and can be readily implemented into existing structures and workflows. Interested in joining our team? cytena is a young, dynamic and highly motivated team. We are looking for new team members who also have interest in developing new and innovative products. Feel free to contact us if you have any inquiries on current open positions.

Cytodiagnostics is a biotechnology and diagnostics company based in Burlington, ON, Canada, and Tulsa, OK, USA, and a Research and Development Position at the Innovate Calgary Life Science Hub at the University of Calgary. Over the past fifteen years, Cytodiagnostics has become the pre-eminent global supplier of gold and silver nanoparticles. With a commitment to providing quality materials, our in-depth knowledge of particle behaviour spans from initial synthesis to chemical functionalization and detection molecule conjugation, giving us a unique advantage for incorporating nanoparticles into diagnostic tests. This realization led to the creation of CytoGROUP, a branch of our business with the mission of using excellent materials to provide top-notch lab-based and point-of-care diagnostics. Our team has applied their expertise with chemical modifications as well as antibody and cutting-edge nucleic acid/aptamer detection molecules to create a range of products from lateral flow tests to plate-based assays, along with custom diagnostic test development services. In addition to our two locations, Cytodiagnostics also has an associate company, CytoGroup, which specializes in lateral flow and vertical flow assays, ELISA, ELASA and Aptamer Development. Both products and development services are available. Our goal is to serve our customers with the highest quality products to ensure success in their research and development efforts.

CytoDyn Inc., a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development. Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards. CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected. We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population. CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category. CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.

Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive Flex-NK™ bispecific antibody and iPSC-derived, TALEN® gene-edited NK-cell platforms. FLEX-NK™ bispecific antibodies are built on a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia's proprietary Flex-NK™ technology. The company is also developing three types of iPSC-derived NK (or iNK) cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. ​ These two technology platforms are being used to develop treatment of patients with solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma as well as hematological malignancies such as relapsed multiple myeloma. Clinical studies are expected to initiate in 2023.

Daicel Arbor Biosciences is a development and manufacturing company founded by scientists to serve our peers in molecular biology applications. We are a passionate organization of scientists determined to deliver cost-effective, user-friendly products to researchers of genetics and synthetic biology. The Daicel Arbor Biosciences team prides itself on providing exceptional customer service and timely technical support to new or advanced users on our array of products. We routinely collaborate with our customers and research partners to develop innovative solutions to address their unique applications. From discussing the feasibility of a project to providing fast, reliable laboratory services, we are here to help.

At Daiichi Sankyo, we create essential medicine for longer, better lives. By uniting cutting edge science and technology with a genuine interest in people, we develop high quality, life changing solutions for the patients of today and tomorrow with great care and unwavering dedication. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.us. See our community guidelines here: https://bit.ly/4fLkZS8

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!

Monoclonal Antibody

Defence Therapeutics is a publicly-traded (CSE: DTC, OTCQB: DTCFF, FSE: DTC) clinical-stage biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

DegenRx is a biotech company developing AAV-mediated gene therapy for the treatment of Alzheimer’s disease. Using Adeno-Associated-Viral (AAV) vectors we deliver genes in the brain that initiate the local production of therapeutic antibodies

Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases. Deka is developing the dual cytokine, (DiakineTM) platform. Diakines are comprised of optimized, stimulatory, or suppressive disease specific IL-10 variants coupled to other stimulatory or suppressive cytokines via a T1/2 life extending tissue targeting, non-immunogenic scFv technology.

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.

Desentum is a clinical-stage, research-oriented biopharmaceutical company specialized in developing novel types of allergy immunotherapy products (aka allergy vaccines) that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. We have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivity reaction, we have made discoveries that allow for improved design of vaccines against common types of allergies. Our goal is to provide long-term relief from allergic symptoms with only a few months of treatment, as well as reduce the social and economic burden allergies cause to both individuals and society.

Detroit R&D is a biotechnology company that specializes in manufacturing ELISA, antibodies, and assay kits.

Receiving blood is receiving life. DIAGAST's goal is to help healthcare professionals transmit life with the help of the best blood group determination technologies. Even though it is not always a matter of life and death, transfusion errors are never acceptable. Over the last 30 years, DIAGAST has developed unparalleled expertise and know-how in the transfusion sector. DIAGAST develops, manufactures and markets reagents (for blood group determination), miniaturized laboratories for manual analysis and automated systems. DIAGAST also ensures the research, manufacturing and marketing of all its products. Moreover, DIAGAST offers a wide range of related services, such as a training center for their automated systems, a hotline and on-site follow-up on automaton calibration. We even make control and measurement tools available over the Internet. DIAGAST is now the worldwide leader in the marketing and development of reagents and instrumentation systems that aim to ensure donor and patient compatibility during blood transfusions.

Using a proprietary nano-scale biosensor for a COVID-19 breath-based diagnostic.

Diagnostic BioSystems is a leading developer of specialty Immunohistochemistry reagents. The company is dedicated to high quality antibody production and development of novel multiplex staining reagents. Building on its strong global presence, Diagnostic BioSystems produces novel, clinically relevant tools for pathology market including: monoclonal and polyclonal antibodies, a wide range of detection systems and ancillary reagents for high quality immunostaining. Custom Monoclonal and Polyclonal Antibody Production Services include peptide synthesis, in vitro and in vivo antibody production, purification and conjugation. Diagnostic BioSystems is an FDA registered medical device manufacturer, operating under FDA 21CFR Part 820 Quality System Regulations and certified under ISO 9001:2008 Quality Management System International standards, manufacturing CE marked medical devices, for use in the European market.

Diagonal Therapeutics is a biotech company pioneering a new approach to discovering and developing agonist antibodies. The Company's DIAGONAL platform combines proprietary computational and experimental techniques to overcome historical challenges associated with agonist antibody drug discovery. Diagonal's emerging pipeline – discovered using the DIAGONAL platform – has the potential to deliver life-changing therapies to patients including therapies for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.

Dianthus is a biotechnology company dedicated to designing and delivering the next generation of best-in-class monoclonal antibodies with improved selectivity and potency. Led by a multidisciplinary team of seasoned biotech entrepreneurs and scientists, we are pioneering selective antibodies of validated and emerging complement targets to allow people with rare and severe autoimmune diseases live healthier lives to their fullest potential.

Diaprost is a private pharmaceutical research and development company based in Lund, Sweden. The company's principal asset is hu5A10, a novel Theranostic Antibody licensed for development in the treatment and diagnosis of prostate cancer. Diaprost has also announced promising new studies for patients with metastatic prostate cancer, and has entered into license agreements with other companies for the development of its products.

Founded in 2002 in Cartoceto (PU), Italy, Diatheva is a biotechnology company established as a spin-off from the University of Urbino. 70% of all employees holds at least a PhD and oversees all phases of activity, from research and development to production and finishing. For 20 years, Diatheva has been engaged in the research, development, and production of: - biotechnological products: including monoclonal and polyclonal antibodies, antibody fragments, recombinant proteins, recombinant enzymes, and antigens - molecular and immunoenzymatic assays: such as in vitro diagnostics (IVD), veterinary kits, food analysis kits, and environmental kits. To achieve this, Diatheva collaborates with companies, public and private entities, mainly operating in the fields of oncology, microbial infections, and pharmacogenetics. Diatheva operates a cutting-edge GMP production facility authorized by AIFA since 2006 for biomolecules (APIs) and since 2023 for medicinal products.

Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders. We are building a unique portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology.

DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.

Harnessing the immune system to reimagine cancer therapy

Diverse Biotech is an innovative, clinical-stage biopharmaceutical research company that is committed to discovering and developing novel therapeutics from its proprietary drug platform.

DJS Antibodies acquired by Abbvie (10/20/22) DJS Antibodies was founded upon a vision of creating the next generation of antibody therapeutics. The company is dedicated to developing novel therapeutics to treat chronic inflammatory diseases through the discovery and development of antibodies.

DNARx is a company developing multiple therapeutics for major unmet medical needs, with demonstrated vaccine capabilities as well as protein expression. The company has been awarded a DARPA contract for up to $10.7 million to develop medical countermeasures against biological threats.

Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients. Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.

DotBio is focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, its proprietary DotBody technology. DotBodies are domain therapeutic antibodies which are multi-specific, humanized and highly-stable. The company was founded by Professor Pär Nordlund and Dr. Ignacio Asial, who designed and conceptualized the DotBody technology based on their expertise in protein and antibody engineering at Singapore’s Nanyang Technological University.

Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. For more information, email info@dragonflytx.com.

Dren Bio is a Foster City, CA based biotechnology company, developing power protein-based technologies to deplete pathogenic cells and agents in numerous diseases.

About DualityBio DualityBio is a clinical-stage company focusing on the discovery and development of the next generation ADC therapeutics for patients with cancer and autoimmune diseases. DualityBio has successfully established a number of next generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights. Building upon deep understanding of disease biology and translational capability, DualityBio has advanced 4 assets into global clinical studies, and developed more than 10 innovative product candidates which are currently in preclinical stage. Additionally, DualityBio is continuing evolving its novel protein engineering and ADC technology platforms for the next wave of “super ADC” molecules including diverse payload classes, bispecific ADCs and dual payload ADCs. For more information, please visit www.dualitybiologics.com. 关于映恩生物 映恩生物（Duality Biologics）是一家临床阶段的创新生物药企，专注于为全球癌症患者和自身免疫性疾病患者研发新一代 ADC 疗法。映恩生物已成功构建了多个具有全球知识产权的新一代抗体偶联药物（ADC）技术平台。基于对疾病生物学机制的深入研究和探索，映恩生物已经拥有四项临床管线与十多项临床前创新项目并持续改进其新型蛋白工程和ADC技术平台，以开发下一代“超级ADC”分子，包括全新作用机制载荷、双特异性ADC和双有效载荷ADC。映恩生物已与海内外多个跨国药企达成多项重磅授权合作，并在全球开展多个国际多中心（MRCT）关键性临床研究。致力于成为世界领先的ADC公司。 如需更多信息，请访问www.dualitybiologics.com

Diagnostics

Dyadic International, Inc. (Nasdaq: DYAI) - We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system - but most importantly to save lives.

Dynamic Cell Therapies is developing controllable CAR T cells to address difficult-to-treat cancers. Our platform technology of dynamic control of engineered T cells will improve the safety, efficacy, and durability of CAR T cell therapies. This system will have immediate applications in hematological cancers, with future approaches in solid tumors and autoimmune diseases.

Driven by science and passionate about advancing patient care, DynamiCure is translating breakthrough insights on immuno-normalization into a pipeline of innovative antibody candidates with first-in-class and best-in-class potential to treat cancer, autoimmune, and other diseases.

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com. To view our community guidelines, click here: https://bit.ly/3BYPnpK

We are a global leader in biochemical reagents, assays, and peptides for academic research and pharmaceutical development. Echelon values integrity in business and providing superior service. We serve all our stakeholders with focus on our customers so together we can continue Elevating Science!

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.

Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

Eigen Therapeutics is a biotechnology company developing therapies that make cancer easier to find and eliminate. Eigen is focused on the development of 'priming' therapies that improve efficacy while reducing the toxicity of small molecule therapies.

Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), with working on various activities together with global partners.

Elasmogen is a therapeutic biologics company developing multi-functional products for difficult-to-treat diseases. The company has built a product pipeline that exploits the advantages of its proprietary, patent protected soloMER technology including first-in-class drug conjugates (SDC) and bi-specific products for the treatment of autoimmune diseases. Our oncology assets include a pipeline of differentiated soloMER-targeted RadioPharmaceutical Therapies (RPT) for the treatment of solid tumour cancers.

Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice. Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting.

Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough hyper concentration microparticle technology platform, Hypercon™, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are headquartered in Boston and innovate globally. Formulating the Future of Biologics™. www.Elektrofi.com

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Our experience is rooted in oncology, and we apply the same rigor and diligence that comes with this knowledge to identifying and developing promising medicines for complex yet under-treated health conditions across a range of therapeutic areas. We develop and assess therapeutics based upon their ability to make a meaningful impact for patients and their treatment experiences. We invest in proven and promising therapeutics at various stages of development and advance them through clinical and regulatory processes with the goal of commercializing improved treatment options for patients and the healthcare providers who treat them.

Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are rethinking drug development by seeking out innovative, selective cancer therapies that can be matched to a patient’s unique tumor characteristics. Our lead candidate, EO-3021, is a potential best-in-class antibody drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated molecular target. EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. We are working to rapidly advance EO-3021 into the clinic in the US across a range of solid tumor indications, as well as exploring other opportunities through new or existing partnerships and business development opportunities to expand our novel oncology pipeline.

At Elevian, we are developing new medicines that promote recovery and regeneration. Our lead program is a recombinant protein for the treatment of stroke in the days following the event, for which there are currently no viable treatments. By promoting regeneration, Elevian’s medicines have the potential to treat and prevent many aging-associated diseases.

Eliem Therapeutics, Inc. is a clinical stage biotechnology company focused on developing therapies for neuronal excitability disorders with the goal of restoring balance in both the peripheral and central nervous systems to help patients live on their own terms. Eliem channels its experience, energy, and passion for improving patients’ quality of life by developing life-changing novel therapies for disorders such as chronic pain, depression, epilepsy, focal onset seizures, and anxiety – conditions that make simple daily activities challenging for impacted patients.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Elixiron Immunotherapeutics is driven by a multi-cultural, international team in Shanghai, Taipei, the USA (San Francisco) and Switzerland (Lausanne) with a shared vision to build a global company that brings next-generation immunotherapies to patients in need. This vision drives our mission to target rare and immunological diseases as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.

Elpis Biopharmaceuticals is a biotechnology company focused on developing innovative cell therapies for cancer treatment. The company has a strong leadership team and has received significant funding to support its research and development efforts.

Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on removing immunosuppressive factors in the tumor microenvironment, by targeting the adenosine pathway and myeloid checkpoints. A pipeline of novel molecules has been developed using its proprietary platforms including a powerful Bispecific Macrophage Engager (BiME®) technology that connects and activates macrophages for solid tumor killing without causing cytokine storms.

Elthera AG is a Swiss biopharmaceutical start-up company bringing together experienced pharma and biotech executives with cutting-edge academic researchers to develop proprietary, first-in-class oncology drugs using a personalized health care approach. Elthera AG is developing antibodies against a novel target whose expression is strongly correlated with an aggressive tumor phenotype and poor prognosis in various types of cancer. By combining targeted therapies with companion diagnostics, Elthera AG is aiming at providing new personalized treatment options for patients with the most aggressive malignancies

Eluminex Biosciences is a clinical-stage biotechnology company focused on development and commercialization of innovative therapeutics to fulfill unmet medical needs in the treatment and management of ophthalmic diseases.

Emglev is a biotechnology company established in 2023 as a spin-off of Institut Curie dedicated to the discovery and the development of transformative immunotherapies to address unmet medical needs in oncology. By leveraging its unique proprietary platform, expertise and innovative approach, Emglev unlocks the current barriers of conventional antibody discovery to provide unique targets and sdAbs selected fully in vitro and validated for therapeutic applications in any format against any target. At Emglev Therapeutics, we have assembled an experienced, interdisciplinary team with a unique vision : to unlock the next level of immunotherapies for the benefit of the patients with high unmet needs.

Emmune, Inc. is a start-up biotechnology company that has a novel approach for treating and preventing HIV infection. We engineered a synthetic antibody from the receptors that HIV uses to infect T cells, CD4 and CCR5. Because this synthetic antibody, known as “eCD4-Ig,” is built from the viral receptor and co-receptor, it recognizes 100% of HIV-1 isolates. A single intramuscular inoculation with an AAV vector expressing eCD4-Ig protected monkeys from multiple intravenous challenges with live virus.

EmstoPA is a first in class antibody-based reversal agent to treat bleeding caused by tissue plasminogen activator (tPA - Activase®, Alteplase®). tPA is a “clot buster” used to remove the blood clots that cause stroke, pulmonary embolism, and myocardial infarction. In the developed world, tPA is most frequently used to treat acute ischemic stroke where the rates of subsequent intracranial hemorrhage (ICH) are 5-7% . EmstoPA belongs to a class of drugs called anti-fibrinolytics, and and the current market for antifibrinolytics is estimated to be $1,100m /year. Currently no specific tPA reversal agents are in development.

ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Our lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis and prolonging patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP. A low cost, time efficient development program provides near-term POC within 18 months from financing. A companion diagnostic will detect ETBR pathway over-expressers creating additional opportunities for indication expansion into multiple tumor types and broader participation in the multi-billion-dollar immunotherapy market.

Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead investigational candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The company’s second investigational candidate, ENV-501 is a human epidermal growth factor 3 (HER3)-targeted antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors.

EnGen is an early-stage biotechnology company pioneering a new approach to preventing and treating influenza. We're developing an effective, easy-to-manufacture, shelf-stable universal flu vaccine that confers long-term immunity to all Type A influenza strains—including those which cause seasonal flu and influenza pandemics. Seasonal flu causes 250,000 to 500,000 deaths every year. The CDC and other experts have cautioned that we are extremely vulnerable to the catastrophic occurrence of a global flu pandemic—on a scale that could far exceed both COVID-19 and the Spanish flu of 1918. In its Global Influenza Strategy (2019–2030) report, the World Health Organization has declared the development of a universal flu vaccine as an urgent need—but the unique nature and genetic makeup of the influenza virus poses a challenge to researchers focused on influenza treatment and vaccination. To address these issues, EnGen Bio is developing universal vaccines for Type A flu prevention. Effective for vaccination in both the $6B human and $0.5B veterinary markets, our antibodies also demonstrate potential for therapeutic treatment of influenza, with an additional $2B prospective market. If successful, our efforts will eradicate flu pandemics and dramatically decrease the global burden of illness and disease caused by influenza.

Engineered BioPharmaceuticals, Inc. is a state-of-the-art biotechnology company focused on advancing dry powder pharmaceutical manufacturing and delivery through Atmospheric Spray Freeze Drying (ASFD) technology. Manufacturing dry powder pharmaceuticals using the ASFD process offers many possibilities including increased stability and shelf life of drug formulations, ability to store at room temperature, reduced weight and bulk, and the ability to facilitate the development of novel self-administration methods of delivery, such as nasal and pulmonary. A significant advantage of the ASFD process compared to its competitors is that it allows pharmaceutical powders to be "engineered" for a wide variety of final use applications. A specific final particle size is easily achieved by adjusting the droplet diameter via the spray nozzle. In addition, the density, and thereby the aerodynamic size, can be adjusted independent of the geometric diameter by altering the starting solute concentration. With our population demanding sophisticated therapeutics to extend life expectancy and improve quality of life, contrasted with the dire need to reduce spiraling healthcare costs, there is enormous pressure and opportunity for the pharmaceutical industry to embrace new technologies that answer the call. We are excited about the innovative work taking place at eBio to advance the field and look forward to the opportunity to use ASFD technology to impact the future of medicine.

Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.

EnPlusOne is on a mission to bring RNA and RNA solutions to the world. Its ezRNA™ synthesis platform is a stepwise innovation that can incorporate a diverse array of nucleotide modifications and promises a manufacturing process that can sustainably deliver therapeutic RNA at commercial scales. In addition to direct RNA synthesis, EnPlusOne's ezRNA™ platform supports a vast array of RNA solution applications. For more information, please visit www.enplusonebio.com

enQuire BioReagents is founded to change how scientists are recognized for their contributions to science. If you believe scientists should benefit more from their discoveries, like we do, then shop and learn about enQuire BioReagents at https://enquirebio.com

Ensigna Biosystems is a contract research organization that provides cutting-edge molecular pathology and genomic services to the biopharmaceutical industry. By combining traditional pathology services with genomics, Ensigna Biosystems is able to characterize biological samples based on protein expression, mRNA levels and mutational status, thus enabling the development of targeted therapies and the implementation of personalized medicine.

We develop first-in-class biologics for several underserved autoimmune conditions. Our therapeutic approach aims to preserve and re-establish organ cell function, transforming the treatment paradigm for intractable autoimmune diseases

For more than 45 years, Enzo Biochem has been a leader in innovation and product development to support a diverse range of needs in biomedical research and healthcare. With a comprehensive portfolio of 20,000 high-quality products including antibodies, genomic probes, assays, biochemicals, and proteins, Enzo supports the work of academic research centers and industry partners who are shaping the future of healthcare around the world. The company’s proprietary products and technologies play central roles in all areas of translational research and drug development, including genomic analysis, protein analysis, cellular analysis, tissue analysis, and small molecule chemistry. Enzo Biochem has a broad and deep intellectual property port-folio, with patent coverage across a number of key enabling technologies.

Enzolytics, Inc. is a Texas based biotech company committed to the commercialization of its proprietary proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. The Company is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in treating HIV/AIDS. IPF is the active component of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has also been shown to modulate the immune system. The Company has also pioneered a proprietary method for creating human cell lines that produce fully human monoclonal antibodies directed against many infectious diseases. One antibody (designated as CLONE 3) has been demonstrated in tests in 5 international labs to fully neutralize over 95% of all strains and viral subtypes of HIV-1 against which it has been tested. This proprietary methodology for producing fully human monoclonal antibodies is currently being employed to produce monoclonal antibody therapeutics for numerous additional infectious diseases, including the Coronavirus (SARS-CoV-2), HTLV-1, Ebola, Influenza A and B, H1N1 influenza, H10N3, Respiratory syncytial virus (RSV), Small-Pox, Tetanus, Diphtheria, Rabies, Herpes zoster, Varicella zoster, Herpes HSV 1/2, Anthrax, Elephant endotheliotropic herpesviruses, Feline Leukemia Virus, Equine Infectious Anemia Virus, and Koala retrovirus. The Company has announced a coherent protocol that it intends to execute to meet the Company’s objective of producing a therapeutic cure for targeted viruses as well as a planned protocol to address existing and future pandemics. This protocol has been defined as a result of the Company’s collaboration with Intel Corporation in the field of applying computer analysis (Artificial Intelligence – A.I.) to accelerate health care discoveries and development.

For over 30 years Enzyme Research Laboratories has been manufacturing and distributing a variety of enzymes and cofactors used in basic coagulation research.By constantly striving for products of utmost quality, ERL has earned the trust of coagulation research communities worldwide. ERL is dedicated to serving the research and diagnostic communities by offering a complementary line of monoclonal and polyclonal antibodies.

EpiBiologics is building a next-generation protein degradation platform that targets membrane and extracellular proteins. EpiBiologics was founded in 2022 based on the pioneering work from academic founder Dr. Jim Wells of the University of California San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner. Headquartered in San Mateo, EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas.

A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers world-wide. Our technologies and products are making studies possible that were not imaginable just a few years ago. Our renowned chromatin researchers possess expertise and unique insight into chromatin biology and drug discovery that benefit our customers in ways other companies cannot. Epigenetics, the study of changes in heritable traits that occur independent of alterations in changes in the underlying DNA sequence, is an emerging and important area of biomedical research with broad impact on human health and disease.

EpimAb Biotherapeutics, Inc., is a China-based, privately held, start-up company founded in 2015 that is developing a portfolio of novel bi-specific antibodies in oncology and immune-oncology. All bispecifics are based on a proprietary platform, FIT-Ig (Fabs in Tandem). Multiple FIT-Igs have already been successfully generated binding to small, large, soluble or membrane-bound antigens with biochemical and biophysical properties similar to their parent monospecific antibodies. The first molecule, EMB-01, is a cMET/EGFR-inhibitor, that is in CMC development in collaboration with WuXi Apptec. EpimAb also has concluded licensing arrangements, e.g. with Kymab and Innovent Biologics, and is open to further partnerships.

Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life. The company's lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase I trial to treat ovarian cancer. This is the world's first IgE therapeutic to enter the clinic.

Epsilon Molecular Engineering (EME) Inc. is an evolutionary molecular engineering based biopharmaceutical drug discovery company. EME was established in 2016 as a venture company from Saitama University in Japan, and has proprietary technologies, unique cDNA display libraries of the heavy chain single domain antibodies (VHH) and cyclic peptides with large diversity (10^13-14), and high-throughput screening methods using next-generation sequence, FACS and Machine learning (Bioinformatics). EME is, currently, conducting several joint research projects, including COVID-19, and 17 ongoing inhouse projects in the arias of cancer, inflammation, and Alzheimer’s disease, etc.

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to pioneer new products with a mission to dramatically improve the lives of patients with severe autoimmune and inflammatory diseases who continue to suffer with high unmet medical needs. By bringing treatments designed to restore the balance of the immune system, we hope to restore the balance of life for patients in need. Our lead product candidate, itolizumab, is a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the activation and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. We believe itolizumab may have broad therapeutic utility and our current pipeline is focused on developing itolizumab as a best-in-class treatment for multiple severe immuno-inflammatory disorders – this includes acute graft-versus-host disease, SLE / lupus nephritis and uncontrolled asthma.

Eradivir is a biotech company that aims to develop a non-immunological targeting agent for use against the virus that causes COVID-19. The company has discovered small bispecific drugs that engage both cytotoxic immune cells and the virus. Binding of the drug to the virus leads to the destruction of the virus by the immune system.

Esox Biologics utilises their extensive knowledge of the aquatic microbiome to provide disease prevention solutions that help improve livestock health and welfare.

Neurodegenerative disorders present a huge societal burden, and one from which few of us remain untouched in some way. Unfortunately, by the time a diagnosis is made, it is often too late and irreversible damage is already done. It is essential that patients get examined as early as possible, and that symptoms get diagnosed accurately. This allows the right patients to receive the right treatments at the right time, to help to slow progression, and mitigate symptoms. Pharma and Biotech companies that are developing disease modifying therapies also have a need for biomarkers for neurodegenerative disorders that can help predict disease presence, monitor disease progression and treatment response. ESP Diagnostics is developing scalable liquid-biopsy tests based upon measurements of specific neurodegenerative disease biomarkers in extracellular vesicles (EVs) extracted from blood, saliva and urine. The ESP biomarker tests will allow early pre-symptomatic detection of neurological disorders such as Parkinson’s Disease, Dementia with Lewy Bodies, and a differential diagnosis of Alzheimer’s. We provide assay services to pharma and biotech companies developing disease-modifying therapies (stratification, disease progression, surrogate endpoints, reverse translation, target engagement), and are developing IVD products for patients, clinicians and healthcare providers worldwide.

Etana Biotechnologies is an Indonesia-based biotechnology company that was founded in 2015. The company is in the business of manufacturing PIC/S standard and marketing high-quality and affordable biosimilars for the Indonesian market. Etana Biotechnologies has also secured funding for its oncology pipeline and has received investments from Chinese VCs, Innovent Biologics Inc., and China Medical System Holdings Ltd.

Etcembly’s vision is to decode immune repertoires for health and disease. The TCR repertoire holds the answers to therapeutics and biomarker information, and Etcembly is assembling the world’s largest health and disease immune database, to revolutionise immunotherapy and personalised therapeutics across all patient groups, globally. We are pushing the frontiers to explore the intersection between immunology and machine learning.

Etna Biotech srl - Zydus Cadila Research Center is a company based out of Italy.

Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer. Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage. Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.

EUROIMMUN'un uzmanlık alanı immünoloji, hücre biyolojisi, histoloji, biyokimya ve moleküler biyolojidir. Otoimmün ve enfeksiyöz hastalıkların, alerjilerin ve gen analizlerinin laboratuvar tanısı için test sistemleri üretir. Hasta numunelerinde antikorların tespiti için test sistemleri ön planda olmakla birlikte, antijenler ve genetik markerlar da mevcuttur. Bunlar, indirekt immünofloresan, mikrotitreli ELISA'lar ve farklı blot teknikleri (Westernblot, EUROASSAY, EUROLINE, EUROLINE-WB) ve moleküler biyolojik (mikroarray) teknikler gibi immünohisto-kimyasal ve biyokimyasal yöntemlere dayanmaktadır. EUROIMMUN üretimini, dünya çapında patentleri taşıyan modern, son teknoloji prosedürleri ve mikroanaliz tekniklerine dayandırır. Şirket, tıbbi laboratuar teşhis ürünlerinin lider üreticilerinden biridir. Ürünlerimiz Avrupa, Amerika, Asya, Avustralya ve Afrika'da yaklaşık 130 ülkede kullanılmaktadır.   Aralık 2017 itibariyle, Amerikan PerkinElmer firması, EUROIMMUN hisselerinin çoğunluğunu elinde tutmaktadır. PerkinElmer medikal ve biyoteknoloji alanında uluslararası bir liderdir. Yenilikçi tespit ve görüntüleme teknikleri ve IT sistemleri ile, teşhis, tıbbi araştırma, çevre ve gıda analizlerinde kapsamlı uzmanlık sağlar.

Eutilex is a KOSDAQ listed company that researches and develops new drugs with a focus on immunotherapy

Everest Biotech discovers, develops and commercializes anti-peptide and goat polyclonal antibodies for the biomedical industry.

Everlywell believes that health tests shouldn't be hard to get – or hard to understand. The Everlywell experience is simple. You order one of our kits online, you collect your sample from home and return it via pre-paid mail to one of our fully-certified partner laboratories. A board-certified physician in your state will review and validate your results before you get them. Everlywell provides a complete, easy-to-read results report online in just a few days. Our comprehensive tests measure key biomarkers through samples that are collected in the comfort of your home. Everlywell empowers individuals by providing easy access to health data. We are proud to offer 30+ consumer-initiated, regulatory-compliant tests…without a lab visit.

What we do: we supply therapeutic molecules of clinical-grade quality for R&D and early drug development. Our solution: we repackage pharmaceuticals. So, we offer aliquots of clinical-grade mAbs, bs-mAbs, fusion proteins, ADCs, and other biologics as laboratory consumables. As an additional service, we provide analytical data to accompany each aliquot. Your advantage: you can order therapeutic molecules in clinical-grade quality as research consumables. Fast . Easy. Cost efficient.

​evitria is specialized in CHO-based transient expression of antibodies (including bispecific and fusion antibodies). With a track record of more than 120,000 successful antibody production runs for our clients, we can offer fast and reliable project execution at high quality standards (all production facilities in Switzerland). You can benefit from our expertise and unique focus when looking to entrust a partner with your complete antibody production or to manage capacity bottlenecks with single projects.

Sinovent is a global biopharmaceutical company focused on discovery, development, and commercialization of innovative therapeutics for the treatment of cancer and autoimmune diseases.

Exalpha Biologicals Inc. is a business that rapidly develops and markets unique products at the forefront of science. We do this by constantly monitoring scientific trends and literature ensuring that we are producing products that answer the end user’s needs. Originally founded in the 1990’s by scientists who’s primary focus is to manufacture superior quality scientific products that reassures the end user that they can focus on the task in hand. In 2022, we became part of Absolute Biotech, a new company that unites multiple life science brands into one organization specializing in antibody reagents and services. Learn more at absolutebiotech.com.

Recombinant Polyclonal Antibodies

Looking for a trusted partner in the development of cell lines and manufacturing processes? Look no further. With over 20 years of experience, we specialize in high-yielding (5-14 g/L), GMP-ready, CHO, and HEK293 cell lines for the production of biologics, biosimilars, and gene therapy (AAV, Adenovirus). We have a proven track record of expressing all types of proteins, including bi-specific mAb, Fc-fusions, viral proteins, cytokines, and more. Our team of scientists is ready to support your project from start to finish, including process development, analytical methods, scale-up, tox-batches, and Master Cell Banking. At our company, we pride ourselves on our commitment to quality and customer satisfaction. Contact us today to see how we can help you achieve your goals and be your trusted partner in cell line and process development.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

ExeVir Bio, a spin out of VIB, is harnessing its Llama-derived antibody (VHH) technology platform to generate robust antiviral therapies providing broad protection against coronaviruses. ExeVir Bio is using a highly innovative and clinically validated VHH technology to develop treatments for viral infections that may pose a significant global threat. Our lead compound, an enhanced variant of VHH72-Fc binds to a unique epitope that is conserved in SARS-CoV-1 and SARS-CoV-2 viruses and this binding prevents these viruses from entering the cell. The importance of this approach is that it could be used both as a therapeutic and prophylactic. Therapeutic use could help slow viral replication in the lungs, reduce inflammation, and give patients valuable time to raise their own productive immune response. Prophylactic use could support the ringfencing of an outbreak, protect healthcare workers, caregivers and support those at increased risk of severe illness from Covid-19.

EXONBIO is a recombinant antibody and recombinant protein company. SPIN (Single Plasma Cell Interrogation) Technology for rabbit recombinant monoclonal antibody (rrMAb) development.

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We’ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.

At Eyam, our mission is to bring “Next Generation” vaccine and therapeutic technologies to market to solve today's health care needs.

EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.

Fabentech is a privately owned biopharmaceutical SME based in Lyon (France) and created in 2009, which develops immunotherapies to address situations of emergency. In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications. Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions in the fields of biodefense, drug intoxication and infectious disease. After having developed Fabenflu®, a product indicated for the treatment of avian influenza (H5N1) in human, Fab’entech is currently focusing on 3 products: a biodefense antidote developed in collaboration with the French army, a treatment for drug intoxication developed in a confidential indication, and an Ebola therapy developed with the support of the European Commission after having been identified by the WHO as the unique therapeutic solution in Europe in 2014.

Fable Therapeutics Inc. was founded with a conviction to revolutionize drug discovery through the purposeful integration of AI techniques. ‍ Our cross-functional team of ML scientists and drug hunters collaborate to design novel medicines with expanded therapeutic potential. ‍ With this passion and vision, we’re designing the future of drug discovery.

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. Its lead program is bexmarilimab, its investigative precision immunotherapy in Phase I/II development as a novel macrophage checkpoint immunotherapy for patients with hematological malignancies. Bexmarilimab is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Faron is based in Turku, Finland and Boston, Massachusetts. Faron is listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market ("Nasdaq First North") under ticker FARON.

FAST BIOPHARMA LTD is a company based in Aston Rowant, Oxfordshire, UK

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Fida Biosystems (Fidabio) offers a new proprietary technology developed for quantification and characterization of proteins and nanoparticles from 0.5 to 1,000 nm Dh, incl. antibodies, liposomes, exosomes, membrane embedded proteins et al. Based on accurate, in-solution, absolute measurements of hydrodynamic radius, the technology provides precise information about Kd, concentration, size, stoichiometry, conformational changes, oligomeric state, immunogenicity, multiple bindings etc. It is characterised by being fast (minutes), requiring very small sample amounts (ul-nl), and being exceptionally tolerant to the sample matrix, incl. plasma, serum, cell lysate, fermentation media etc. Contrary to most other procedures, the methodology is based on binding in homogenous solution; complications related to non-specific surface adsorption and challenging assay development are therefore avoided. I.e. the unique features of the FIDA technology enable characterisation and quantification in native (biorelevant) environments and in-built assay quality control and automation.

Fina Biosolutions, LLC was founded in 2006 by Dr. Andrew Lees with an initial focus on helping emerging market vaccine manufacturers learn to make affordable conjugate vaccines. The company offers bioconjugation, protein expression, purification, immunoassay design, analytics, training, and consulting services.

Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.

For-Robin Therapeutics, (F-R), is an antibody immunotherapy company, founded in 2012 by Dr. Kate Rittenhouse-Olson. The company name is in honor of Robin Quataert, the Founder’s sister, who died at age 31 of estrogen and progesterone receptor negative breast cancer. For-Robin’s primary mission is treating breast cancer patients. Our proprietary technology (the monoclonal antibody JAA-F11 and humanized variants of it) targets all breast cancer cell subtypes including triple negative breast cancer which currently has no targeted therapy. In addition, this technology should be applicable to colon, prostate, and bladder carcinoma patient populations. For-Robin plans to bring its core humanized JAA-F11 technology as an adjunct therapy to patient populations as quickly, safely and efficaciously as possible.

Fortis Life Sciences® partners with diagnostics and life sciences companies to design, validate, and manufacture solutions to solve their complex development problems. Fortis’ tailored approach and end-to-end capabilities accelerate the work of its customers as they bring the next generation of medicines and diagnostics to market. Fortis serves a global customer base and has offices across North America including four R&D sites and three GMP and ISO 13485 compliant manufacturing facilities. Fortis offers a world-class portfolio of in-house manufactured and validated reagents and solutions through our industry-leading brands: Abcore, Arista Biologicals, Bethyl, Empirical Bioscience, IPOC, nanoComposix, and Vector Biolabs. We are a single partner with the: - Expertise to solve your most complex development problems. - Flexibility to design and validate solutions. - Scale to meet your manufacturing requirements.

Fortis Therapeutics is an immuno-oncology biotech company focused on developing new antibody drug conjugate therapies against CD46 for the treatment of late-stage prostate cancer and multiple myeloma. FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has seven marketed prescription pharmaceutical products and over 20 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children’s Hospital and Sentynl.

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business. Fosun Pharma is patient-centered and clinical needs-oriented. The company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products. Fosun Pharma’s innovative products mainly covered core therapeutic areas such as tumors (solid tumors and hematologic tumors), immunology, central nervous system, and chronic diseases (liver disease/metabolism/kidney disease). Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of “Innovation Transformation, Integrated Operation and Steady Growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global pharmaceutical and healthcare markets.

FREZENT is a preclinical stage oncology therapeutics company based in New York. The company is developing bispecific antibodies and antibody-drug conjugates for targeting dormant cancer cells that may cause cancer recurrence. Dormant cancer cells are tiny residual parts of a tumor, that was not completely eliminated by the treatment. They can remain in the body undetectable for a period of time but eventually these cells can transform back into a fast growing tumor. FREZENT is developing a novel cancer treatment that will block the reactivation of dormant cancer cells. To achieve this goal, we are developing novel cancer therapeutic that can neutralize metabolic factors supplied tumor microenvironment to support the dormant cancer cells. Being in a dormant state, cancer cells depend on these external supplies, and thus blocking this supply will starve cancer cells and induce cell death. Join us in our mission to ensure the future where long-lasting remission is the reality for ALL cancer patients.

F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.

For over 30 years, FUJIFILM Diosynth Biotechnology’s mission has been advancing tomorrow’s medicine. As a CDMO, we work in partnership with the most innovative biopharma and biotech companies across the world who are reimagining healthcare’s potential. We help to accelerate their progress, expand their capabilities, streamline their processes, and strengthen their innovation. So when our customers’ potential cures, vaccines, biologics, and accomplishments make strides – or even become new realities for patients – we know our work, our manufacturing expertise, and our partnership helped make it happen. FDB isn’t simply a workplace. It’s a place of passion – a place of what we call Genki. A place where diverse perspectives and people come to life. Where opportunity for growth has no end. Where passion is followed, discovered, and nurtured. Where the energy is undeniable, enthusiasm is pervasive, and drive is infectious. All of our global locations burst with curiosity, inspiration, and extraordinary purpose. So as we continue to grow our teams, our global locations, and our capabilities, Genki will always be our cultural tie. That’s why we’re always looking for passionate, mission-driven people who want to commit their life’s work to enabling better outcomes for patients and their families. For a full listing of jobs that will propel, inspire, and fulfill you, please visit: fujifilmdiosynth.com/careers/ We created this space on LinkedIn to give people a window into work and culture at FDB. We’re highlighting employees’ passion, current openings, and why it’s never been a more exciting time to join FDB.

Fujirebio is a global leader in the field of high-quality in vitro diagnostics (IVD). We are an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms. Through this business model, we ensure that the potentially life-changing diagnostic markers meet the largest global need in the shortest possible time. Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions. Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network. Fujirebio is today a consolidated subsidiary of H.U. Group Holdings, Inc. (listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1,200 people in Asia, Europe and America.

Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiopharmaceutical company with operations in Europe and China.

Since 2001, Fusion Antibodies has been dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry. We offer a complete range of antibody-related services in Discovery, Engineering and Supply and have guided hundreds of projects through critical preclinical stages. Fifteen of our client's projects have advanced to clinical stages, some as far as Phase II. We deliver a superior service for the development of antibodies by beginning each project with the end in mind. Our scientists are experts in early stage discovery of biologics. We offer this personalised service because we know that investment at the early stages saves not only millions of dollars but also months, even years of time, on projects that go awry at later stages of development. Through our vast experience we have developed a number of our own proprietary platforms for Antibody Humanization (CRX™), Affinity Maturation (RAMP™) and Developability optimisation (ADD™). Fusion Antibodies is a publicly held company, trading on the London Stock Exchange (LSE FAB.L) with headquarters in Belfast, Northern Ireland.

On June 6, 2024, AstraZeneca announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most advanced programme, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), and brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca. It also strengthens AstraZeneca’s presence in and commitment to Canada. As a result of the acquisition, Fusion has become a wholly owned subsidiary of AstraZeneca, with operations in Canada and the US. At Fusion, we are pushing the boundaries of science to create innovative precision medicines for cancer. We are a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. We have developed our Targeted Alpha Therapies, or TAT, platform together with our proprietary Fast-Clear™ linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the therapies to tumors.

Fzata, Inc. is a oral biologics biopharmaceutical company based in Halethorpe, MD within the vibrant BioHealth Capital Region. Fzata’s vision is to reduce health inequities by expanding patient access to therapeutic biologics. This is made possible with our proprietary first-in-class oral Bioengineered Probiotic Yeast Medicines (BioPYM™) platform. BioPYM enables orally administered yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI disorders like infectious diseases, inflammation, metabolic diseases, (e.g., diabetes), colon cancer, and more. Our oral biologic drug candidates are intended to help patients that inject biologic medicine by 1) offering affordable, non-refrigerated, convenient oral capsules, 2) improving quality of life with no needles and no need for health-care administration and 3) improving patient outcomes with expected high safety and high efficacy targeted to GI.

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjogren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.a r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Galderma is the leading company solely dedicated to skin and advancing the future of dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Through trusted partnerships with healthcare professionals, we ensure to meet individual consumer and patient needs with superior outcomes.

We are Gemina Labs, a point-of-care test developer with a proprietary breakthrough chemistry platform. Founded in 2020, the Gemina chemistry platform is an advanced, “universal” bio-sensing toolkit that enables a new generation of diagnostic tests for infectious diseases and beyond. The chemistry platform isn’t just high-performing. It also overcomes many supply chain accuracy bottlenecks in the sector and cuts the development time for prototype tests to weeks. Best of all, the platform empowers “quantitative testing” (not just positive/negative tests) that opens up new applications in personal well-being (stress, fatigue monitoring etc.)

GenCirq is a biotechnology company that is developing a novel class of bacterial therapeutics with the latest advances in synthetic biology.

GENCLIS SA is a privately-held French Biotechnology that discovered a unique biological mechanism referred as to Transcription Infidelity (TI). Transcription Infidelity is a newly discovered and patented mechanism that incresases RNA-DNA sequence divergences (RDD). TI can lead to base substitutions, insertions and deletions. The latter cause translational frameshifts that have important consequences in determining protein immunogenicity. Genclis currently focuses on defining the effects of TI proteins translated from gapped RNA on normal and pathological humoral immunity.

In the past decade, the digitization of biological research has accelerated, and the science of biology has increasingly moved from the lab to the computer. Geneious aims to ease that process for scientists, allowing them to stay focused on science, while software handles the data management. Geneious creates powerful, integrated and visually appealing bioinformatics solutions, with a strong emphasis on ease of use and overall user experience. We are the market leaders in bioinformatics, constantly iterating and innovating to ensure our software solutions deliver everything our customers need. Headquartered in New Zealand with users in 125 countries worldwide, Geneious solutions enhance productivity in more than 4,000 universities, research institutes and businesses. In 2022, Geneious became part of Dotmatics, the world's largest and most powerful scientific R&D software platform. Combining an open data informatics framework with best in breed applications like Geneious Prime and Geneious Biologics, we offer the first true end-to-end solutions for biology, chemistry, formulations, data management, flow cytometry, and more. Together, our company can better: connect science, data, and decision-making and ultimately drive meaningful transformation for our customers.

About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or patientinfo@gene.com. Community Guidelines: 1. We want to foster positive conversation and diverse community around the issues we are passionate about. To that end, we remove profanity, content that contains credible threats or hate speech, content that is aimed at private individuals, personal information meant to harass someone, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.

GeneQuantum, headquartered in China, is a global leader in the ADC field, distinguished for its advancement of enzymatic site-specific conjugation technologies. Our pioneering technologies, iLDC and iGDC, serve as the foundation of our comprehensive ADC drug development platform, spanning from the initial design to seamless commercial production. The technology offered by GQ provides numerous advantages, such as exceptional product homogeneity, elevated process quality, and enhanced metabolic stability. Our continuous conjugation process seamlessly integrates with standard antibody production, ensuring the efficient creation of high-quality ADC drugs that rival the efficiency of antibody drugs. GQ's integrated approach leads to a substantial reduction in commercial production costs for ADCs. GQ remains steadfast in its commitment to delivering vital technical support, expediting global ADC drug development. Our dedication to collaborative synergy underpins mutual growth and success across diverse domains of ADC development.

GeneQuantum, headquartered in China, is a global leader in the ADC field, distinguished for its advancement of enzymatic site-specific conjugation technologies. Our pioneering technologies, iLDC and iGDC, serve as the foundation of our comprehensive ADC drug development platform, spanning from the initial design to seamless commercial production. The technology offered by GQ provides numerous advantages, such as exceptional product homogeneity, elevated process quality, and enhanced metabolic stability. Our continuous conjugation process seamlessly integrates with standard antibody production, ensuring the efficient creation of high-quality ADC drugs that rival the efficiency of antibody drugs. GQ's integrated approach leads to a substantial reduction in commercial production costs for ADCs. GQ remains steadfast in its commitment to delivering vital technical support, expediting global ADC drug development. Our dedication to collaborative synergy underpins mutual growth and success across diverse domains of ADC development.

Generate:Biomedicines is a new kind of therapeutics company—existing at the intersection of machine learning, biological engineering, and medicine—pioneering generative biology to create breakthrough medicines. Through The Generate Platform, we are able to expand the breadth of technical possibilities in order to fundamentally change the way medicines are made.

As a multinational antibody manufacturer, GeneTex's primary goal is to provide bioscience researchers with thoroughly validated reagents to accelerate their discovery. Established in 1997 in San Antonio, Texas by scientists with expertise in clinical oncology, cancer biology, and infectious disease, the company's initial focus was breast cancer biology and prognostic marker research. This evolved to incorporate a comprehensive portfolio of immunological reagents used by scientists probing the underlying mechanisms common to many forms of cancer. GeneTex's catalog has since expanded to offer a broad and diverse selection of antibody products covering a full range of research areas. GeneTex is proud to offer the highest quality antibody reagents supported by extensive research, development, and validation. We are committed to the highest standards of product performance.